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SUMMARY
In recent years basic research has contributed greatly 
to defining the role of the liver and its subcellular 
components in drug metabolism, and has drawn attention to 
various factors which may alter the activity of hepatic 
drug metabolising enzymes (such as enzyme induction). 
However, the clinical relevance of much of this information 
remains to be established. In this thesis I have attempted 
to explore certain drug-liver interactions, with particular 
reference to the clinical significance of drug stimulation 
of hepatic biotransformation, and the effect of liver 
disease on drug metabolism.
Chapter I outlines the evolutionary development of hepatic 
biotransformation [a more appropriate term than detoxication 
or drug metabolism since many naturally occurring endogenous 
and exogenous substrates are metabolised (not necessarily 
to inactive products) by a microsomal enzyme system of 
broad specificity]. This process can usefully be considered 
to occur in two phases, and details of the subcellular 
localisation and properties of the enzymes involved are 
reviewed. Rate limiting steps both in vivo and in vitro, 
and various pharmacological consequences of hepatic 
biotransformation are also discussed.
Chapter II summarises important genetic and environmental 
factors affecting hepatic biotransformation. Particular 
attention is paid to the phenomenon of hepatic microsomal 
enzyme induction. Various direct and indirect methods 
(morphological, pharmacological and biochemical) used to 
measure the activity of hepatic microsomal enzymes in man 
(and thus to determine the presence of the "induced state)
are reviewed. These include the merits and disadvantages 
of the measurement of urinary D-glucaric acid excretion, a 
technique applied in subsequent clinical studies (Chapters 
IV and V) to assess enzyme induction.
As the liver plays such a central role in the metabolism 
of both endogenous and foreign compounds, liver disease 
might be expected to have important consequences for drug 
metabolism. The conflicting evidence is outlined in 
Chapter III, together with data obtained from a collab­
orative study in patients with hepatic cirrhosis, using 
chlorpromazine as the test drug, and measuring the plasma 
disappearance and cerebral effects of this phenothiazine. 
Although no significant difference in plasma clearance of 
chlorpromazine (compared to normal controls) was found, 
the cirrhotic group was undoubtedly more sensitive to the 
sedative effects of this drug. Various mechanisms which 
might disturb hepatic biotransformation in patients with 
liver disease are discussed. Pharmacokinetic concepts are 
used in an attempt to explain the altered sensitivity to 
sedative drugs which is characteristic of cirrhotics, 
and a critical appraisal made of previous studies invest­
igating drug metabolism in liver disease.
An excellent example of the clinical application of advances 
in the basic sciences has been provided by attenpts to 
stimulate hepatic biotransformation in man using enzyme 
inducing drugs, such as barbiturates. This technique has 
been used most widely in the treatment of various types of 
jaundice, and is reviewed in Chapter IV. While undoubtedly
effective in lowering bilirubin levels, the mechanism of 
action remains obscure as hepatic enzyme induction is 
accompanied by several other drug mediated effects on the 
hepatocyte and whole liver. The results of clinical and 
animal studies undertaken in an effort to determine the 
relative importance of enhanced bilirubin conjugation 
compared to increased choleresis in the reduction of plasma 
bilirubin levels seen after phenobarbitone administration 
are presented. While not providing a conclusive answer, 
they emphasise the importance of species variation in 
response to hepatic enzyme inducing drugs, and the need for 
caution before extrapolating results from experiments in 
animals to man.
Additional possible therapeutic applications resulting from 
enhancement of hepatic biotransformation are considered in 
Chapter V. Although of theoretical interest in a number 
of clinical situations (Cushing's syndrome; dissolution of 
gallstones; treatment of inherited enzyme deficiency states; 
etc.) the practical value of enzyme induction seems limited. 
However, adverse effects are certainly of clinical import­
ance, and altered drug pharmacokinetics; enhanced drug 
toxicity, and teratogenesis are discussed. Much interest 
has also centred on the possible role of drug mediated 
hepatic enzyme induction in the production of vitamin 
deficiency. Clinical studies on anticonvulsant osteo­
malacia, and folate deficiency, are presented^ Our data 
showed a correlation between the extent of enzyme induction 
(as measured by the urinary excretion of D-glucaric acid) 
and both serum calcium and serum/red cell folate levels. 
These observations provided support for the suggestion that 
disorders of calcium metabolism after long-term anti-
convulsant therapy may be a consequence of altered hepatic 
biotransformation (enzyme induction). Moreover they 
suggested that the folate deficiency commonly seen in 
treated epileptics (and occasionally in other subjects on 
long-term therapy with other enzyme inducing drugs) may 
also be a consequence of hepatic enzyme induction. Although 
unproven, the hypothesis elaborated fits many of the 
observed facts. Data from further studies presented in 
this chapter indicate that hepatic enzyme induction may 
occur during human pregnancy.
The work described so far was all undertaken at the Liver 
Unit, King's College Hospital, and provided the basis for 
further studies on a unique form of drug-liver interaction. 
These were carried out at the University of California 
Medical Center, San Francisco, and are described in the 
final chaper (VI), which examines the curious sensitivity 
shown by patients with the hereditary hepatic porphyrias, 
to many drugs (particularly barbiturates).
This group of pharmacogenetic disorders of porphyrin and 
haem synthesis is characterised by marked idiosyncrasy 
towards lipid soluble drugs. Interestingly, most of 
these drugs, which can precipitate acute attacks of 
porphyria, are recognised as being inducers of the hepatic 
haeraoprotein cytochrome P450, the terminal oxidase in drug 
metabolism.
The primary genetic defect in the hereditary hepatic 
porphyrias is partial deficiency of an enzyme in haem 
synthesis (which may result in secondary de-repression of 
ALA-synthetase, the initial and rate limiting enzyme in the 
pathway). We considered whether the unique sensitivity
to drugs in this group of disorders might be related to the 
genetically determined partial block in haem synthesis. 
Partial inhibition of haem synthesis was produced 
experimentally in rats (by administration of lead, which 
Inhibits several enzymes in the pathway). This had only 
minor effects on ALA-synthetase activity, but greatly 
enhanced the sensitivity of this enzyme to induction by 
various drugs and steroids which alone had little or no 
inducing effect.
These studies provided a rational explanation for many of 
the previously obscure features of the hereditary hepatic 
porphyrias. In particular, the "idosyncratic" reaction to 
many drugs which is such a characteristic feature of this 
group of disorders, can now be seen to be a direct conse­
quence of the primary genetic defect in haem synthesis. In 
this context> acute attacks of porphyria precipitated by 
drugs, can be regarded as another adverse effect of hepatic 
enzyme induction.
CHAPTER I
HEPATIC BIOTRANSFORMATION
(1) HISTORICAL AND EVOLUTIONARY ASPECTS
The therapeutic effect of decoctions of plants and fruits on ailments 
of the liver was mentioned in the Ebers papyrus in BC 1550 (Clarke, 
1967), but recognition of the central role of the liver in the 
metabolian of most drugs, and of the influence of many drugs on 
hepatic structure and function was delayed for almost 3500 years.
Claude Bernard's classical studies in the 19th century initiated modem 
scientific investigation of liver function, and cooteriporary interest 
has centred on this organ's role in detoxification processes. Whipple 
(1913) pioneered the study of the role of the liver in drug metabolism, 
and more recently over the past 25 years, R.T. Williams in England 
and Bernard Brodie in the U.S.A have established the study of hepatic 
biotransformat ion as an important branch of biochenical pharmacology, 
The increasing number of scientific publications and new journals 
devoted to this subject attest to the growing interest in this field.
Although basic laboratory studies have contributed greatly to 
defining the role of the liver and its sub-cellular components in 
drug metabolism, the clinical relevance of much of this information 
remains to be established. This thesis attempts to explore the 
clinical significance of certain drug-liver interactions with 
particular reference to stimulation of hepatic biotransformation by 
drugs, and the effect of liver disease on drug metabolism.
In an evolutionary sense the development of hepatic drug metabolism 
can be regarded as a relatively recent phenomenon. Aquatic mammls 
have a poor capacity to oxidise or conjugate drugs, but the disposal 
of lipid soluble compounds presented' no problen before the evolution 
of terrestrial life since these substances readily diffuse through 
lipoidal gills to be diluted in the surrounding aqueous environment. 
Before animals could live peimanently on land, another means of 
disposing of lipid soluble impurities had to be developed, as the 
kidney is unsatisfactory for this purpose. Examination of renal 
structure reveals why this is so. Foreign organic compounds flow 
down kidney tubes lined by a collodial membrane, so that highly lipid 
soluble compounds will be almost completely reabsorbed, while lipid 
insoluble substances will pass through into the urine.
Indeed the kidney is so poorly equiped to excrete lipid soluble 
substances that it has been estimated that highly lipid soluble drugs 
such as thiopental or quinine would have had a half-life of about 
100 years if the body lacked the means of making these substances less 
lipid soluble (Brodie, 1964). The problem was solved by the evolution 
of a completely non-specific enzyme system capable of metabolising 
foreign lipid soluble compounds to polar derivatives which could be 
excreted by the kidney. These include not only the lipid soluble 
dietary compounds first faced by land dwelling animals several million 
years ago (such as hydrocarbons, alkaloids, terpenes and sterols 
ingested in food, which would accumulate to enormous levels if they 
were not converted to water soluble excretable derivatives), but also 
the great variety of lipid soluble drugs, pesticides, food additives 
and other xenobiotics which man has to contend with today. Thus the 
evolutionary development of hepatic drug metabolising enzymes may be 
considered as an adaptive response to the movement of life from an 
aquatic to a terrestical environment.
It is of interest that in drug metabolism ontogenesis appears to 
parallel phylogenesis. The development of the endoplasmic reticulum 
in rat liver is histologically complete within 5 days of birth, but 
several weeks elapse before the specific activity of the processing 
(drug metabolising) enzymes reaches adult levels (Dallner et al, 1966), 
Even at this stage however, the total detoxicating capacity of the 
liver is several hundred times lower than that of adult liver (Soyka, 
1969). This immaturity of the liver microsomal enzyme system responsible 
for the metabolism of many drugs is seen not only in laboratory animals, 
but also in the human infant (Pelkonen et al, 1973). Jndeed impaired 
drug metabolism in infants has resulted in sensitivity to many drugs, 
and occasionally in serious and even lethal toxic reactions (Remuer, 1970)
(2) GENERAL FUNCTIONS OF HEPATIC BIOTRANSFOEMATIOSr
The biological effect and fate of a drug is determined by various 
factors (which may be subjected to genetic or environmental control as 
is discussed in a later section of the thesis) including its absorption, 
distribution in the tissues, metabolism and excretion (into air, bile 
and urine).
Table 1
Relative ability to metabolize [unit w t./u n it time)
PHENOBARBITONE
(Rat)
THIOPENTONE
(Rat)
PHENOL . 
(Guinea pig)
N-ACETYLSEROTONIN
(Rabbit)
LIVER 100 100 100 100
KIDNEY 0 52 48 0
BRAIN 0 24 3 -
MUSCLE 0 0 3 -
HEART 0 19 0 0
LUNG - - n o 0
SPLEEN ' - 22 0
From R. T,  Williams (1972)
Relative drug metabolising ability of various organs from the rat, 
guinea pig and rabbit. Adapted from Williams (1972)*
The role of drug metabolism or biotransformation will be considered 
in scare detail.
After drugs are absorbed into the body they may undergo three possible 
fates.
1) They may be excreted unchanged.
2) They may change spontaneously into other compounds, without 
intervention of enzymes, because they meet the ri^it conditions of 
temperature and pH for spontaneous breakdown, or because,.they can react 
chemically with certain compounds or groups \diich are present normally 
in the body. Thalidomide is one example of such a drug (Williams, 1972).
3) However, the majority of drugs are metabolised by enzyme systems 
with the production of more polar, water-soluble, substances which 
can be easily excreted by the kidney. Although many tissues can 
metabolise drugs, by far the most active tissue per unit weight is 
the liver (Table 1). Other tissues including the adrenal, brain, 
liver, heart, muscle, spleen, intestinal mucosa, testis and skin 
show minor activity towards certain drugs, and the gut flora can 
also metabolise drugs in certain circumstances (Scheline, 1973). 
However, vdien the size of the liver and its blood flow are 
considered, its predominance in drug metabolism is readily 
appreciated (Williams, 1972).
Within the liver cell drug metabolising enzymes are present in the 
sap (soluble fraction) and mitochondi'ia, but the majority of reactions 
of drug metabolism are carried out in the liver by enzymes located in 
the smooth endoplasmic reticulum (Gillette, 1966). This cellular 
conponent can be separated after homogenisation by high speed centrifu­
gation to give the fraction called raicrosomes (operationally defined as 
the portion of liver homogenate that sedJjnents at 100,000g) which with 
appropriate cofactors, can be used to study drug metabolism in vitro.
Table 2
Relative rate of metabolism
Fraction of Liver PHENACETIN* CODEINE*
Whole homogenate 100 100
Nuclei (crude) 8 13
Mitochondria 0 0
Microsomes 0 0
Cytosol (soluble fraction) 0 0
Nuclei + cytosol 15 26
Mitochondria + cytosol 8 0
Microsomes + cytosol 85 75
*  0 “ dééthylation by rabbit liver 
+ 0 -  déméthylation by rat liver From R.T.  Williams (1972)
Relative drug metabolising ability of various fractions and 
recombinations of liver homogenate. Adapted from Williams (1972)
Table 2 shews the relative abilities of the various fractions of 
liver homogenate to carry out two reactions, namely oxidative de - 
éthylation of phenacetin to paracetamol (p ethoxy acetanilide^p 
hydroxy acetanilide), and oxidative déméthylation of codeine to 
morphine (3 methyl moiphine morphine). Apart from whole homogenate, 
the most active fraction is that containing the microsomes (which 
contain the drug metabolising enzymes) plus the cell sap/soluble 
fraction, #iich contains NADPH (reduced nicotinamide - adenine 
dinucleotide phosphate) a cofactor necessary for enzyme activity.
The soluble fraction can be replaced in an in vitro system by the 
addition of NADPH, or an NADPH generating systen.
(3) PHASES OF DRUG METABOLISM
An important concept introduced by Williams is that drug metabolism takes 
place in two phases. In the initial phase drugs undergo reactions 
classified as oxidations, reductions, and hydrolyses in which polar 
groups (OH, OOOH, NH^, and SH ) are introduced into the non-polar drug 
molecule, or alkyl groups are removed to uncover potential polar 
groups. This allows the drug metabolite to undergo the second phase which 
consists of conjugation of the polar derivatives with the formation 
of glucuronides, sulphates, and amino acid conjugates containing glycine 
( fe; g. hipp^icL acid ) glutamine, or cysteine. Méthylation and 
acétylation of drugs also occur as Phase II reactions. The net effect 
of these reactions of hepatic drug metabolism is that lipid soluble 
drugs which can be reabsorbed by the kidney are converted into water 
soluble polar metabolites which are then readily excreted by the kj-dney.
The metabolism of benzene is a good example of how the two phases of 
drug metabolism progressively convert a lipid soluble parent caipound 
to a highly ionised water soluble product. Benzene first undergoes a. 
phase I reaction of oxidation to phenol, a weak acid, which is then 
glucuronidated to the strong acid phenyl glucuronide which is virtually 
completely ionised at physiological pH.
This useful concept is necessarily an over simplification as drugs may 
be subjected to several competing pathways simultaneously. Furthermore 
not all drugs undergo two phase metabolism, since those which already 
contain a suitable polar group may undergo only a Phase II reaction
(conjugation), while alcohol for example, only undergoes a Phase 
I reaction since it is readily oxidised to CDg.
(4) HEPATIC MICROSOMAL DRUG METABOLISING SYSTEM
(a) Mixed Function Oxidation (Phase I Drug metabolism)
Reactions catalysed by non-microsomal (cytosol) hepatic drug 
metabolising enzymes are of minor importance. Only two play a 
clinically significant role in drug metabolism (acétylation of drugs 
such as isoniazid, certain sulphonamides and phenelzine; and 
oxidation of alcohol by alcohol dehydrogenase - the microsomal 
contribution to alcohol metabolism is controversial) and they will 
not be considered further.
The first description of the metabolism of a foreign compound by 
hepatic microsomes was given in 1949 by Mueller and Miller who 
showed that the microsanal fraction of a liver homogenate was 
capable of metabolising amino-azo dyes. Later Brodie et al (1955) 
demonstrated that a similar enzyme system located in hepatic 
microsomes was responsible for the metabolism of many drugs. 
Recombination of the various cell fractions of liver homogenate 
revealed a requirenent for both soluble and microscxnal fractions. 
However full activity resulted from the microsomal fraction alone 
when the soluble fraction was replaced by NADPH or by a NADPH. 
generating system consisting of NADP, glucose-6-phosphate, and 
glucose-6-phosphate dehydrogenase.
Mason (1957,1965) suggested the term " mixed function oxidases " for 
enzymes mediating this type of reaction, while Hayaishi in 1964 
introduced the designation " mono-oxygenases ", considering the NADPH 
dependent reaction merely a class of the general category of oxygenase 
reactions (Mannering, 1971). This latter terminology implied that 
these enzymes catalysed the consumption of one molecule of oxygen per 
molecule of substrate, with one atom of oxygen appearing in the product 
and the other undergoing two equivalent reduction. Direct support 
for this view was obtained in studies employing labelled oxygen and 
water, which showed that the oxygen utilised in the hydroxylation of 
acetanilide is derived from molecular oxygen rather than from water 
(Posner et al, 1961). The microsomal mixed function oxidase system 
catalyses a wide variety of oxidations including hydroxylation, side
Table 3
1, AROMATIC irYTHGXTLATION 3. N-OXIMTÏON
Acetanilide
Anabolic/contraceptive steroids
Aniline
Benzene
Naphthalene
Phenformin
Phenobarbitone
Phenylhydra z ine
2. ALIPHATIC IIYBROXYLATION
Amitrypt i1ine
Antipyrine
Imipramine
Meprobamate
Metronidazole
Pentobarbitone
Tolbutamide
3. N-BBALKYLATION
Aninopyrine
Chiorproma zine
Codeine
Diazepam
Imipramine
Pethidine
Morphine
Chiorpr oma z ine 
Guanethidine 
Imipramine 
Nicotinamide
6. SULFOXIDATION
Phenothiazine 
Chiorpromaz ine
7. DEHALOGENATION
CC14
DDT
Halethane
Trichiorethylene
T3, T4
8. EPOXIDATIQN
Squalene insecticides 
(Aldrin, Heptachlor)
9* DEAMINATION
Amphetamine
Ephedrine
4. O-DEALKILATIQN
Codeine
Griseofulvin
Phenacetin
Mixed function oxidase (Phase l) reactions, with examples of drugs 
metabolised by each.
Chain oxidation, N-oxidation, sulfoxidation, N, 0, and S-deaUkylation,• 
deamination and désulfuration (Table 3). However this great versatility 
of the microsomal drug metabolising systen seems less remarkable when
the reactions are visualised simply as different kinds of hydroxylation
requiring a reducing agent (NADPH) and molecular oxygen (Brodie et al, 
1958). These workers suggested that NADPH participated in the reaction 
by reducing a liver microsomal component X, that then reacted with 
Og to form an " active oxygen complex ", which in turn hydroxylated 
various substrates by a group of non specific enzymes. -
Gillette (1963), formulated the overall reaction for oxidation of a 
drug by the hepatic microsomal system as follows:
1) NADPH + X + H*  XH2 + NADP
2) XEI2 + Og ----^ ” active oxygen "
3) " active oxygen" + drug > oxidised drug + X + H^O
NADPHgf Og + drug ---- 5- NADP , + H^O + oxidised drug
The scheme requires that equivalent amounts of NADPH, oxygen and 
substrate (drug) be utilised in the reaction. Subsequently it was 
established that the liver microsone component (X) reduced by NADPH 
was in fact the CO sensitive haemoprotein cytochrome P450 (Cooper 
et al, 1965).
There has been much speculation regarding the interaction of the 
components of the microsomal mixed function oxidase system responsible 
for drug metabolism, and about the nature of the associated electron 
transport system. Various elaborate schemes have been proposed 
(Mannering, 1971) and a relatively simple one is shown in Figure 1 
(Qnura, 1965) which illustrates our present understanding of the 
processes involved in the microsomal oxidation of drugs. The 
flavoprotein enzyme NADPH cytochrome reductase (f^ ) is thought to 
transfer electrons (reducing equivalents) fran NADPH to cytochrome 
P450, either directly or via an unidentified carrier X. This 
accomplishes the reduction of oxidised cytochrcxne P450 (Fe ) to 
reduced cytochrome P450 which is essential to the overall reaction.
Fig. 1
NADP
NADPH
Fp (red)
CYTOCHROME 
C
REDUCTASE
Fp (oxid)
P 450
NHI 
Fe+++
NON HAEM 
IRON PROTEIN
[p 450 Fe++ O 2]
P 450  
Fe+++
(Omura et ol 1965)
RCH2CH3
DRUG
RCHgCHgOH 
OXIDISED DRUG
A simplified scheme showing interaction of components of the 
microsomal mixed function oxidase system. Electrons are transported 
from NADPH via flavoproteins for reduction of oxidised cytochrome 
P 450 (Pe -i--t-+) prior to substrate oxidation. Modified from Omura 
et al (1965).
++
Reduced cytochrone P450 (Fe ) then combines with molecular oxygen 
(Og) to form an " active oxygen complex” (red P450 - Og). Binding 
of drug substrate to this complex now takes place which allows 
activated oxygen to be transferred to the drug molecule to give 
oxidised drug. The process involves the splitting of a molecule of 
" activated” oxygen, one atom being transferred to the drug, the 
other being incorporated into a molecule of water.
(b) Microsomal oxidation and electron transfer
The microsomal mixed function oxidase system has (in corauon with the 
mitrochondrial enzyme systen) the capacity to transport electrons to 
a final cytochromal acceptor.
D + 2e + 2H* + Og -----^ D: 0 + H^O
As shown above two electrons are used in the reduction of one 
molecule of oxygen; one for the reduction of one aton of oxygen to 
water, the second oxygen atom being incoiporated in the substrate (D).
However in the endoplasnic reticulum (unlike mitochondria) there is 
no evidence that oxidation and electron transport is coupled with the 
formation of high energy bonds. Reduced NADP (probably derived from 
glycolysis) functions exclusively as an electron donor. The electrons 
are picked up by an NADPH dependent flavoprotein, cytochrome-C- 
reductase, and flow from the reduced flavin enzyme to cytochrome P450. 
The reduced heme of cytochrome P450 is now able to bind one molecule 
of oxygen which is activated, presumably by picking up one electron 
from the heme iron. How the second electron which is necessary for 
mixed function oxidation comes into play, and how one atom of the 
oxygen reacts with the available substrate is not yet known.
(c) NADPH cytochrome c reductase
This microsomal flavin enzyme, which reduces cytochrome P450 (directly 
or possibly indirectly via an intermediate carrier) is believed to be 
the rate limiting step in the overall process, as the rate of drug 
metabolism (for certain substrates at least) has been shown to be more 
closely related to the rate of cytochrome P450 reduction, than to the 
total amount of cytochrome P450 (Davies et al, 1969).
(d) Cytochrone P45Q
A pigment in liver microsomes was first described by Klingenberg in 
1958. A large number of mixed function oxidase reactions had previously 
been described, and it was recognised that thd. microsomal fraction of 
the liver and adrenal cortex was the site of such enzyme systems. 
However nothing was known about the nature of this pigment, or the 
mechanism of oxygen activation by these enzyme systems until 
Estabrook, Cooper, and Rosenthal in 1963 detected a CO-lbinding pigment 
in adrenal cortex. This had an absorption maximum at 450nm, comparable 
to the liver microsomal pigment earlier described by Klingenberg, and 
was able to hydroxy late progesterone.
For the first time a function could now be assigned to this 00- 
binding microsomal pigment, which on account of its spectral 
characteristics was called cytochrome P450 (Qmra and Sato, 1964) or 
reticulochrome because of its association with the endoplasmic 
reticulum. Subsequent studies established that the same cytochrome 
was responsible for drug hydroxylations (Remmer and Merker, 1965) and 
that the hypothetical liver microsomal component (X) which Brodie 
and his colleagues had previously postulated might reactjwith oxygen 
to form an "active oxygen complex" was in fact this 00 sensitive 
haemoprotein, cytochrome P450 (Qnura, Sato, Cooper, Rosenthal and 
Estabrook, 1965).
(e) P450 binding to drugs
Studies by Remmer et al (1966) and Iraai and Sato (1966) showed that 
drugs and other foreign conpounds combined non-specifically with the 
oxidised form of cytochrome P450 to cause small but significant changes 
in its absorption spectrum. This reaction preceded the hydroxylation 
process, and two general types of reversible binding could be 
distinguished spectrophometrically when lipid soluble drugs were added 
to microsomal sysponsions. The difference in the absorption of 
microsomal suspensions without and then with added substrates, called 
the binding spectrum, has been widely used as a tool for studying drug 
metabolism. Two general types of spectral change have been recognised, 
and compounds giving these spectra have come to be known as TYPE I or 
TYPE II drugs.
Type I drugs include hexobarbital, aminopyrine, and ethylmorphine, 
and cause diminished absorb^ce at 420nm and a peak at 385nm. Type II 
compounds include nicotinamide and aniline, and cause maximal and 
minimum absorbance at 430nm and 390nm respectively. Thus, with opposing 
A  max and Aniin, type I and type II spectra are approximately mirror 
images of each other. However this distinction is not absolute and 
some substances appear to cause an intemediate type of spectral 
change.
The most persuasive evidence that these spectra do in fact result 
from interaction of drug with cytochrome P450 was the finding that 
solubilised and partially purified P450 combined with Type I and Type 
II compounds to give characteristic binding spectra (Lu et al, 1969).
It is of interest that compounds which induce microsomal drug 
metabolism tend to be Type I compounds, and that the diminished 
ability of microsomes to metabolise certain drugs when stored in the 
cold, is probably due to loss of Type I binding sites. Storage has 
little or no effect on Type II binding (Shoanan et al, 1969). 
Nicotinamide ( a Type II compound) was frequently added in the past 
to incubation mixtures when drug metabolism was studied in vitro, to 
prevent loss of NADP by inhibiting nucleotidase. However tin 
concentrations commonly used it was found that drug metabolism was 
inhibited, probably because it binds to P450, and it is now excluded 
from incubation mixtures (Schenkman et al, 1967).
(f) Different Species of P450
The presence of at least two types of cytochrome P450 was surest ed 
by studies demonstrating a preferential effect of certain inducing 
agents in causing increased metabolian of some drugs but not others.
The mechanism by which phenobarbitone and many other drugs stimulate 
the synthesis of the microsomal drug metabolising enzymes has long 
been considered to be different from that by which polycyclic 
hydrocarbons such as 3 methyl cholanthrene and 3,4 benzpyrene produce 
their inductive effect (Mannering, 1971). This assumption was based 
on the evidence that drugs such as phenobarbitone induce the increased 
metabolism of a much larger number of drugs and other foreign 
substances than do the polycyclic hydrocarbons, and it was concluded 
that the polycyclic hydrocarbons caused the synthesis of a modified 
form of cytochrome P450.
Alvares et al (1967) provided further evidence for this suggestion 
when they showed that the A  max of reduced microsomal protein bound 
to 00 obtained after administration of polycyclic hydrocarbons 
differed slightly from that in untreated animals, being at 448nm 
instead of the usual 450nm, and named this modified cytochrome, 
cytochrome P448. Although it is established that administration of 
polycyclic hydrocarbons causes a change in microsomal haemoprotein, 
there is still controversy as to whether this change reflects 
formation of a new molecular species of haemoprotein or ..whether the 
change simply represents an alteration in the relative amounts of 
interconvertible forms of a single haemoprotein. Most of the 
evidence leads to the conclusion that administration of polycyclic 
hydrocarbons causes biosynthesis of a molecular species of cytochrome 
P450 (P448) not normally detectable in appreciable amounts in 
microsomes from untreated or phenobarbitone treated animals. The 
possibility that small amounts of cytochrome P448 may be found in 
untreated animals cannot be excluded. Indeed this might be expected 
as polycyclic hydrocarbons or other substances capable of inducing 
the synthesis of cytochrome P448 are present in the atmosphere, and 
may be ingested in the diet, or produced by intestinal flora. Questions 
regarding the number of haem containing enzymes in the endoplasmic 
reticulum cannot be answered definitely at present, but the available 
facts surest there are two (Lu et al, 1973). The evidence strongly 
suggests that this is a relatively non-specific enzyme system. It is 
difficult to conceive of a large number of enzymes using haem as a 
cofactor, each reacting specifically with a particular type of chemical 
configuration (Remner, 1970). Further evidence for the exJ.stance of 
only a limited number of foims of this haanoprotein is suggested by 
the finding that certain drugs such as SKF 525A which have a high 
affinity for cytochrome P450, can inhibit the metabolism of nearly all 
compounds reacting with this pigment (Anders & Mannering, 1966).
(g) Conjugation (Phase II Drug Metabolism)
The second phase of drug metabolism consists of the conjugation of 
the polar derivatives of drugs with a number of substances. However, 
glucuronide formation is the most common route of Phase II metabolism 
for many drugs (possibly because of the general availability of 
glucose in biological systems) and quant it ively accounts for a major 
share of drug metabolites (Dutton, 1966).
The reaction involves the condensation of the drug or its 
biotransformation product with D-glucuronic acid, and does not take 
place directly, but requires the activation of glucuronic acid by 
the synthesis of UDPGA from 13DP glucose. This is mediated by a 
dehydrogenase present in the supernatant fraction of liver, while 
the interaction of UDPGA with the acceptor drug is catalysed by 
glucuronyl transferase, a microsomal enzyme. In addition to a 
large number of drugs, many normally occuring substrates such as 
steroids, thyroxine and bilirubin are also conjugated with 
glucuronic acid. There is evidence that several glucuronyl 
transferases exist, but although competition can be shown between 
substrates for the same transferase reaction, their exact substrate 
specificity is unclear. In general glucuronide formation abolishes 
the biological properties of a drug. Glucuronides are more water 
soluble than their parent drugs because of the large hydrophilic 
carbohydrate moiety. At the same time they are usually stronger 
acids, and so more ionised at physiological pH. Such compounds are 
less likely to penetrate menbranes than the parent drugs, are 
poorly reabsorbed by kidney tubules, and more readily excreted 
(Smith & Williams, 1966). Drug glucuronide conjugates may be 
hydrolysed by ^  glucuronidase, a lysosomal enzyme. Hydrolysis of 
a drug conjugate by ^ glucuronidase may restore the free aglycone 
in sufficiently high concentration to produce toxicity, but the 
exact function of this enzyme is not clear. It is of interest that 
a natural inhibitor of ^  glucuronidase (D-glucaric acid) is 
produced as an end product of the glucuronic acid pathway in the 
liver, and that drugs which induce the synthesis of hepatic enzymes, 
stimulate the production of this metabolite. This observation has 
been used as the basis for a clinical test of hepatic enzyme 
induction, and will be discussed in more detail in Chapter II.
Glucuronides are usually excreted by the kidney either by tubular 
secretion, or for conjugates of higher molecular weight, by glomerular 
filtration alone. In some species however biliary excretion of 
glucuronides is predominant. In the rat for example conjugates with a 
molecular weight in excess of 400 are usually actively secreted in 
the bile, while lower molecular weight derivatives are less likely to 
be transferred by this route.
Various factors including species variation, age, and drugs, have 
been recognised to affect glucuronide conjugation (Dutton, 1966).
It is deficient in the cat and the Gunn rat. The former can 
synthesise UDPGA and is able to conjugate various endogenous 
compounds as glucuronides, but not so drugs - apparently because 
cats lack the glucuronyl transferases used in drug conjugation.
The Gunn strain of rat is characterised by unconjugated hyperbilirubin- 
aemia and diminished ability to conjugate certain compounds with 
glucuronic acid. Although UDPGA levels are normal, and sniline and 
nitrophenol are excreted as glucuronides, o-glucuronyl transferases 
are deficient, and bilirubin, o-aminophenol and o-aminobenzoic acid 
do not foim glucuronide derivatives (Arias, 1961). A similar 
situation may explain the congenital unconjugated hyperbilirubaemia 
in children with the Crigler-Najjar Syndrome (Arias et al, 1969),
Drugs which are normally conjugated with glucuromic acid may 
aggravate kernicterus in these individuals by further impeding the 
formation of bilirubin. The activity of glucuronyl transferase is 
influenced by microsomal enzyme inducers and thyroxine. In the 
newborn of most species, glucuronyl transferase activity is remarkably 
low (Dutton, 1966). Neurological damage due to unconjugated bilirubin 
in infants (Kernicterus) can be aggravated by novobiocin'_.an ■ 
antibiotic which inhibits glucuronyl transferase activity (Hargreaves 
and Holton, 1962). Recent attempts to prevent or treat kernicterus 
by stimulating the activity of conjugating enzymes in the newborn by 
drug treatment will be discussed in a subsequent section of the thesis 
on therapeutic implications of hepatic enzyme Induction (Chapter IV).
(5) RATE LIMITING STEPS IN DRUG METABOLISM IN VITRO
The rate of drug hydroxylation is extremely low compared with other 
known enzyme reactions, and differs between substrates, species and 
individuals. As discussed previously, the rate limiting step in drug 
hydroxylation is thou^t to be the reduction of the haem iron of 
cytochrome P450, catalysed by cytochrome-C-reductase. This varies 
with the type of substrate and its binding to cytochrone P450 
(Schenkman et al, 1967A). It is increased if a type I substrate is 
bound to the hydrophobic region of cytochrome P450, while basic 
(Type II) compounds inhibit reduction (Remmer, 1970).
In intermediary metabolism the turnover number (number of substrate 
molecules convert ed/mole of enzyme/minute ) is many orders of magnitude 
(10^ - 10^) greater than the number of molecules of drug converted by 
cytochrome P450 (Alvares et al, 1969). This low turnover may be 
largely explained by the non-specific nature of the microsomal mixed 
function oxidase syston. Despite this most drugs seem to be metabolised 
at a reasonable speed, because of the surprisingly large capacity of 
the hydroxylating mixed function oxidase system. It has been estimated 
that Ig of rat or rabbit liver contains between 1.8 and 2.4mg of 
cytochrone P450, and that this haemoprotein accounts for greater than 
1% of the total liver protein (Remuer, 1970). Human liver contributes 
only 2% of total body weight (conpared to 4% in the rat) and contains 
about half to one third the amount of cytochrone P450 found per gram 
of rat liver. This species difference in cytochrone P450 content 
corresponds to the observation that man metabolises drugs in vivo 
at a rate 2 to 10 times slower than the rat (Quinn,Axelrod & Brodie, 
1958).
Fasting increases the cytochrome P450 content of hepatic microsomes 
as does administration of phenobarbitone, hydrocarbons, and many 
other conpounds known to increase in vitro and in vivo drug metabolism. 
A fuller description of this phenomenon of de novo synthesis of 
hepatic microsomal enzymes, and of its clinical relevance will be 
presented in subsequent sections of the thesis. However in addition 
to changes in the content and kinetic properties of drug metabolising 
enzymes which alter drug metabolism in vitro, certain other factors 
may affect the rate of drug metabolism in vivo.
(6) RATE LIMITING STEPS IN DRUG METABOLISM IN VIVO
Although the kinetic properties of hepatic microsomal enzymes are 
normally of central importance in determining the overall rate of 
drug metabolism in vitro, non enzymic factors are important in the 
whole animal, and under certain circumstances marked changes in 
enzyme activity may have little effect on metabolism of drugs in vivo. 
The difficulty of extrapolating from in vitro data to the in vivo 
situation is also emphasised by the recognition that metabolism of 
drugs in vivo may be affected by factors that are difficult if not 
inpossible to evaluate with tissue homogenates (Gillette, 1971).
These include the following:
(a) Competitive Inhibition
The non-specific nature of the mixed function oxidase system results 
in the fact that most drugs competitively inhibit each others 
metabolism in vitro (Tephly & Mannering, 1967). However such conpetition 
rarely occurs in vivo because the free concentration of most drugs 
in the body is considerably below the concentration required to half- 
saturate the enzyme (Km). Thus when the free concentrations of two 
drugs are both below their Km values, competitive inhibition becomes 
negligible. Even if in vivo concentrations of both drugs are as high 
as their Km values, they will inhibit each others metabolism by only 
approximately 33% (Gillette, 1971).
(b) Limited Availability of Cofactors
Liver perfusion systems have provided evidence that starvation may 
decrease the metabolism of drugs by decreasing the level of NADPH in 
hepatocytes (Gillette, 1971). Fasting and feeding have important 
regulatory effects on the induction of microscmal enzymes in animals 
(Conney, 1967; Bonkowsky et al, 1973) but it is not known whether 
starvation might also impair glucuronic acid synthesis fi?on glucose 
and hence inpair glucuronidation by limiting the availability of 
UDPGA. Ascorbic acid has been shown to be required as a cofactor in 
microsomal drug metabolism (Krasner et al, 1974) and in a subsequent 
section (Chapter V) some evidence is presented to suggest that folate 
deficiency may also inpair drug metabolism both in vitro and in vivo.
(c) Hepatic Blood Flow
The hepatic extraction ratio (ER) for a given drug is a measure of 
the capacity of the liver to metabolise that drug. It may be 
calculated as follows:
ER = Q.(Ca - Cv) Where: Q - blood flow to liver
O Ca Ca = arterial concentration 
of drug
Cv - venous concentration of 
drug
This expression simplifies to ER = ~ ^  and with drugs that
Ca
are metabolised by very active enzymes in the liver, or rapidly 
excreted into the bile so that they are cleared in a single passage 
through the liver, the extraction ratio equals or approaches 1.
Now, clearance (Cl) = Q. ER 
Thus with drugs whose extraction ratio approaches one, clearance 
equals flow. This consideration is inport ant with drugs which have 
high extraction ratios such as oxyphenbutazone (Whitsett et al, 1971) 
lignocaine (Thcmson, Melmon et al, 1973) and propranolol (Branch et al, 
1973), Under these circumstances in vivo drug metabolism is carpletely 
limited by the rate of blood flow to the liver, and independent of the 
activity of drug metabolising, enzymes. Thus inpaired elimination of 
such drugs in patients with chronic liver disease may be a consequence 
of reduced hepatic blood flow, rather than impaired drug metabolising 
capacity (Chapter III). Most drugs however have relatively low 
extraction ratios (^ %  0,1) and their in vivo metabolism is not sig­
nificantly affected by changes in hepatic blood flow (Gillette, 1971).
(d) Drug Distribution and Protein Binding 
The half life (t|) of a drug may be derived from the following 
formula (Gillette, 19711
0.693 Vd. Ca. K
ti  =  " -
F. Cv.
IVhere : Vd = volume of distribution of the drug 
Ca = arterial concentration of drug 
Cv = venous concentrât ion of drug 
F, = fraction drug unbound to plasma protein 
K = kinetic constant 
Where the extraction ratio is low, Cv approximates to Ca, and the 
equation sinplifies to:
0.693 . V4 . K
t& ~
F
The formula emphasises that drug elimination in vivo is affected 
both by the volume of distribution of the drug (Vd) and by the 
fraction of unbound drug in the blood (F). Changes in tj are directly 
related to alterations in Vd, but the effect of changes in the degree 
of protein binding of a drug on its elimination (metabolism) is more
complex. If the activity of drug metabolising enzymes in the liver 
is so high that virtually all the drug is cleared from the blood in 
one pass through the liver (ER% 1) an increase in binding of the drug 
by plasma proteins could accelerate its metabolism, by increasing 
the rate at viiich it is carried to the liver. However for the 
majority of drugs with low extraction ratios (ERf^ 0.1) the equation 
holds true and an increase in plasm protein binding of the drug may 
be expected to prolong its biological half-life. The magnitude of 
the effect depends on the degree of protein binding. Binding of a 
drug to albumin prolongs its t i  by only 11% when 50% of the drug is 
bound, and only 33% when 75% is bound. This effect becomes 
therapeutically important when 90% or more of a drug is bound to 
albumin. At this level small changes in the degree of binding have 
large effects on biological half-life (Gillette, 1971),
(7) PHARMACOLOGICAL CONSEQUENCES OF DRUG METABOLISM
Hepatic biotransformation does not necessarily imply detoxification, 
since in addition to conversion of an active drug into a relatively 
inactive metabolite, the first phase of drug metabolisra^can change a 
drug into another compound with similar (or different) pharmacological 
activity, or it may convert an inactive compound into an active drug. 
These three possible consequences of Phase I metabolism are 
illustrated by the following examples.
PHENACETTN - this drug is by itself an active analgesic agent, but 
its activity is largely due to its oxidation product paracetamol 
(acetaminophen) formed enzymatically in the liver. This subsequently 
undergoes a Phase II reaction and is conjugated to form the inactive 
product paracetamol glucuronide (acetaminophenylglucuronide) which is 
then excreted.
Alternative pathways of Phase I metabolism of phenacetin also occur 
as was shown by the investigation of two sisters who readily developed 
methaetiïDglobinaania after exposure to this drug, and who were found to 
excrete excessive 2-hydroxyderivaties of phenacetin, but relatively 
little of the normal de-ethylated metabolites (Shahidi, 1968). Recent 
studies indicate that paracetamol also undergoes a further Phase I 
reaction, to form a hepatotoxic intermediary (follow et al, 1973).
When paracetamol is taken in overdose, sufficient quantities of the 
toxic metabolite may be produced so that hepatic necrosis, and 
occasionally death, results (Clark, et al, 1973).
PRONTOSIL - this drug has no antibacterial activity in vitro, but is 
active in vivo. It is converted by reduction in the liver to 
sulphanilamide, the active charotherapeutic agent, which is then 
inactivated by subsequent acétylation (Bemhein, 1941).
PHENOBARBITONE - is partly metabolised and partly excreted unchanged 
in man. The two Phase process.of metabolism involves oxidation to 
hydroxyphenobarbitone, a relatively inactive metabolite, which is 
then conjugated to. an inactive excretory product (Butler, 1955).
CHAPTER II
GENETIC AND ENVIRONMENTAL INFLUENCES ON HEPATIC BICTRANSFORMATION
(1) GENETIC FACTORS MODIFYING DRUG METABOLISM
(a) Species Differences
Various studies indicate that drugs which are pot subject to metabolic 
transformation (usually highly lipid insoluble compounds) and which 
are mainly eliminated from the body through thé kidney ( a process 
not particularly different from one species to another) have 
remarkably similar pharmacological activities in various mammalian 
species including man. For exanple the parenteral dose of 
tubocurarine required to produce a 90-100% neuro-muscular block 
varies only between 1 and 5mg/kg in 9 species including man (Zairais, 
1953) and the effects of about 300 ganglion blocking agents, all 
quaternary ammonium compounds, vary even less (100-200%) in 5 
species of animals (Nador, 1960).
However, comparative pharmacological studies clearly show that the 
majority of drugs which are lipid soluble and undergo enzyme 
catalysed hepafic biotransfoimation show major differences in both 
the rate and pathway of drug metobolism between different species 
(Williams, 1971). The quantitative aspects of species differences 
in hepatic drug metabolism, which may be related in part to species 
differences in cytochrome P450 content, were mentioned in Chapter I. 
Considering the evolution of hepatic drug metabolising enzymes it is 
perhaps not suiprising that the activity of a particular enzyme is 
vastly different from one species to another, and in some species 
may be completely lacking. The cat is generally deficient in drug 
metabolising enzymes, and completely lacks the ability to conjugate 
drugs as glucuronides (although it is able to conjugate various 
endogenous compounds with glucuronic acid). In addition the relative 
inportance of multiple pathways of drug metabolism may vary from 
one species to another. Deamnati^on is the major route of metabolism 
in the rabbit, but in the dog and rat this reaction is virtually 
absent, and dqneibh^ lati^ o^  (dog) and k^^o^latipn (rat) are the 
major pathways. Although the patterns of metabolism of certain drugs 
in monkeys may be similar to those in man, the relative inportance of 
different pathways vary greatly in new and old world monkeys.
Ihese qualitative and quantitative differences in drug metabolism 
limit both the usefulness of laboratory animals for drug screening, 
and the validity of extrapolating results from animals to man. Some 
apparent species differences in respect of the effect of inducing 
drugs on hepatic bile flow and bilirubin metabolian between man and 
the rat (Maxwell et al, 1973) will be presented in Chapter IV.
(b) Inter-individual variation in drug metabolism
Biochemical differences between individuals are ultimately determined by 
genetic variability which controls the make up of proteins and enzymes 
regulating metabolic processes. Because most drugs undergo enzyme 
catalysed metabolic transformations, it is not surprising that inter­
person differences in the rate and manner of drug metabolism ( so 
called "pharmacological individuality") might also occur. Studies in 
man have confirmed this, and have shown that there are often 
pronounced individual differences in the disposition and metabolism 
of drugs, accompanied by differences in response (Alexanderson et al, 
1969; Rawlins, 1974). This pharmacological variability may of course 
be due not only to hereditary differences but also to environmental 
factors such as drug-drug interactions, and the effects of'hepatic 
enzyme induction, which are often difficult to separate (Conney,1967).
Sir Archibald Garrod, who pioneered the study of inborn errors of 
metabolism (Garrod, 1902) first suggested that unusual reactions to 
drugs might be caused by aberrations in metabolic pathways. The term 
" pharmacogenetics", introduced by Vogel (1959), originally referred 
only to the study of genetically determined variants detected by their 
unusual drug effects or responses. This definition, which was rather 
restrictive, has been extended to include a broad range of topics at 
the interface of pharmacology and genetics (Nfotulsky, 1969) and now 
covers the study of all clinically important hereditary variations in 
response to drugs (Vesell, 1972; 1975).
The evidence that genetic factors are involved in pharmacological 
variability in man has come not only from recognition of untoward 
drug responses in inborn errors of metabolism, but also from population 
and twin studies utilising accurate pharmacokinetic techniques to 
estimate the range of variation in drug response or drug metabolism.
Two main types of variability may be demonstrated from population
studies. Where the data shows a discontinuous frequency distribution 
(bimodal or polymodal), and if environmental factors can be largely 
excluded, genetic differences are likely to account for the 
subpopulations (Evans, 1971). Classical examples of human genetic 
polymoiphism in drug metabolism revealed by a polymodal distribution 
include the inactivation of isoniazid (Evans, 1960) and other drugs 
metabolised by cytoplasmic acetylases such as hydralazine, various 
sulphonamides and monoamine oxidase inhibitors; and the hydrolysis 
of succinylcholine by plasma pseudo-cholinesterase. As a 
generalisation it seems likely that polymorphism in drug metabolism 
is more likely to be observed with drugs whose metabolism is largely 
due to a relatively specific enzyme working in functional isolation, 
as is the case with the plasma pseudocholinesterase or cytoplasmic 
acetylase (Evans, 1971). However with the majority of drugs which 
are metabolised by the non-specific mixed function oxidase system of 
several interdependent microsomal enzymes, it is not surprising that 
variability has been shown to be uniraodal. Here genetic influences 
are multifactorial, and the contribution to variability from alleles 
at various loci is of a similar order, and results in a single 
contiguous frequency distribution. Thus for the majority/of drugs 
metabolised by hepatic microscmal enzymes minor variations in the 
various enzymatic steps encountered in drug metabolism result in a 
continuous frequency distribution curve. Phenylbutazone is one 
example of such a drug whose metabolism has been demonstrated to be
under polygenic control (Whittaker & Evans, 1970).
An additional approach to the demonstration of genetic factors in 
drug metabolism has been provided by twin studies. If monozygotic 
(identical) twins exhibit a virtually identical response when given 
the same dose of a drug, while dizygotic (fraternal) twdns show 
differences, it is reasonable to infer that genetic factors play a
significant role in drug response. Twin studi.es for a variety of
drugs such as isoniazid (Bonicke & Lisboa, 1957), phenylbutazone 
(Whittaker & Evans, 1970). and antipyrine and dicoumarol (Vesell,1972) 
have confirmed the importance of genetic factors in drug metabolism.
ITom such studies it is possible to estimate the " her it ability 
index", a measure of the per cent variation of the parameter studied 
which is due to genetic factors (Osborne & De George, 1959). For 
many drugs this has been found to be around 90-95% suggesting that 
under the conditions of the experimental studies (healthy, adult, 
non-hospitalised, non-medicated twins) environmental factors 
played a negligible role in the control of drug metabolism.
There is relatively little information as yet on genetically 
determined qualitive differences in human drug metabolism. One 
possible example concerned two sisters who readily developed 
methaemoglobinaemia after exposure to phenacetin, and who were shown 
to excrete excessive 2-hydroxy derivatives of phenacetin, but 
relatively little of the normal de-ethylated metabolites (Chapter I). 
Pretreatment with enzyme inducing drugs worsened the condition, and 
the findings were interpreted as suggesting that in the relative 
absence of the dééthylation pathway, an increased amount of 
alternative metabolites were excreted which were responsible for 
methaemoglobin formation (Shahidi, 1968),
Many previously obscure adverse effects and idiosyncratic reactions 
to drugs are now recognised as having a pharmacogenetic basis 
(Motulsky, 1969; Vesell, 1972). The hereditary hepatic poipihyrias 
are a particularly interesting group of pharmacogenetic disorders, 
as these patients show unusual sensitivity to enzyme inducing drugs. 
Some studies which attempt to explain the mechanism of this drug 
idiosyncrasy will be presented in a subsequent section (Chapter VI).
(2) EiWIRONMENTAL FACTORS AFFECTING DRUG METABOLISM
As a matter of clinical experience physicians have long recognised that 
when patients are treated for prolonged periods with certain drugs, a 
progressive diminution in drug response (tolerance) is often observed. 
In fact the first example of such tolerance to drugs is usually 
ascribed to King Mithridates who died in 63 BC. He murdered his 
family and concubines, and trusting no one, is said to have 
repeatedly taken small doses of poison throughout his life to prevent 
his enemies from poisoning him.
After his ultimate defeat by the Roman araiy under Pompey, he was 
unable to kill himself with poison, and had to order a mercenary 
to behead him. His actions are commemorated by the teim 
" mithridatism", and by this means the novelist Alexandre Dumas 
also thwarted attempts to poison his fictional hero, the Count 
of Monte Cristo.
(a) Hepatic enzyme induction
It is now recognised that a number of environmental factors can 
regulate the activity of drug metabolising enzymes in liver microsomes, 
and the subject has recently been reviewed by Remmer (1972). Most 
attention has been directed to the role of drugs and chemicals, but 
the activity of these enzymes may also be altered by dietary and 
nutritional factors, X- irradiation and hormonal changes (Conney,1967).
The first evidence that enhanced hepatic biotransformation might 
provide a partial explanation for drug tolerance came from studies 
which showed that livers from rats and mice fed commercial diets 
were considerably more active in metabolising amino-azo dyes in vitro 
than those fed grain or a purified diet (Brown et al, 1954). Later 
it was demonstrated that animals slept for progressively shorter 
periods of time after repeated administration of barbiturates (Conney 
et al, 1960).
Investigation of the metabolic changes responsible for this 
adaptive phenomenon showed it to result at least in part from 
enhanced microsomal drug metabolising activity in the livers of drug 
treated animals. After administration of certain compounds such as 
barbiturates and polycylic hydrocarbons the livers of treated animals 
exhibited an increased capacity in vivo and in vitro to metabolise 
not only that compound, but also a great many others via the 
microsomal mixed function oxidase system (Conney & Bums, 1959; Conney 
et al, 1960).
More than 200 drugs including hypnotics, sedatives, CNS stimulants, 
tranquillisers hypoglycaemic agents and anti-inflanmatory (adrenocortical) 
steroids are now loiown to stimulate the activity of drug metabolising 
enzymes in liver microsomes of experimental animals (Conney, 1967; 1969).
In addition many chemicals present in the environment have this 
property. Examples include the polycyclic aromatic hydrocarbons 
found in cigarettes smoke, polluted city air and certain cooked 
foods (Welch et al, 1969), hsLlogenated hydrocarbon (organochlorine) 
pesticides (Hunter et al, 1972) urea herbicides (Kinoshita et al,
1966) and certain food preservatives (Creaven et al, 1966). Some 
colouring agents and various anutrients present in food-stuffs such 
as caffeine (Mitoma et al, 1968), flavones (Wattenberg et al, 1968) 
terpenes and safrole (Parke & Rahman, 1969) as well as cèdar-chip 
bedding material (Ferguson, 1966) are ' potent stimulators of drug 
metabolism in laboratory animals.
(b) Factors controlling drug stimulation of hepatic enzymes
Stimulation of hepatic microscmal drug metabolising enzymes has been 
observed in all mammalian species including man, and is dose-dependent 
(Breckenridge et al, 1973) but the response is highly variable, 
depending on the agent used, species, strain and sex of animal 
studied, and its hormonal and nutritional status (Conney, 1967). In 
addition the ambient temperature and circadian rhythm can play a role 
in defining the response of microsomal enzymes to enzyme inducing 
agents. (Food, Cosmet, Toxicol, 1970) As a generalisation, the 
higher the intrinsic rate of drug metabolism in a given species, the 
greater the dose required to stimulate drug metabolising enzymes 
(Remmer, 1970).
Clinical studies have been limited by the difficulties in assessing 
hepatic enzyme activity in man, and the number of drugs presently 
recognised as being clinically important enzyme inducers is 
relatively small and almost certainly incomplete (Chapter V). In 
addition genetically determined individual variations in the magnitude 
of response to these drugs in man appear to be important, as shown by 
inconsistent responses to standard doses of inducing agents (Whittaker 
& Evans, 1970), and also by twin studies which have demonstrated large 
genetically detemined differences in the inductive response to 
phenobarbitone (Vesell & Page, 1969). Interestingly, the greatest 
inductive responses occurred in those subjects with the longest drug 
half-lives before administration of the inducing agent.
The majority of lipid soluble compounds metabolised by the microscmal 
mixed function oxidase system (and sane that are not, such as alcohol 
and barbital) are potential stimulators of drug metabolising enzymes. 
However clinically important hepatic enzyme induction appears to be 
limited to lipid soluble compounds with a long half-life, low 
hepatic extraction, and which achieve intracellular concentrations 
capable of initiating enzyme induction when given in usual 
therapeutic doses (Remmer, 1970).
(c) Morphological and Biochemical aspects
The exact mechanism responsible for the increased synthesis of 
microscmal enzymes after administration of drugs is still obscure, 
but the morphological and biochemical changes accompanying this 
adaptive response have been investigated. Administration of pheno­
barbitone to an experimental animals results in proliferation of 
the hepatic endoplaanic reticulum (visible with the electron 
microscope) and concomitant hypertrophy of the liver (Remmer & Merker, 
1963). These morphological changes are accompanied by a co-ordinated 
sequence of biochanical events associated with an increase in 
phospholipid and protein moieties of the endoplasmic reticulum. The 
earliest change observed in rat liver is an increase in total 
microscmal protein synthesis, maximal at 3-4 hours after pheno­
barbitone injection (Kuriyama et al, 1969). This suggests the 
establishment of a primary membrane on which subsequently induced 
enzymes are deposited. Within 4-6 hours (in the rat) an increase in 
the activity of ^ amino-laevulinic acid synthetase, the rate 
controlling enzyme in haem synthesis, is detectable and becomes 
maximal at about 12 hours. This response is followed in turn by 
increased haon synthesis, and is assumed to provide the additional 
haen necessary for increased synthesis of haemoproteins, and in 
particular for cytochrome P450 which accounts for more than 80% of the 
haem synthesised by induced liver cells (Meyer & Marver, 1971). A 
maximum increase in cytochrome P450 is seen 24 hours after a single 
injection of phenobarbitone in the rat, and if drug treatment is 
continued, a further increase in cytoclrrcme P450 occurs until a new 
steady state is reached within 4-5 days with levels about three to four 
times above pretreatment values (Tephly, Hasegawa & Baron, 1971).
Increase in cytochrone P450 concentration is accompanied by 
stimulation of NADPH cytochrone c reductase (Ernster & Orrenius, 1965 ) 
and an increased rate of both glucuronide formation (Zeidenberg et 
al, 1967) and overall drug metabolism in vitro (Bums & Conney, 1965). 
Drugs which stimulate the activity of hepatic microsomal drug 
metabolising enzymes tend to be type I compounds, and (like 
phenobarbitone) generally have a non-specific effect in that they 
increase not only their own metabolism, but also that of many other 
unrelated compounds. This ability of a large number of single drugs 
to stimulate the rate of metabolism of a host of other unrelated 
compounds stems from the apparent lack of substrate specificity of 
the cytochrome P450 dependent enzyme system. In contrast seme of the 
carcinogenic polycyclic hydrocarbons show considerable specificity 
(Conney, 1967). A possible explanation for this specificity is that 
polycyclic hydrocarbons cause a selective increase in the synthesis 
of a specific species of cytochrome (P448) which participates in 
only a limited number of detoxification reactions (Chapter I).
(d) Regulation of hepatic drug metabolising enzyme activity
Enzyme levels in manmalian cells are regulated by three mechanisms : - 
activation which involves conversion of a pre-existing biologically 
inactive protein (zymogen) to an active form (for example conversion 
of pepsinogen to pepsin) and does not require synthesis of new 
protein; stabilisation which affects the level of enzymes by 
regulating their rate of breakdown - a diminished rate of degradation 
resulting in an absolute increase in enzyme concentration (Schimke et 
al, 1965), and induction or de novo protein synthesis vbich increases 
the rate of formation of protein, usua].ly in response to a specific 
stimulus.
According to the theory of Jacob and Monod, (derived from study of 
bacterial protein synthesis) the control of protein synthesis by 
induction is mediated by Inactivation of a normal regulatory genetic 
repressor of protein synthesis (i.e de-repression). Drugs appear to 
affect the level of hepatic proteins and enzymes involved in 
biotransformation by at least two of these mechanisms. Studies of
the kinetics of isotopically labelled precursors and the use of 
inhibitors that interfere with various steps in protein synthesis 
have shown that phenobarbitone increases microsomal phospholipid 
by stabilisation (Holtzman & Gillette, 1968; Stein & Stein, 1969) 
while microsomal cytochrome P450 is augmented by de novo protein 
synthesis (Arias et al, 1969; Greim & Renmer, 1970). However NADPH 
cytochrome c reductase seems to be increased by both stabilisation 
and induction (Jick & Shuster, 1966; Kuriyama et al, 1969).
(3) EVALUATING THE ACTIVITY OF THE HEPATIC MICROSOMAL ENZYlViE; . SYSTEM IN MAN
There is growing awareness that a major contribution to inter-person 
variability in response to a fixed dose of many drugs is due to 
differences in individual rates of hepatic biotransformation (Sjoquist 
& Von Bahr, 1973). Among the major factors known to influence the 
activity of the hepatic microsomal drug metabolising system in man 
are genetic make-up, age, sex and various environmental factors, 
including treatment with certain drugs or other foreign chemicals 
(Chapter V). Considerable effort has been spent in recent years in 
investigating the clinical implications of sane of these factors. 
Investigation of the phenonenon of hepatic enzyme induction in 
particular has greatly furthered understanding of certain drug 
interactions, drug detoxification, and the mechanism of action of 
some hepato-toxins. In addition, this important concept has provided 
new and potentially valuable modes of therapy as well as insight into 
the pathogenesis of various metabolic disorders. (Qiapters V & VI)
Blood or plasma concentrations of a drug correlate more closely with 
pharmacological response than does administered dose. As tissue drug 
levels are deteimined by a balance between the rate of drug 
administration and the rate of elimination, quantitation of individual 
differences in drug metabolism assumes clinical importance. Considerable 
success has been achieved in individualising dosage regimens of drugs 
excreted primarily by the k i ^ ^  (Ped^ et al, 1973). This success is 
due to the availability of simple tests of renal function (urea, 
creatinine or insulin clearances) which correlate in a predictable 
manner with the renal clearance of many drugs.
Table 4
MORPHOLOGICAL TEGîmiQHES
Electron microscopy to detect proliferation of hepatic SEE. 
Qualitative - identify enzyme inducing compounds 
Quantitative - morphometry
PHARMACOLOGICAL TECHNIQUES
Qualitative identification of enzyme inducing drugs and the induced 
state in vivo,
i. Alteration in drug effects
(Animals - hexobarbital sleep time; zoxazolamine paralysis. 
Man “ effect on dicoumarol anticoagulation).
ii. Alteration in_pharmacokinetics
Plasma drug kinetics; urinary drug metabolic excretion, 
Quantitation of activity of hepatic microsomal enzjanes in vivo,
i. Use of model compounds (e.g. antipyrine) 
ii. G labelled drugs and CO^ breath analysis.
BIOCHEMICAL TECHNIQUES
In vitro - measurement of hepatic drug metabolism, or components 
of hepatic mixed function oxidase system (e.g. p 450)*
In vivo - measurement of endogenous products of hepatic metabolism,
i. Plasma gamma glutamyl transpeptidase (g GT) activity.
ii. Urinary 6B hydroxycortisol excretion
iii. Urinary ascorbic acid or D-glucaric acid excretion.
Methods of evaluating the activity of hepatic microsomal enz^mies in 
man and laboratory animals.
However, the lack of suitable techniques for assessing Myer 
microsomal activity in man has hampered quantitative studies of 
drugs eliminated primarily by hepatic metabolism. Most studies on 
hepatic enzyme induction have been limited to experiments on 
animals using techniques inappropriate to clinical investigation, and 
with findings which may not be applicable to man (Conney, 1967;
Remmer, 1972). Indeed it has been stated that one of the urgent needs 
of medical research is " the development of methodology ...for 
measuring changes in drug metabolism in patients that could be used as 
readily as the common tests that are now used to examine liver 
function" (Committee on Problems of Drug Safety of the National 
Academy of Sciences) This section of the thesis attempts a critical 
review of the currently available methods for assessing qualitatively 
or quantitatively the activity of the hepatic drug metabolising 
enzymes, with special reference to the clinical detection of hepatic 
enzyme induction and the identification of enzyme inducing agents.
The techniques available can be classified, into three categories: 
Morphological; Pharmacological; and Biochemical (Table 4 ). Methods
available within each category will be outlined, together with some 
examples of their practical application in clinical studies, and a 
brief assessment of their assets and limitations.
(a) Morphological techniques
Examination of the hepatic parenchymal cell under the electron 
microscope reveals proliferation of the smooth surfaced endoplasmic 
reticulum (S.E.R) in animals treated with phenobarbitone (Remmer & 
Merker, 1963). Other non-specific inducers of liver microsomal 
enzymes such as tolbutamide, nikethamide, chlordane and DDT also 
cause proliferation of the endoplasmic reticulum (Conney, 1967), 
However the carcinogenic polycyclic hydrocarbons, which show 
considerable specificity as inducers, have a rmich smaller effect on 
this organelle (Fonts & Rogers, 1965).
In clinical studies the value of this morphological approach is 
restricted by ethical and practical considerations which limit the 
availability of liver biopsy material.
Where clinical indications have permitted biopsy, electron microscopy 
of liver tissue has shown typical proliferation of S.E.R. (and thus 
presumptive evidence for hepatic enzyme induction) in children 
treated with barbiturates (Thaler et al, 1972) after rifampicin and 
diazepam therapy (Jezequel et al, 1971; 1974), chronic alcohol 
ingestion (Rubin & Lieber, 1971) and interestingly, during pregnancy 
(Perez et al, 1971). Schaffner & Popper (1969) have speculated that 
hypertrophy of the smooth endoplasmic reticulum might under certain 
circumstances be associated with hypoactivity of microsomal enzymes, 
for example during certain stages of viral hepatitis. However, there 
is little evidence that hypertrophy of the S.E.R. is ever dissociated 
from increased in vitro activity of the hepatic microscxnal drug 
metabolising enzymes.
While electron microscopic detection of proliferated hepatic S.E.R. 
can provide a qualitative index of induction of hepatic microsomal 
enzymes, observer variability in detecting and quantitating these 
changes is a major problem. Inability to quantitate changes may be 
partially overcome by the use of morphometric techniques (Weibel et 
al, 1969; Jezequel et al, 1974). However these are time consuming, 
technically demanding, and require specialised equipment.
(b) Pharmacological techniques
Various simple phaimacodynamlc and pharmacokinetic tests have been 
utilised experimentally to identify possible enzyme inducing compounds 
(or to infer the presence of hepatic enzyme induction) in man and to 
quantitate the in vivo activity of the liver microsomal drug 
metabolising system.
i) Identification of enzyme inducing drugs and the induced state.
- alteration in drug effect. Hexobarbital ( a short acting barbiturate 
sedative) and zoxazolamine (a muscle relaxant) are useful test drugs 
for screening potential inducing agents in experimental animals because 
their duration of action is regulated largely by the activity of 
hepatic microsomal enzymes.
Most inducing agents decrease the action of one or both drugs. For 
screening purposes it is necessary to study both, since the 
polycyclic hydrocarbons selectively accelerate the metabolism of 
zoxazolamine, while both test drugs are metabolised more rapidly after 
treatment of an animal with one of the non-specific inducers such 
as phenobarbitone (Conney, 1967). Measurement of sleeping time 
(return of righting reflex) after hexobarbital, and duration of 
paralysis following zoxazolamine correlate well with in vitro drug 
metabolising activity. Pentobarbital, another short acting sedative, 
may be used in place of hexobarbital (Borzecella & Manthei, 1957; 
Breckenridge et al, 1971). In a similar way, reduction in the 
intensity of coumarin anticoagulation has been used to identify 
indirectly those compounds vhich can cause clinically irnportant 
induction in man. Interactions between enzyme inducing drugs and 
coumarin anticoagulants (which are also metabolised by microsomal 
enzymes - Ikeda et al, 1968) are cannon, therapeutically important, 
and relatively easy to detect as both the pharmacological action 
and plasma concentration of the coumarins can be measured (Koch- 
Weser & Sellers, 1971). When induction of enzymes that metabolise 
coumarin anticoagulants occurs, the metabolism of these drugs is 
accelerated, their plasma half-life is shortened and their total 
and free concentrations in plasma decrease. The resulting change in 
half-life and decreased anticoagulant effect reflects the degree of 
enzyme induction caused by the suspected inducing agent. This increase 
in the rate of coumarin metabolism following administration of an 
inducing drug has been shown to be reproducible (Breckenridge &
Orme, 1971), but there is considerable inter-person variability in the 
degree of inducibility of in vivo metabolism, whicli may be largely 
genetically determined (Vesell & Page, 1969).
The administration of therapeutic doses of many drugs, including 
barbiturates, diphenylhydantoin, griseofulvin, glutethimide and 
dichloralphenazone has been shown to increase coumarin metabolism 
and thus they are considered to be inducers of hepatic drug 
metabolising enzymes in therapeutic doses (Breckenridge et al,1971; 
Aggeler & O'Reilly, 1969; Catalano & Cullen, 1966; Cucinell et al, 
1965; MacDonald et al, 1969).
This indirect technique for testing whether drugs are clinically 
important hepatic enzyme inducers has a number of limitations.
Because of the well known inter-individual differences in drug 
metabolism (Vesell & Page, 1969; Sjoquist & Von Bahr, 1973) it is 
usually necessary to study the same individuals before and after 
administration of the drug under investigation. Where such a 
paired comparison is not possible, large numbers of subjects may 
have to be studied. If the end point to be studied is a change in 
the steady state level or pharmacological effect of coumarin, 
observations may have to be extended over many weeks (Breckenridge 
et al, 1971) with the inconvenience of multiple venepunctures, and 
uncertainty regarding patient coopliance in taking the test 
medication. Furthermore, use of anticoagulant drugs is not without 
hazard. Although the concomitant administration of vitamin K will 
lessen the risk of bleeding without altering coumarin metabolism 
(O'Reilly et al, 1962), the ability to follow clotting parameters 
is lost. Recent work has demonstrated the complexity of interactions 
involving warfarin and has revealed another major difficulty in using 
changes in coumarin kinetics or phaimacologica]. effects as a 
clinical test of hepatic enzyme induction. (Lewis et al, 1974) After 
administration of phenylbutazone, instead of simple displacement of 
warfarin followed by enzyme induction as expected, the drug was 
found to have opposite effects on the metabolism of the R and S 
enantiomers of warfarin. Phenylbutazone caused a more rapid rate of 
disappearance of R, while slowing the disappearance of S. Since the 
enantioners of warfarin have different pharmacological potencies, 
(SJSR), the net result is usually an increased anticoagulant effect. 
The significant differences in the metabolism of the R and S isoners 
suggests that warfarin is not an ideal drug for use in studies of 
enzyme induction.
- alterations in drug kinetics.
(i) Plasma drug studies:
Another indirect measure of changes in hepatic microsomal drug 
metabolising activity can be provided by demonstrating an alteration 
in the rate of plasma disappearance (or steady state level) of a 
suitable test drug.
Such a drug must of course be metabolised by liver microscxnal 
enzymes, and be sensitive to changes in the activity of these enzymes. 
Thus a suitable test drug should have a low hepatic extraction ratio- 
that is to say its clearance must be limited by the capacity of 
hepatic microsomal enzymes, and be unaffected by changes in hepatic 
blood flow (Gillette, 1971).
Antipyrine, a non-toxic anti-pyretic agent which is well absorbed 
orally and distributes into total body water, has some of these 
properties. It is not appreciably bound to plasma proteins nor 
excreted unchanged by the kidney (Soberman et al, 1949), has no 
stereo-isomers, and is eliminated by hepatic metabolism. In addition 
antipyrine is relatively easily measured and so has been widely used 
to investigate factors regulating drug metabolism. Furthermore it can 
be measured in saliva, allowing kinetic studies to be perfoimed 
without the necessity for repeated venepunctures.
Antipyrine has been widely used in clinical studies of hepatic 
microsomal enzyme activity. These have included studies investigating 
the effect of physical stress, thyroid function, and chronic renal 
failure on hepatic drug metabolism, and the role of genetic factors 
in controlling hepatic enzyme induction (Vesell & Page, 1969). In 
addition the metabolism of antipyrine and phenylbutazone have been 
used as indices of microsomal activity in studies investigating the 
effect of chronic exposure to DDT in workers manufacturing the 
insecticide (Kolmodin et al, 1969; Poland et al, 1970), and the effect 
of oral contraceptives (O'Malley et al, 1972; Carter et al, 1974) and 
of various hypnotics (Stevenson et al, 1972) on hepatic microsomal 
function. These agents have also been used to study the effect of 
concomitant therapy with enzyme inducing drugs on microsomal enzyme 
function in patients with liver disease (Levi et al, 1968) as well 
as. in the investigation of the effect of various potential enzyme 
inducers on coumarin metabolism (Breckenridge et al, 1971).
The importance of genetic factors in explaining individual differences 
in the rate of plasma disappearance of drugs metabolised by hepatic 
microsomal enzymes is now well established (Vesell, 1972; 1975), but 
it is not clear whether the metabolism of different drugs is under 
separate regulatory control (Poland et al, 1970).
Although an excellent correlation has been demonstrated between the 
degree of change in plasma warfarin levels and change in half-life 
of antipyrine after administration of an enzyme inducing drug 
(Breckenridge & Qrme, 1971), cross over studies of the in vivo 
metabolism of two or more drugs in the same individual have shown 
poor correlations between drugs of different classes (Sjoquist &
Von Bahr, 1973; Davies et al, 1973). Antipyrine appears to be a more 
suitable test drug than phenylbutazone, as the latter is less 
sensitive to alterations in drug metabolising capacity in man 
(Stevenson et al, 1972; Carter et al, 1974). In addition phenylbutazone 
carries a small but definite risk of hypersensitivity reactions.
The pharmacokinetic approach to the clinical study of alterations in 
hepatic biotransformation is limited by the considerable inter­
individual genetic differences in drug metabolism and response to 
enzyme inducing agents (Vesell & Page, 1969; Whittaker & Evans, 1970). 
Consequently there is overlap in kinetic parameters between "induced" 
and control populations. This necessitates a paired conparison of 
subjects studied before and after administration of the drug under 
investigation, or where this is not possible, the accumulation of 
data from relatively large numbers of control and test subjects. The 
method also has the practical disadvantage of requiring multiple 
venepunctures and plasma drug level analyses. Moreover, a theoretical 
objection is the possibility of competitive inhibition of the test 
drug by the potential inducing agent, particularly when the latter 
has a higher affinity for the non-specific microsomal enzyme system 
than the test drug (Stitzel et al, 1968; Gillette, 1971; Reraner et al, 
1973). In this connection, the time chosen for phaimacolcLnetic 
testing in relation to administration of the drug under investigation 
may be critical (Rarmer et al, 1973). In addition, alternative 
explanations for observed changes in drug half-life (such as alteration 
in Vd or in protein binding) should also be considered when interpreting 
the results of such studies.
- alterations in drug Kinetics.
(ii) Urinary metabolite excretion patterns:
Measurement of the total urinary excretion of the oxidative metabolites 
of a drug, which reflects the activity of the hepatic mixed function 
oxidase system, may also provide an index of hepatic microsomal activity,
The criteria outlined earlier for the choice of an ideal test drug 
for plasma pharmacokinetic studies also apply, and an additional 
requironent in urinary studies which measure absolute amounts of 
drug or metabolite is that the drug administered should be 
ccxipletely absorbed (or given intravenously) otherwise comparison 
of urine data is invalid. Special pharmacokinetic techniques are 
available for deriving drug elimination rate constants from 
cumulative urinary excretion measurements. This however conplicates 
the collection and analysis of data, and limits its application 
to co-operative subjects.
A number of animal and human studies have utilised measurement of 
the urinary metabolites of dipyrone, a soluble derivative of 
aminopyrine (Reamer, Schoene & Fleischman, 1973; 1973A). In clinical 
studies this drug was administered orally, and the urinary excretion 
of its major oxidative metabolite, 4-amino-antipyrine, determined 
over a six hour period. These studies showed considerable inter-person 
variability in the excretion of the metabolite (possibly due to 
individual differences both in absorption and metaboliam of the parent 
drug). As excretion of 4-amino-antipyrine was reasonably constant 
for a given individual, increased urinary metabolite excretion was 
regarded as signifying enhanced hepatic drug oxidation. However, 
little or no augmentation of 4-amino-antipyrine excretion occurred 
when dipyrone was given concomitantly with an inducing drug, despite 
significant elevation in the hepatic concentration of cytochrome P450, 
a central and readily induced component of the mixed function oxidase 
system. This anomalous finding was considered to result from 
competition for microsomal enzyme binding sites between dipyrone and 
the inducing drug, as increased metabolite excretion was found vjhen 
the test was repeated shortly after withdrawal of the inducing drug. 
Competition between test drug and inducing agent is thus likely to 
produce misleading results in pharmacokinetic tests of hepatic 
enzyme activity, particularly in the investigation of enzyme induction 
in subjects ex^ xased to environmental inducers or on continuing drug 
therapy. These considerations, together with the potential risk of 
agranulocytosis from dipyrone, the critical requirement for accurately 
timed and complete urine collection, relatively small changes in 
4-amino-pyrine excretion, and the necessity for paired studies, would 
seem to seriously limit the usefulness of this procedure.
other test drugs may prove more suitable, and pharmacokinetic 
analysis of cumulative excretion data could provide a more 
sensitive index of changes in hepatic drug metabolising activity 
than measurement of the total excretion of metabolites over an 
arbitrary period. An example of this type of approach was a study 
of the cumulative urinary excretion over 8 days of metabolites of 
14 C Warfarin (as a percentage of the total administered dose) in 
two subjects, before and during the administration of a inducing 
drug (antipyrine). There was considerable variation between the two 
subjects, but the rate of excretion of radioactivity was greater 
after administration of antipyrine (Breckenridge et al, 1971).
Identification of agents capable of causing enzyme induction and of 
patients in whom enzyme induction has taken place represents a 
separate area from attempts to quantify an individual's capacity to 
eliminate drugs. The preceding sections dealt with the former problem, 
while the next section is concerned with pharmacological techniques 
designed to quantitate drug metabolism in individual patients.
ii) Quantitative methods of assessing microsomal activity in vivo
The wide inter-individual differences in rates of elimination of 
drugs metabolised by the liver, which for some drugs can exceed a 
thirty fold range, has already been emphasised (Sjoquist & Von Bahr, 
1973). For this reason it might be desirable to know the rate of 
elimination, or more precisely the plasma clearance,of a drug in a 
given patient. Then, individualised dosage regimens could be 
designed to attain and maintain any desired blood or plasma 
concentration of the drug. Ability to precisely individualise drug 
therapy may be very important for drugs with narrow therapeutic 
ratios or serious toxicity, or when it is necessary to achieve 
efficacious blood levels rapidly for a drug with a prolonged half- 
life and small margin of safety. The most obvious means for determining 
the disposition of a particular drug in an individual patient is to 
administer that drug, measure blood levels over time, and determine 
the kinetic parameters. However, for seme drugs this approach may 
not be possible, either because the drug cannot be measured in plasma, 
or because insufficient time is available for such a study.
For these reasons it has been felt that it would be useful to have 
a laboratory test involving the administration of a model drug, the 
results of which could be used to predict the plasma clearances of 
other drugs eliminated by microsomal metabolism in an individual 
patient.
- model compounds
The useful properties of antipyrine have led to the wide use of this 
drug as a model compound in pharmacokinetic studies. However this 
approach has met with only limited success, Davies et al (1973) were 
able to show that although there was a poor correlation between 
antipyrine half-life and phenylbutazone half-life when both were 
given as a single dose, the correlation was excellent when 
phenylbutazone was continued for 5 days. The reason for this discrepancy 
is not understood. In this same study there was a fairly good 
correlation in 4 subjects between antipyrine half-life in vivo, and 
ethylmoiphine N-demethylase activity in vitro, but no correlation 
was apparent between the drug half-life and P450 reductase or 
cytochrome c reductase activities. Vesell and co-workers were unable 
to demonstrate a correlation between antipyrine half-life and 
dicouraarol half-life, although such a relationship appeared to exist 
between phenylbutazone and dicoumarol (Vesell & Page, 1969), Kadar . 
et al (1973) in a crossover study using four drugs hydroxylated by 
the liver microsomal enzyme system - antipyrine, amobarbital, 
sulfinpyrazone and glutethinmide - were also unable to find any 
correlation between antipyrine half-life and the half-life of any 
of the other three drugs. However, positive correlations were 
demonstrated between the remaining pairs of three drugs.
Although seme investigators have reported correlations of 
antipyrine clearance or half-life with clearances or half-lives 
of other drugs (Symposium on " Assessment of Drug Metabolism in 
man - methods and clinical applications " Dundee, March 1974) many 
others have reported poor correlations between antipyrine and 
other drugs both in normal subjects and in patients with liver disease. 
It is becoming more apparent that many factors other than specific 
enzyme activity control the rate of metabolism of drugs in vivo 
(Chapter I).
TWO of the most important of these seem to fee alteration in the 
protein binding of drugs (both tissue and plasma protein binding), 
and in liver blood flow. Until it is possible to define the rate- 
limiting steps for certain classes of drugs, it would appear that 
the use of model compounds will be unsatisfactory.
The blood or plasma half-life of a drug, the index which has been 
most frequently used in making comparisons between drugs, is itself 
affected by two other variables - clearance and volume of distribution 
(Vd). Since the volume of distribution of a drug is independent of 
the rate of its metabolism, clearance is the preferred index. It 
should be emphasised however that plasma clearance is the sum of 
renal and metabolic clearance. Even when metabolic clearance is 
calculated it may not be entirely hepatic, and it also is an 
indirect estimate of hepatic microsonal activity since the rate- 
limiting step in the metabolism of any drug will still determine its 
clearance.
- C labelled drugs and COg breath analysis.
Another approach to the quantitative assessment of hepatic microsomal
enzyme activity in vivo is the measurement of radioactive C0„ in expired
14air. The technique is analogous to the C glycocholic acid breath
test used to demonstrate bacterial deconjugation in the gut (James et
al, 1973). The basis of the method is the selection of an appropriately
labelled drug which liberates during metabolism by the liver. In
14rats the rate of exhalation of 00„ has been used to calculate
14déméthylation rates of 4- dimethyl - C aminoant ipyr ine (aminopyrine) 
after intravenous administration. Excellent correlations were found 
when this method was compared with simultaneously determined plasma 
disappearance curves. Increased déméthylation rates could be detected 
after induction by phénobarbital and decreased rates after partial 
hepatectomy (Lauterburg & Bircher, 1973).
14Recently a similar but technically sinpler technique using C
aminopyrine has been tested in man. Using interval rather than total
COry breath collection, a strong correlation was demonstrated between
14serum aminopyrine half-life and 12 hour breath output.
14Differences in plasma aminopyrine half-lives and COg output could
also be demonstrated in patients with hepatic dysfunction, and after
phénobarbital or disulfiram pretreatment. Correlations were also
found between output and antipyrine plasma half-lives, and
14still obtained when tracer rather than usual doses of C aminopyrine 
were used (Hepner & Vesell, 1974), Similar results in normal volunteers 
and patients with liver disease have been reported using 
dimethylaminoant ipyr ine (Gikalov et al, 1975).
The advantage of this technique is that it is non-invasive to the
patient and relatively simple to perform. However breath analysis is
also subject to the same limitations mentioned earlier for pharmacokinetic
tests involving model compounds; namely that different drugs seem to
have different rate-limiting factors influencing their hepatic
clearance. Moreover it has not yet been reported whether correlations
exist between COg output and the hepatic clearance of other drugs.
14A further disadvantage of the OOg breath analysis technique as it
has thus far been applied is that it appears to be less quantitative
than plasma drug assay techniques. This is most likely due to the use
of interval samples, since OOg output may vary with time, and the use
of estimated rather than measured total OOg output, for calculating the 
14 C specific activity of the expired OOg. Despite these limitations 
the technique has much premise and deserves further investigation.
(c) Biochemical techniques
All the techniques to be described in this section have as their primary 
function the identification of compounds which may act as inducers of 
hepatic microsomal enzyme activity, or of patients in whom an induced 
state may exist. Although widely utilised in research studies, none 
is particularly useful for the clinician in adjusting therapy. They 
do have both advantages and disadvantages when compared with 
morphological and pharmacological techniques previously mentioned, and 
these will be discussed.
i) Measurenent of components of the hepatic mixed function oxidase 
system in vitro.
The most direct test of whether a compound induces drug metabolising 
enzymes is of course to assay the activity of hepatic drug metabolising
enzymes in treated animals with suitable drugs as substrates. A 
great many drugs and foreign compounds tested in this way have been 
foundto stimulate the activity of hepatic microsonal enzymes (Conney, 
1967) while others such as components of commercial diets (Brown 
et al, 1954) insecticides (Hart et al, 1963) and cedar-chip bedding 
material (Ferguson, 1966) have been discovered fortuitously. ,
Analysis of the hepatic concentration of cytochrome P450 may be a 
more generally useful test for enzyme induction than assay of overall 
drug metabolising activity, since the concentration of this carbon 
monoxide binding haemoprotein is easily measured in liver microsome 
suspensions (Qnura & Sato, 1964), and increases after treatment with 
all stimulators of drug metabolism including the polycyclic hydro­
carbons which are rather selective inducers of drug metabolising 
activity.
Direct assay of the components of the hepatic mixed function oxidase 
system (such as cytochrome P450 concentration) or of overall drug 
metabolising activity in human liver tissue is clearly limited by 
ethical and technical considerations. However a number of reports 
have demonstrated directly the stimulating effect of drugs on human 
liver microsomal enzymes, using tissue obtained either by surgical 
or percutaneous needle liver biopsy. Higher values for the hepatic 
concentration of cytochrome P450 and enhanced activity of bilirubin 
UDP-glucuronyl transferase were found in patients who had received 
phenobarbitone or other medication prior to upper abdominal surgery 
(Billing & Black, 1971). Administration of phenobarbitone lOmg/kg 
daily for 5 days increased activity of NADPH cytochrome c reductase 
(that component of the mixed function oxidase system which is 
considered to be rate-limiting in microsomal drug metabolism) assayed 
in needle biopsy specinens from 5 of 8 children studied. (Thaler et 
al, 1972).
Percutaneous needle biopsies generally yield only around 20 to 40 mg, 
of liver tissue, but recently micromethods have been developed which 
allow determination of cytochrome P450 content in addition to the 
activity of NADPH cytochrome C reductase and certain other enzymes 
in homogenates prepared from less than 20 ngs of liver (Schoene et al, 
1972).
Induction of cytochrome P450, as well as increase in the rate of drug 
tp- nitroanisole) hydroxylation in vitro (but not of glucose - 6 - 
phosphatase or pseudocholinesterase, enzymes which are also located 
on the endoplasmic reticulum) were found in subjects taking 
rifampicin and phenytoin in therapeutic doses. Although large inter­
individual differences in in vivo drug metabolism in man are well 
recognised, surprisingly small inter-individual differences have 
been found in the concentration of cytochrome P450 and in vitro 
rates of metabolism of sane ccnmonly used substrates using human 
liver biopsy material (Billing & Black, 1971; Schoene et al, 1972). 
This finding again emphasises the Importance of non-enzymatic factors 
in drug metabolism, and may partly ezglain the poor correlation which 
exists between drug oxidation in vivo and in vitro (Sjoquist & Von 
Bahr, 1973).
Apart from the practical and technical difficulties encountered 
when working with human liver biopsy material, caution must be 
exercised when enzyme activities measured in milligram amounts of 
biopsied liver are extrapolated to an organ weighing many grams. In 
laboratory animals enzyme activities derived from assay of small 
samples of liver may not be representative of the entire organ, and 
significant variation has been found when sampling from different 
lobules (Pouts, 1973). This variation may be caused by structural 
differences in the composition of the liver biopsy ( for example, 
in the relative amounts of fibrous and parenchymal tissue). In 
addition, there may be a genetic ejqjlanation for sample variation. 
Under certain circumstances the liver may contain a mosaic of two 
populations of cells, with one predominating in the liver as a 
whole or in a certain anatomical area. Thus samples from one area 
may differ considerably in activity from those from another area 
(Conn, 1973),
Clearly hepatic enzyme activity measured by a test reflecting the 
functional capacity of the whole organ would be advantageous. Three 
such tests, all involving measurement of endogenous products of 
hepatic metabolism, have been proposed as indirect measures of 
hepatic microsomal enzyme function.
il) Measureioent of endogenous products of hepatic metabolism.
- Plasma gamma glutamyl transpeptidase activity (GGT)
This enzyme is formed in several tissues including liver, Icidney 
and prostate. Administration of hepatic microsomal enzyme inducing 
agents has been shown to result in elevation of Œ3T activity in a 
number of patients, in some of whom a relationship appears to exist 
between the extent of alterations in enzyme activity, and changes in 
rates of drug oxidation (Rosalki et al, 1971; Whitfield et al,1973). 
However exceptions occur sufficiently frequently to make assay of 
plasma GGT activity an unreliable index of alterations in hepatic 
biotransformation. Tiie theoretical basis for these changes in GGT 
activity is obscure, and furthermore elevated plasna activity of 
this enzyme occurs with hepatocellular damage, and may also be 
seen following administration of drugs which do not alter rates of 
drug oxidation.
Urinary ^  hydroxycortisol excretion
Endogenous compounds, such as steroids, and bilirubin, as well as 
drugs, are metabolised by the same non-specific microsomal mixed 
function oxidase system. Compounds that stimulate microsomal drug 
metabolian also stimulate the hydroxylation of steroids in animals 
and man (Conney, 1967; Kuntzman et al, 1968). 6^ hydroxy cort isol 
is a polar metabolite of cortisol produced by the microsomal 
hydroxylation of cortisol in the 6^ position. The urinary excretion 
of this cortisol metabolite is stimulated by various drugs such as 
phenobarbitone (Burstein & Klaiber, 1965; Brooks et al, 1972), phenytoin 
(Werk et al, 1964) and phenylbutazone (Kuntzman et al, 1966). In 
experimental animals these same drugs have been shown to stimulate 
the hepatic microsomal enzyme system responsible for metabolising 
cortisol. Chronic administration of a non-hypnotic barbiturate (N - 
phenylbarbital) to volunteer subjects caused a greater than three-fold 
increase in the urinary excretion of 6^ hydroxycortisol, without 
affecting the excretion of urinary 17 hydroxycorticosteroids. This 
would indicate that the increased 6p hydroxycortisol excretion did 
not result simply from an increased adrenal output of cortisol 
(Kuntzman et al, 1968).
Increase in the urinary excretion of this cortisol metabolite 
has been used as a measure of increased hydroxylating capacity of 
the hepatic endoplasmic reticulum, and thus as evidence of 
induction of hepatic microsonal enzymes in a number of clinical 
studies. Significant increases in both Qp hydroxcortisol excretion 
and phenylbutazone metabolism have been reported in workers exposed 
to organachlorine insecticides (Poland et al, 1970; Jager, 1970) 
which are potent enzyme inducers in animals. However no correlation 
was found between the rate of phenylbutazone disappearance and Gp 
hydroxycortisol excretion in these subjects. This may not be 
surprising, since endogenous steroid output probably differs 
considerably between subjects. In another report a two to three fold 
increase in ^  hydroxycortisol excretion after administration of 
therapeutic doses of antipyrine and dichloralphenazone was 
inteipreted as indirect evidence of enzyme induction (Breckenridge 
et al, 1971). In their study the number of subjects was limited, and 
no correlation with other tests of activity of drug metabolising 
enzymes was reported. Smaller but again significant increases in both 
the total excretion of Qp hydroxycortisol and the ratio of 6p  
hydroxycort isol to total 17 corticosteroids were reported in an 
investigation of changes in human drug metabolism after long term 
exposure to various hypnotics in subjects taking standard doses of 
amylobarbitone and the non-barbiturate hypnotic diphenhydramine- 
methaqualone (Mandrax). A significant decrease in the plaana 
antipyrine half-life was also found with the use of these drugs.
Again it was not stated whether a correlation existed between antipyrine 
half-life and 6p hydroxycortisol excretion (Stevenson et al, 1972). 
However, Smith et al (1972) were unable to find any correlation between 
the plasma half-life of antipyrine, warfarin or phenylbutazone, and 
the daily urinary output of ^  hydroxycortisol or D-glucaric acid.
Nor was there any significant relationship found between the 
excretion of §B hydroxycortisol and the metabolism of glutethimide, 
amobarbital, antipyrine or sulfinpyrazone in another clinical study 
(Kadar et al, 1973).
There is no evidence that the urinary excretion of this endogenous 
metabolite correlates well enough with an individual's ability to 
metabolise drugs to be useful as a clinical guide to therapy (Sjoquist 
& Von Bahr, 1973).
However the theoretical basis of the test as an index of hepatic 
enzyme induction seems reasonably well established. The absence 
of change in total urinary oxogenic steroid excretion following 
administration of inducing drugs suggest that increased 6p  
hydroxycortisol excretion represents enhanced microsomal cortisol 
hydroxylation rather than increased cortisol secretions due to 
drug administration. Unfortunately there is overlap between "induced" 
and normal values, and measurement of ^  hydroxycortisol is 
somewhat time consuming as it involves successive extractions of 
the polar metabolite followed by paper chromatography (Kuntzman 
et al, 1968; Thrasher et al, 1969). However the test does have the 
advantage of patient acceptability, as it is non-invasive and avoids 
the potential hazards associated with tests requiring the 
administration of drugs.
- Urinary ascorbic acid and D- glucaric acid excretion.
An incidental and unejq)lained observation reported in the study of 
the stimulatory effect of phenytoin on 6p hydroxycortisol excretion 
referred to earlier (Werk et al, 1964) was the finding of 
significantly increased inhibition of p  glucuronidase in vitro by 
urine from subjects receiving the drug. It is now recognised that 
this effect is due to the stimulatory action of drugs on another 
endogenous metabolite, D- glucaric acid, which is an end product 
of glucuronic acid metabolism in man, and a potent inhibitor of p  
glucuronidase.
In fact evidence for the stimulatory effect of drugs on the 
metabolism of carbohydrates via the glucuronic acid pathway in man' 
was first reported almost 30 years earlier when aminopyrine and 
antipyrine were found to elevate the urinary excretion of L-xylulose 
in patients with essential pentosuria (Margolis, 1929; Enklewitz & 
Lasker, 1935). These drugs were also found to stimulate ascorbic 
acid synthesis in the rat (Longenecker et al, 1940). Now a variety 
of drugs and foreign compounds which differ widely in chemical 
structure have been found, to be capable of both increasing the 
activity of drug metabolising enzymes in liver microsomes, as well 
as of stimulating the biosynthesis of L-ascorbic acid from glucose 
through the glucuronic acid pathway (Bums, 1959; Conney & Bums, 1959)
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The urinary excretion of ascorbic acid may be used as an index 
of enzyme induction in rats (Conney et al, 1961) but not in 
primates or guinea pigs. These mammals are unable to synthesise 
vitamin C, and their end product of glucuronic acid metabolism is 
D-glucaric acid rather than ascorbic acid, as is shown in Fig. 2
D-glucaric acid ("acid potentiated inhibitor of B-glucuronidase") 
can be measured quite simply by its specific inhibitory effect on 
p- glucuronidase (Marsh, 1963; Hunter et al, 1971), Since a number 
of drugs have been shown to cause a parallel acce].eration in the 
synthesis of D-glucaric acid and in drug metabolism, an increase in 
the urinary excretion of this endogenous metabolite has been 
proposed as a clinical test for hepatic enzyme induction (Aarts,1965). 
Increased excretion of this metabolite in man has been shown after 
administration of a wide range of drugs known to induce hepatic 
microsomal enzymes including barbiturates, primidone, phenytoin and 
organochlorine pesticides (Hunter et al, 1971; Hunter et al, 1972), 
antipyrine and phenylbutazone (Aarts, 1965), progesterone (Fahlm et 
al, 1969) and high dose oral contraceptives (Mowat, 1968). 
Interestingly during pregnancy D-glucaric acid excretion is also 
elevated (Chapter V). A relationship has been demonstrated between 
the urinary excretion of D-glucaric acid and the total dose of 
various anticonvulsant drugs (measured by a simple scoring system) 
which suggests that excretion of this metabolite, like microsomal 
enzyme induction itself, is a dose-dependent phenomenon. Furthermore 
excretion of D-glucaric acid strikingly increased (up to ten fold) 
after treatment with barbiturates, and correlated well with plasma 
levels of exogenous and endogenous substrates known to be metabolised 
by microsomal enzymes (Hunter et al, 1971; Hunter et al, 1972;
Maxwell et al, 1973).
The urinary excretion of D-glucaric acid parallels natural 
variations in microsomal enzyme activity, being low in the neonate 
and rising with maturity (Hanna et al, 1970) and showing a circadion 
rhythm in the adult similar to that seen in the activity of drug 
metabolising enzymes (Radzialowski & Bosquet, 1968) with peak 
excretion occurring in the afternoon and evening. Increased D- 
glucaric acid excretion in man is detectable as early as 4 to 6 hours 
after administration of an inducing drug, which is similar to the 
time of onset of increased microsomal enzyme activity following
administration of phenobarbitone to experimental animals (Marver & 
Schmid, 1968). In guinea pigs a significant correlation has been 
found between the urinary excretion of D-glucaric acid and the 
total hepatic content of cytochrome P450, Pretreatment of these 
animals with an inhibitor of protein synthesis (Actinomycin D) 
prevented both the rise in cytochrome P450 concentration and in 
D-glucaric acid excretion normally seen in response to phenobarbitone, 
providing evidence that the increased metabolite excretion is due 
to de novo protein synthesis (Hunter et al, 1973).
The glucaric acid pathway is carplex, and both cytosol and 
microsomal enzymes are involved. Glucuronolactonase, a microsomal 
enzyme which catalyses the conversion of glucuronic acid to 
glucuronolactone can be induced (Kawada et al, 1961) but it is 
unlikely to be the critical step since glucuronic acid synthesis - 
(an earlier event) is also readily induced after drug administration. 
UDP glucose dehydrogenase vhich catalyses the foimation of UDP 
glucuronic acid fron UDP-gluçose can also be stimulated by drugs, 
but it is not known whether this is the rate limiting enzyme.
Although the precise mechanism is still unknown, it seems likely 
that drugs 'which stimulate the activity of microsomal enzymes 
involved in hepatic biotransformation also increase D-glucaric acid 
excretion by a similar effect on enzymes of the glucuronic acid 
pathway. An attractive but at present speculative explanation for 
enhanced activity of the glucuronic acid pathway following the 
administration of inducing drugs is that this process is an 
adaptive response occurring in parallel to the induction of microsomal 
oxidative drug metabolising enzymes. Increased activity of this 
pathway may provide additional glucuronic acid for conjugation of 
drugs after they have undergone initial (Phase 1 or oxidative) 
metabolism. In addition, the end product of the pathway (D-glucaric 
acid) provides a natural inhibitor of p-glucuronidase, an enzyme 
which is widely distributed in liver, kidney, and gut (Chatterjee 
et al, 1901). D-glucaric acid may thus have a role in preventing 
deconjugation of drugs (by the ubiquitous p glucuronidase) before 
they can be excreted.
Neither 6p hydroxycortisol nor D-glucaric acid correlate well 
with pharmacokinetic tests used to study hepatic drug metabolising 
activity (Smith et al, 1972). Thus it is unlikely that these 
biochemical tests will prove to be useful as clinical guides to 
individualising drug therapy (Sjoquist & Von Bahr, 1973; Kadar 
et al, 1973). However this does not reflect on their validity as 
tests of enzyme induction, as they both appear capable of 
detecting increased activity of hepatic microsomal enzymes, and 
share the advantages of patient acceptability and safety.
Excretion of D-glucaric acid appears more sensitive to changes 
produced by inducing dru^s than does 6p hydroxycortisol, and has 
the additional advantage of simplicity of assay. More information 
is needed on the regulation of the glucuronic acid pathway, but 
measurement of D-glucaric acid excretion seans to have some 
advantages over other currently available tests in the evaluation • 
of hepatic enzyme activity, particularly in the study of large 
numbers of subjects on continuing drug therapy, or in the 
investigation of the possible effects of environmental inducing 
agents.
IHELÜMCE OF CHHONIC LIVER DISEASE CCIRRHDSIS) ON DRUG METABOLISM
CHAPTER III
(1) INFLUENCE OF CHRŒIC LIVER DISEASE (CIRRHOSIS) ON DRUG METABOLISM
The liver plays a central role in the detoxication of foreign conpounds 
(Chapter I) and impaired drug metabolism is found in animals with 
various forms of liver damage. Partial hepatectomy (Masson & Belaud, 
1945); obstructive jaundice (McLuen & Fouts, 1961); carbon tetrachloride 
administration (Kato et al, 1962); viral hepatitis (Kato et al, 1963) 
and experimental cirrhosis (Marshall & McLean, 1969) have all been 
shown to reduce drug metabolism in laboratory studies.
(a) Clinical Studies
Not surprisingly patients with hepatic cirrhosis have been considered 
to have impaired drug metabolism (Sherlock, 1968). With decreasing 
liver function a reduced elimination rate of drugs metabolised by the 
liver might be expected, but the available evidence is conflicting. 
However, the clinical impression that patients with cirrhosis tolerate 
drugs, especially hypnotics and sedatives, less well than noimal 
subjects has been confirmed by studies showing that morphine (Laidlaw 
et al, 1961) and chloiprcmazine (Read, Laidlaw & McCarthy, 1969) can 
cause changes in the clinical state and EEG wave pattern, particularly 
in patients with impending or overt hepatic coma. As both these drugs 
are transformed to inactive compounds by hepatic microsonal drug 
metabolising enzymes (Yoshimura, 1969; Coccia & West erf eld, 1967) the 
increased sensitivity of cirrhotic patients might be explained, at 
least in part, by impairment of drug metabolising capacity.
Consequently, sedative drugs that are excreted largely unchanged via 
the kidneys, rather than as metabolites, have been recomnended for 
these patients (Sherlock, 1968).
Direct investigation of drug metabolian in cirrhotic patients has 
produced conflicting results (Tables 5 & 8 ). In many of the earlier 
studies no difference from normal could be detected with such varied 
drugs .as pentobarbital (Sessions et al, 1954), phenylbutazone (Weiner 
et al, 1954; Brodie, Burns & Weiner, 1959); chloranphenicol (Kunin et 
al, 1959); alcohol (Lieberman, 1963; Winkler et al, 1969); tolbutamide 
(Nelson, 1964) and digoxin (Marcus & Kapadia, 1964).
Table 5
DRUG AUTHOR ASSAY
PHARMOMINETIC
IZASÜPEMEUTS
1) ALCOHOT. V/einer et 
al (1954)
Micro
diffusion
Metaboiism gm/h
2) Winkler et 
al (1969)
5) i\MIU0PYRI!5 Brodie et 
al (1959)
Spectre
4) ANTIPYRIUE -Brodie et 
al (1959)
Spectre fè
5) CHLORAMPHE^TICOL Kunin et
al (1959)
Biolog.
K
f c
6) CULGUPROMZIUE ÎTaxvæll et
al (1972)
GLC t“l, ksi
7) DICOUMAROL .'Brodie et 
al (1959)
SpGctro tt-
8) DIGOXHT liarcus et
al (1964)
-H-cligoxin tl- plasma, u.rinc, 
faeces
9) PEET03ARRITAL Sessions 'H 
al (1954)
Spectre Plasma levels only 
up to 60 min after 
infusion.
10) ?.TrETHLB[JTAZ0T5 Weiner et 
al (1,954)
Spectre 4^ rate disappearance 
per day.
11) Brodie et 
al (1959)
Spectre t&
12) Kvidber^; et 
al (1974)
Spectre tl, kel
15) SADICYCLIC ACID Brodie et 
al (1959)
Carboxyl 
salicyclic 
acid
ti
.......
14) TOLBTITMUTJE île 13 on (1984) Spectre
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Table 5 (c ont i nue d)
W.
PATIENT DATA 
AETIOL. SEVERITY BIOCHEM
ALTERED
SENSITIVITY?
1) 10 severe Al c g). 101 i c 1 i ver 
disease
9 9
2) 10 severe 4 jaundice
i-'
5) 10 ? 9 9 9
4) 9 9 ? 9 9
5) 11 ? 10 bil t 
5 ascites
? 9
6) 24 Variable Compensated. 4- Yes
7) é 9 9 9 9
8) 5 Alcoholic Jaundiced 4- 9
9) 21 Mostly
alcoholic
Ascites + ?
10) 11 9 "Advanced" 9 9
•Î
11) 11 9 "Severe" 9 9
12) 6 Alcohol 4 
Idiopathic 2 "Variable"
4- 9
15) 8 ? ? 9 9
14) 10 9 "Variable" 4- 9
Table 5 (continued)
CONCOMITANT THERAPY 
DETAILS CO: HINTS
1)
2)
•? Alcohol metabolised largely by non-mi cr os orna 1 
systems*
5) 9
4) 9 "Results suggest that metabolism of certain drugs 
is not affected in Laennec’s cirrhosis,"
5) 9
6) 9 Factors from jaundiced serum may interfere with 
biolog, assay. Imperfect oorrelu ty with bilirub, 
Metab. chloramphenicol essentially normal in 
majority of patients with cirrhosis.
7) 4- Increased sensitivity to sedative effects most 
apparent in those with previous history of PSE,
8) 9
9) 9 Unsatisfactory assay - contribution from inter­
fering substances and pharmacologically inactive
forms. Crude clinical and pharmacokinetic 
assessment.
10) 9 Insufficient sampling.
11) 9 "Severe cirrhosis does not significantly alter 
the rate of phenylbutazone transformation."
12) 9
15) -1- Correlation between kel and galactose elimina­
tion capacity in cirrhotics, tj determined after 
4 days treatment. "Further pharmacokinetic data 
needed. "
14) 9 Assay measures drug and main metabolite. lie 
controls studied (historical controls.)
15)
..... '...... .
■
Levi, Sherlock and Walker (1968) suggested that the maintenance of 
normal drug metabolising capacity in cirrhosis might be due to 
hepatic enzyme induction as a result of concomitant administration 
of other drugs such as barbiturates, anticonvulsants and corticosteroids. 
However in their study no distinction was made between patients with 
cirrhosis and those with acute liver disease. The former group is 
more likely to be receiving continuing drug therapy, while 
experimental production of acute hepatitis has been shown to result 
in definite impaixment of drug metabolism.
(b) In Vitro Studies of drug metabolism by cirrhotic liver
Measurement of the activity of drug metabolising enzymes in liver 
biopsies from patients with cirrhosis has demonstrated a reduction in 
the content of cytochrome P450, together with a lowering of the 
demethylating activity of drug metabolising enzymes (Schoene et al,
1972). This approach is limited by the sample variability characteristic 
of cirrhotic liver (Soloway et al, 1971). Furthermore in vitro studies 
of drug metabolism do not take into account the total hepatic capacity 
for drug metabolism, and disregard the influence of tranport processes, 
hoimones and the in vivo availability of NADPH in the intact 
hepatocyte (Chapter I). Such studies are consequently difficult to 
inteipret, and most effort has been directed to the in vivo study of 
the effect of chronic liver disease on drug metabolism by examining 
drug kinetics in patients with cirrhosis.
(2) PLASMA DISAPPEARANCE AND CEREBRAL EFFECTS OF CHLORPRCMAZINE IN CIRRHOSIS
In deciding to investigate the problem further chlorprcmazine was 
chosen as the test drug as it is often used for sedation, particularism 
of those with alcoholic liver disease, and because a method was 
available for its specific and accurate assay in plasma (Curry, 1968).
There had been no previous study in cirrhotic patients in which the 
cerebral effects of a sedative drug had been assessed in parallel with 
its metabolism, using objective quantitative techniques (Maxwell et al,
1972).
(a) Patients and Methods
Chlorpromazine (25mg) was administered by intravenous injection over
Table 6
CLINICAL DETAILS OF PATIENTS WITH CIHHHOSIS
PATIEITl? AGE
I
DIAGNOSIS ASCITES ' VARICES '
PREVIOUS
ENCEPHALO
J.B. 59 Chronic active 0 4- 0
E.P. 58 Chronic active 0 + 0
W.L, 48 Chronic active + 4- 4.
J.S. 70 Chronic active 0 4- 0
E.R. 49 Chronic active 0 4- 4-
T.J. 25 ' Chronic active 0 4- "0
J.C. 46 Alcoholic 0 4- 0
P.ÏÏ. 64 Alcoholic 4- 0 +
J.W. 49 Alcoholic 4- 0 0
G.E.* 47 Alcoholic 0 4- 0
B.J. . 26 Cryptogenic 0 4- 0
N,W. 57 Cryptogenic 4- 4- 0
H.A, 57 Cryptogenic + + 4-
D.J. 61 Primary biliary 0 + 0
P.O. 60 Primary biliary 4- 0 -h
G.B. 70 Haemochromatosis 0 0 0
J.S. 71 Chronic active 0 4- p
E.G. 49 Chronic active 0 0 0
C.C. 52 Chronic active 0 0 0
E.S, 58 Primary biliary 0 0 0.
D.J. 48 Primary biliary ■ 0 0 0
C.V.* 29 'Primary biliary 0 4- 0
JB.T4. 47 Post hepatitic 0 + 0
A » S . 55 Alcoholic + 0 0
Not involved in plasma level study
Table 6 (continued)
BIOCHEMICAL DETAILS OP PATIENTS WITH CIRRHOSIS
SERUM
ALBUMIN BILIRUBIN 
g/lOO ml mg/lOO ml
PROTHROMBIN TIME . 
SECONDS CONTROL
CONCOMITANT THERAPY WITH 
INDUCING DRUGS
2.5 4,0 9
2.4 1.2 5 ”
5.1 6.0 1 —
2.5 1.2 4 —
2.2 1.7 0 —
2.9 1.7 4 —
5.1 0.5 2
5.0 1.9 5
4.0 2.0 4 -
5.4 1.5 6 -
5.5 0.8 5 —
2.9 1.0 4 —
5.Ô 2.9 4 —
2.5 1.7 1 —
2.4 6.0 5 -
2.6 0.5 1
2.1 0.9 4 Prednisone
2.7 2.2 2 Prednisolone
2.8 2.6 5 Prednisone
5.4 1.7 0 Phenobarbi t one/Prednis one
2.9 8.5 2 Prednisone
5.5 2.9 1 Phenobarbitone
4.2 0.5 1 Tolbutamide/Phenoformin
4.0 4.0 4 Phenobarbitone
one minute to twenty-four patients aged frcm 25 to 71 years with 
cirrhosis (proven histologically or at laparoscopy) of whan eight 
had been on therapy with enzyme-inducing drugs for at least one 
week before the study, and were therefore considered to be ’induced’. 
Clinical and biochemical details of these patients are provided in 
Table 6 . None had clinical features of encephalopathy at the
time of study, although five had a past history of this. The 
thirteen control patients had various medical conditions not known 
to affect hepatic or cerebral function and were matched for age, 
sex and weight. No patients in either group had clinical or biochemical 
evidence of renal impairment on the basis of history and all had 
nomal blood urea on biochemical screening. Infoimed consent was 
obtained in each case after the purpose of the investigation had 
been eiglained in detail. Venous blood samples were collected at 
various times up to 48 hours after administration of chlorprcmazine, 
and plasma concentrations were measured by using a gas-liquid 
chromatography technique in which unchanged chlorprcmazine is 
completely separated from its metabolites. The method is capable of 
detecting nanogram amounts of the drug (Curry, 1968).
Clinical tests of cerebral function included assessment of alertness 
and orientation, writing and drawing of a five pointed star and the 
presence of asterixis. These tests were done before, 30 minutes and 
6 hours after administration of chlorpromazine. EEG recordings were 
also made at these times in eight of those with cirrhosis including 
four with previous encephalopathy and in four patients without liver 
disease. Frequency analysis of the EEG recordings was performed with a 
B.N.l. low-wave form frequency analyser. Epochs (10s) from the right 
and left parieto-occipit al regions were analysed and the skew mean- 
doninant“frequency (skew MDF) was calculated by a method which takes 
into account only those frequencies of greater than average abundance 
(Laidlaw & Aitken, 1966). Usually only three to five frequencies are 
included in this calculation and thus the skew MDF is less affected 
by slow and fast frequency artifacts in the recording than is the 
absolute mean-dominant-frequency. The techniques for EEG recording and 
autonatic wave form analysis have been described by Parkes et al,(1970)
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Semi“logarithmic plot for chlorpromazine concentrations in a 
control subject analysed into two components* l’as! component
(— ---«), time constant , intercept Aj slow component (— ) ,
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Plasma disappearance of chlorpromazine in controls (#) and in 
patients with cirrhosis (o).
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CHLORPROMAZINE CLEARANCE IN CIRRHOSIS
200 induced
non-lnducedE
^ 100
c
- 50
N
<
5
o
oc
a.cc
O
20
X
CJ 10
2412O 6
TIME HOURS
Plasma disappearance of chlorpromazine in cirrhosis, the patients 
being subdivided into induced (Q) and non-induced (®) groups.
(b) Pharmacokinetics
In general, the plasma drug concentrations in each subject showed 
a smooth pattern of decline from the highest in the earliest sample 
to the lowest concentration at the latest time of sampling (Pig. 3 )
However, in a few subjects a fluctuating pattern was seen with 
unexpected increases in concentrations of the drug at 6 or even 24 
hours. Mean drug concentrations (together with the SEM) at each 
sample time were deteimined for the complete group of control and 
cirrhotic patients (Fig. 4 ), and for the latter subdivided according
to whether they were considered to be induced or not (Fig. 5 ). When 
this data was analysed by Student ’ s t test for non-paired ccmparisons 
no differences in the drug concentrations in the control and cirrhotic 
patients, or in the induced and non-induced subgroups were evident at 
any sampling time.
The fluctuations in plasma concentration in some of the subjects
already referred to occurred at various times, and when the values at
each time-point from all patients were averaged, the resulting 'mean
curve' showed a relatively smooth decline in concentration. It is
apparent from these mean curves (Figs. 4 and 5 ), and from the curve
for an individual patient in vÆiora no fluctuation occurred (Fig. 3 )
that these could not be fitted by a single exponential, and a double
exponential model was therefore applied making use of the methods
of Riggs (1963). In the patient shown in Fig. 3 such an analysis
gave values for the tè of the earlier fast component of 2.1 hours
(rate constant ^  = 0.33hours~^) and for the later slow ccnponent of
-116.Ohours (rate constant ^  = 0.043hours ). The extrapolated lines 
of the first and second components gave intercepts of 77ng/ml (A) 
and 60ng/ml (B) respectively, from which the theoretical drug 
concentration at time zero (Cp^) was calculated to be 137ng/ml 
(Cp^ = A+B). The plasma concentrations recorded during the first hour 
could not be accommodated by this double-exponentia3. model, but 
insufficient early points were recorded in this particular study to 
allow multiple-exponential analysis.
The true elimination rate constant Kel, which provides the best 
assessment of the rate of removal of drug from plasma, was calculated 
by the foimula of Riegelman et al (1968) where:
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PRE CHLO R PRO M AZINE
60i»V
1 mmc
+ 30 f*în
+ 360 min
Effect of chlorproiïiazine on electroencephalogram of a patient 
with cirrhosis and no history of encephalopathy* Tracings taken 
before and after (^0 and y60 min) chlorpromazine*
k/K f + B / f
A, B; ^  and p  were derived from analysis of the plasma disappearance 
curve. This gave a kel value for the patient illustrated in Fig. 
of 0.084“  ^hours, and when the mean curves for the various patient 
groups (Figs. 4 and 5 ) were analysed in the same way the 
values obtained varied little (Table 7 ), This again indicates
the lack of any significant difference in drug metabolism between 
cirrhotic and control patients, although a larger number of samples 
at later time points might have affected the values calculated for 
B and B.
(c) Effect of Chlorprcmazine on the E.E.G.
Visual .assessment of the recordings showed a change after
administration of chlorpromazine in all patients with cirrhosis whether
or not there was a past history of encephalopathy (Fig. 6 ). Slowing
of the wave pattern was apparent at 30 minutes after administration of
the drug, with a return towards normal at 6 hours. The calculated
value of the skew mean-dominant-frequency before chloipromazine in
+
the cirrhotic patients without a history of encephalopathy (7.1 - 1.29 
Hz) was just below the lower limit of normal (9 - llHz) and was
4-
abnoimally low in those with previous encephalopathy (4.5 - 0.6Hz). In 
both controls and cirrhotics there was a reduction in mean dominant 
frequency 30 minutes after administration of the drug, with a return 
toward normal at 6 hours (Fig. 7 ). The most marked slowing was
noted in those with a past history of encephalopathy, #iere the mean- 
dominant frequency decreased to 4.1 - 0.2 Hz. All subjects were 
initially alert and well orientated but experienced drowsiness after 
administration of the drug. Both the controls and those with cirrhosis 
but without a history of encephalopathy could be readily aroused to an 
alert state and performed clinical tests well. In three of the four 
patients with a past history of encephalopathy mild confusion and 
deterioration in the test of writing and drawing was caused 
temporarily.
(d) Discussion
Fig. 7
EFFECT of CHLORPROMAZINE on E.E.G. MEAN DOMINANT FREQUENCY
EoQ
0 30min 6hr 0 30min 6hr 0  30min 6hr
Controls Cirrhosis Cirrhosis & PS E.
Effect of chlorpromazine on EEG skew mean-dominant frequency (Hz) 
in control and cirrhotic groups with and without a history of 
porto-systemic encephalopathy.
The results of the present investigations show no modification of 
plasma concentrations of chloipramzine in patients with compensated 
cirrhosis and are thus in keeping with the majority of reports of 
drug metabolism in cirrhosis (Table 5 ). The unexqpected fluctuations
in plasma concentration of chlorpromazine seen in some of the subjects 
in the present study have also been observed in dogs (Curry et al,1970) 
and the increases are greater than those which could have arisen as 
artifacts due to analytical error. The double exponential 
concentrât ion-time curve found from 1 to 24 hours after the dose has 
also been observed with a number of other drugs. The initial faster 
component represents the concentration declining in plasma and rapidly 
perfused tissues such as blood cells, lungs, brain, liver and 
kidney (distribution phase), whereas the slower component may represent 
the declining concentration in the whole body (elimination phase), and 
predominates when distribution equilibrium with all tissues has been 
fully achieved. This slower component has often been taken as a 
measure of the rate of metabolism of a drug. However, the half-life 
obtained from this portion of the plasma disappearance curve is a 
poor measure of the activity of processes removing the drug from 
plasma as this slope is affected not only by metabolism and excretion 
of the drug, but also by its redistribution between plasma and 
tissue compartments. The elimination constant (kel) provides a better 
assessment of the processes of drug-metabolism and/or excretion, as 
it takes into account the major contribution to plasma concentrations 
made by continual re-entry of drug into blood from tissue stores. 
However, even this parameter showed only minor differences between the 
patients with cirrhosis and those with normal liver function.
In the present study, only the disappearance of unchanged chlorprcmazine 
was measured and we have no information as to any possible changes 
in the pattern of metabolism in cirrhosis. Chlorpromazine is metabolised 
by microsomal drug-metabolising enzymes to more polar metabolites such 
as chlorpromazine sulphoxide and various demethylated and hydroxcylated 
derivatives (Coccia & Westerfeld, 1967).
,(3) POTENTIAL MECHANISMS FOR ALTERATION OF DRUG KINETICS IN PATIENTS 
WITH CIRRHOSIS.
These can best be appreciated from a consideration of formulae 
previously presented in Chaper II for calculation of the elimination
half-life for a given drug.
0.693. Vd (Apparent volume of distribution) 
t& = ---------------
Q(blood flow).E (Extraction ratio)
From this derivation it can be seen that a].teration of a number of 
different variables in patients with cirrhosis could affect the t& 
of an administered drug.
(a) Altered Hepatic Blood Flow
This factor is important for drugs which have a high hepatic 
extraction ratio ( cd 1) and whose metabolism is thus flow limited, 
but has little effect on the majority of drugs which have a low 
extraction ratio (Chapter I).
(b) Altered Hepatic Extraction
In contrast, this variable can be expected to affect the half-life 
of drugs with low hepatic extraction ratios which are capacity 
(rather than flow) limited. Such an effect may be brought about in 
a number of ways.
i) Decreased serum albumin binding of the drug. If hepatic 
metabolism is dependent upon the concentration of free 
(unbound) drug in the plaana, accelerated clearance of 
drug from plasma might be expected in situations in 
which the percentage of unbound drug is greater than 
normal (Rowland, 1972). The reduction in plasma protein 
levels seen in advanced cirrhosis could provide such a 
situation. Alternatively displacement of drug from protein 
could result as a consequence of hyperbilirubinaeraia in 
chronic liver disease, as con^etition for albumin binding 
sites between bilirubin and drugs occurs in this 
situation (Hooper et al, 1974).
ii) Altered hepatic uptake and/or binding characteristics of the 
drug.
iii) Reduced hepatic drug metabolising activity. As the 
majority of drugs are metabolised by the hepatic 
microsomal mixed-function oxidase system (Chapter I) 
their rate of elimination is a function of the activity 
of this enzyme system.
(c) Altered Drug Distribution ,
Alteration in the apparent volume of distribution of a drug (Vd) 
may also be expected to alter its half-life, since these kinetic 
variables are directly correlated, as demonstrated by the above 
derivation.
In patients with cirrhosis the net effect of the disease process 
on the elitnination of capacity limited drugs will thus reflect a 
balance between any increase in the percentage of unbound (free) 
drug, qflhich will result in accelerated plasma clearance of the 
drug; and factors diminishing the rate of drug elimination such as 
impaired synthesis of microsomal proteins, reduction in the capacity 
of the liver microsomal enzyme system to metabolise the drug, or an 
increase in apparent volume of distribution of the drug.
(4) WHY 18 METABOLISM OF SOME DRUGS UNAIFECTED IN COMPENSATED CIRRHOSIS ?
The maintenance of relatively normal drug metabolisn in patients with 
impairment of other aspects of liver function is surprising, and is 
still unexplained. The contribution of compensatory alterations in 
drug disposition in cirrhosis already referred to may be important, 
but a number of additional or alternative explanations should be 
considered.
The possibility that significant extra-hepatic metabolism of drugs 
occurs in cirrhotic patients cannot be discounted, although this 
seems unlikely for chlorprcmazine as in vitro studies have provided 
no evidence for metabolism of this drug by heart, muscle, brain, 
lung, kidney or spleen (Gillette & Kairni, 1960).
Electron microscopic appearances of the hepatocyte in certain types 
of experimental cirrhosis show proliferation of the endoplaanic 
reticulum (Stenger, 1970) but these appearances have not been
described in human cirrhosis (Steiner et al, 1965). Our data do 
not support the suggestion that maintenance of relatively normal 
drug metabolism in cirrhotic patients is due to concomitant 
therapy (Levi et al, 1968), but it may represent a form of 
adaptive or compensatory response, possibly due to endogenous 
induction of the non-specific microsomal enzymes by natural 
substrates such as steroids or terpenes. However, patients with 
chronic liver disease are capable of responding to treatment 
with enzyme inducing drugs with enhanced in vivo drug metabolism 
(Branch, Herbert et al, 1973).
(5) ALTERED SENSITIVITY TO SEDATIVE DRUGS IN PATIENTS WITH CIRRHOSIS
Increased sensitivity to the CNS effects of moiphine has been 
conclusively demonstrated. in patients with cirrhosis with a history 
of impending or overt hepatic coma (Laidlaw et al, 1961). However, 
there are conflicting reports as to the effects of barbiturates in 
this setting. Shideman et al (1949) showed that the duration of 
action of a standard dose of thiopentone was significantly prolonged 
in a group of 6 patients with abnormal liver function (only one of 
whom had unequivocal cirrhosis) compared to controls. In a clinical 
study Dundee (1952) reported that 21 patients with "severe liver 
damage" of unspecified type required substantially less thiopentone 
to produce prolonged anaesthesia than did normal subjects. However 
Sessions et al (1954) found that patients with chronic liver disease 
were not more affected by pentobarbitone \ than were healthy controls 
Wien responses were assessed using a crude clinical scoring system.
With a similar clinical scoring system which assessed the presence of 
lateral nystagmus, impaired co-ordination and altered level of 
consciousness at intervals after injection of the drug, Mawer et al 
(1972) demonstrated that although the response of cirrhotic patients 
with slow amylobarbitone metabolism was increased after I.V. 
administration of this barbiturate, it was not significantly greater 
than that seen in a group of cirrhotic patients with nomal amylobarbitone 
metabolism. However, sedative effects were not assessed in a control 
group of patients, and none of the studies using barbiturates stated 
whether the cirrhotic patients examined included any with a history 
of encephalopathy.
In the present study using chlorpramzine more sensitive and 
objective criteria were available to assess the sedative effects of 
the test drug. Despite the apparently normal clearance of 
chlorprcmazine from the plasma, increased sensitivity of patients with 
cirrhosis to the sedative effects of this drug was apparent, 
particularly in those with a previous history of encephalopathy. 
Chlorpromazine caused a comparable fall in the EEG skew MDF in both 
control subjects and patients with cirrhosis, but in the latter the 
initial EEG activity was already depressed, particularly ' in the 
subgroup of patients with a history of porto-systemic encephalopathy 
(Fig. 7 ). .
In these patients chlorprcmazine resulted in a fall in the skew MDF 
to around 4.0 Hz, which is comparable with values found in patients 
with overt hepatic encephalopathy (Hawkes et al, 1970). In the 
present study these EEG changes were accompanied by severe drowsiness 
and deterioration in ability to perform graphic tests. Thus the 
susceptibility shown by some patients with cirrhosis to chlorprcmazine 
(and presumably to other sedatives Which have also been reported to 
cause EEG changes both in cirrhosis (Laidlaw et al, 1961) and in 
normal subjects (Malpas et al, 1970) appears to be related to an 
underlying abnormality of cerebral function, resulting in an increased 
sensitivity to the drug, rather than impaired drug metabolism. However 
enhanced clinical effects due to greater concentrations of free 
(unbound) drug cannot be excluded. All central nervous system 
depressant drugs may therefore be potentially dangerous to patients 
with cirrhosis, even where there is only minor evidence of 
encephalopathy either at the time or in the past. Thus there may be 
no rational basis for advocating sedatives that are eliminated by 
renal, rather than hepatic, mechanisms. Indeed there is probably 
no ideal sedative for patients with cirrhosis, but theoretically a 
drug which is minimally protein bound, with a short half-life, and 
given in small doses, would appear to be the safest compromise.
(6) CRITIQUE OF CLINICAL STUDIES OF DRUG METABOLISM IN CIRRHOSIS
Although patients with liver disease are said to have impaired 
detoxication of drugs (Sherlock, 1968), many of the earlier studies
Table 8
DRUG AUTTfOR ASSAY
PÏÏARFACOKIHETIG
MEASUHïïriEBTS
1) AMYLOBARBITONE Mawer et 
al (1972)
GO Vd, t-J-, Cl and 
nrinary exern 
metab.
2) AHTIPYRIHS Branch et 
al (1974)
9 ty, Cl
5) Forrest et 
al (1975)
GO tu
4) A2ATHI0PRIIU3 Phelan and 
Sherlock
(1972)
Bioassay "Sérum immuno­
suppressive 
activity."
5) DIAZEPAM Avant et 
al (1974)
GO ti, Vd, Cl
6) DIPHEmirrDAUTOIH Kntt et 
al (1964)
Spectre Plasïvi^levels with 
constant dosing; 
urinary metabol­
ite (HPPH) output
y ) LIGUOGAIUE Tlicraso.n et 
al (1973)
GC Vd, ti, Cl
8) Forrest et 
al (1975)
GO ty
9) PHETTLBUTAZOrrE Levi et 
al (1963)
opectro ■ ty
10) TOLBUTAMIDE Ueda et 
al (1963)
Spectre t&
BOITE STUDIES SIIGOESTIÏTO ITT AI RED DRUG METABOLISM 
lU PATJEUTS V/ITIÎ CIRRHOSIS
Table 8 (continued)
ITO,
PATIENT DATA 
AETIOL. .severity DIOCIST'I
ALTERED
SENSITIVITY?
10 Varied, 2 not 
cirrhotic
5 hypoal- 
buninae'T!- 
ia
No
20
15
Stable
Varied, 2 not 
cirrhotic
20 10 ACE 
6 PBC 
4 miscellan­
eous
Variable -t-
Alcoholic
15 Variable 
1 not 
cirrhotic
16
Alcoholic
Varied, 2 not 
cirrhotic
Advanced
10
10 4
Table 8 (continued)
GONcaaTAiyp t u e r a i t
DETAILS
COIIYLEG
:
2 of 10 patients vnith chronic liver disesse did 
not bave cirrhosis. Crude clinical assessment 
of drug effect, \[/ drug me tab, seen in patients 
’•jith 4^  serum albiunin where ty and cl reduced 
to half.
9 Increase in ty- most narked in patients with 
severe liver disease* Albumin 4 bilirubin 
correlated with ty. Clearance not reduced if 
albumin normal.
Abnormal in 9 with decompensated liver disease* 
t-j correlated with albumin and PT ratio.
9 Not Imovm whether impaired immune suppressive 
activity in chronic liver disease is due to 
impaired absorption, hepatic biotransformation 
or endorgan response.
4 t-y in cirrhotics more than double that in 
controls due primarily to decrease in cl.
Tes Uncontrolled study, A of 15 patients (1 with 
hepatitis) showed lowered clinical tolerance 
to standard doses DPK, with plasma drug accum 4 
low urinary output of metab (HPPH).
9
9
Significant fall in ty and Cl but lignocaine is 
flow limited drug - results could reflect 
changes in hepatic blood flow rather than impai­
red metabolism.
4 Arbitrary distinction between significant 
pretreatment and no pretreatmont. No distinction 
made between acute and chronic liver disease.
9 Non-specific assay measures tolbutamide 4 major 
metabolite, ty normal in 5, reduced in 5 who 
had renal impairment which may have been 
responsible for increased t-y.
of drug metabolism in patients with cirrhosis (as in the present 
investigation of chlorpromazine) have failed to show any effect of 
chronic liver disease (Table 5 ). In contrast a number of studies
have claimed to demonstrate such a distinction (Table 8 ). A
critical analysis of these various papers suggests that a number of 
factors may have contributed to the current controversy over the 
influence of liver disease on drug elimination.
(a) Study Design
Certain reports can be criticised on the basis of faulty or 
inadequate experimental design. For example the paper by Kutt et al, 
(1964) is widely quoted as evidence that phenytoin metabolism is 
inpaired in cirrhosis. However this conclusion was based on the 
anecdotal reports of four out of fifteen patients who showed lowered 
clinical tolerance to standard doses of the drug. Moreover one of 
these four patients had acute hepatitis and not cirrhosis, and the 
study was completely uncontrolled. Again no controls were included 
in Nelson’s (1964) study of tolbutamide metabolism in cirrhosis.
Instead his results were compared with control values taken from the 
literature.
(b) Patient Selection
The varying aetiology of cirrhosis, and the difficulty in defining its 
stage and severity has made evaluation and comparison of different 
studies difficult if not impossible. Some studies have included 
patients with non-cirrhotic chronic liver disease (such as hepatic 
fibrosis or chronic cholestasis), while in the paper by Levi et al, 
(1968) no distinction was mde between patients with acute (hepatitis) 
and chronic (cirrhosis) liver disease - a crucial point viien 
inferences are made concerning the possible effects of concomitant 
drug therapy. In some reports clinical and laboratory details regarding 
the severity of liver disease in patients studi.ed have been conpletely 
omitted. "Where such information has been provided it is apparent that 
some investigators have studied relatively well patients with a 
compensated cirrhosis, while others have investigated ill, poorly 
nourished subjects with decompensated cirrhosis accompanied by ascites, 
hypoalbuminaemia, and frank jaundice.
That the severity of the underlying liver disease and its 
accompanying biochemical derangements is important in determining 
the effect on drug metabolism in patients with liver disease is 
suggested by several studies (Lieberman, 1963; Mawer et al, 1972;
Hvidberg et al, 1974; Branch et al, 1974).
(c) Analytical Methodology
Earlier studies relied on non-specific and insensitive 
spectrophotometric or biological techniques to assay drugs in plaana 
and urine. The former method is not entirely satisfactory because 
of the possibility of non-specific absorption by interfering 
substances and by pharmacologically inactive forms of the drug with 
a consequent inability to separate parent drug from its metabolites.
For example the spectro-photoraetrlc assay used by Ueda et al, (1963) 
measured not only tolbutamide but its major metabolite carboxytolbutamide, 
The latter conpound, which is normally rapidly eliminated by the 
kidneys, accumulates in renal impairment and may have spuriously 
resulted in a prolonged tj for tolbutamide in several patients with 
cirrhosis accompanied by renal impairment in Ueda's study (Nelson, 1964). 
Some biological assays for drugs are also readily affected by factors 
present in jaundiced serum (Kunin et al, 1959). Improved assay methods 
have eliminated some of these problems, and it might be of interest 
to repeat some of the earlier studies using more sensitive and 
specific techniques.
(d) Choice of test drug
In interpreting these studies the distinction between capacity and 
flow limited drugs has rarely been made. It should be remembered that 
certain drugs such as lignocaine and propranolol (Thomson et al,1973; 
Branch et al, 1974) have a high hepatic extraction ratio and their 
elimination is limited by hepatic blood flow rather than the metabolic 
capacity of the liver. Thus the impaired elimination of such drugs 
seen in patients with cirrhosis is more likely to be due to 
reduction in effective hepatic blood flow (for example by porto­
systemic shunting) than to impaired drug metabolising activity.
(e) Drug Interactions
Most of the earlier studies did not document the drug therapy patients 
were receiving at the time of study, nor was the possible significance 
of hepatic microsomal enzyme induction appreciated in these patients. 
Thus some investigators may have failed to demonstrate impaired drug 
metabolism as a result of the masking effect of enzyme induction 
(Levi et al, 1968) which has been shown experimentally to enhance 
drug metabolism in patients with chronic liver disease (Branch et al,
1973).
(f) Pharmacokinetic considerations
A general criticism of many of the earlier studies is that they 
utilised only the crudest pharmocokinetics parameters, such as drug 
elimination half-life. (In some studies not even this simple parameter 
was calculated. For exanple the investigation by Sessions et al (1954) 
on phenobarbitone elimination in cirrhosis analysed blood levels of 
the drug for only 60 minutes after its infusion, a time interval too 
short to allow calculation of the elimination half-life of the drug).
As discussed previously (Chapter II) plasma drug clearance (Cl) 
provides a better index of processes eliminating a drug from the 
body than does the half-life (t^ ). Moreover it is now appreciated 
that factors other than changes in hepatic metabolism may alter the 
t&, and that hepatic cirrhosis may produce a number of disposition 
changes, often acting in opposite directions, whose net effect may 
be an unaltered t&. These changes in disposition and hepatic 
metabolism are difficult to identify by simple pharmacokinetic 
measurements.
(g) Future studies
Future investigation of the effect of liver disease on drug metabolism 
should take account of the experimental and methodological criticisms 
of previous studies discussed above. Such studies should aim to 
clearly define and quantify the precise changes in drug disposition 
and response occurring in patients with liver disease of well defined 
type, aetiology and severity. Ideally both flow and capacity limited 
drugs should be used as investigative tools.
In addition to the drug elimination half-life, the apparent volume 
of distribution, plasma clearance changes, changes in protein 
binding and urinary excretion profile of both parent drug and 
metabolite(s) should be examined, and objective criteria used to 
assess patient response. Ultimately such studies should lead to 
the development of useful predictive tests #iich would permit 
easier and more rational evaluation of correct dosing regimes in 
patients with liver disease.
CHAPTER IV
EFFECT OF HEPATIC ENZYME INDUCING DRUGS ON 
PLASMA BILIRUBIN AND BILE FLOW
(1) EFFECT OF PHENOBARBITONE ON PLASMA BILIRUBIN IN JAUNDICED PATIENTS.
(a) Clinical Studies
An excellent example of the application of advances in the basic 
sciences to medical practice has been provided by the use of 
phenobarbitone and other enzyme inducing agents in the treatment of 
various types of hyperbilirubinaeraia. The stimulus for this therapeutic 
advance came from a better understanding of bilirubin metabolism (Billing 
& Black, 1971), and from the recognition that the non-specific hepatic 
microsomal enzyme systan responsible for the biotransformation of drugs 
and other xenobiotics was also concerned with the metabolism of 
endogenous substances such as bilirubin and steroids, and could be 
stimulated by a large number of different compounds (Conney, 1967;
Chapter III,
Bilirubin is the nonpolar tetrapyrrole pigment derived from the breakdown 
of haem. It is produced mainly by the catabolism of effete circulating 
red cells, but a small contribution (early labelled bilirubin) is derived 
from non-haemoglobin haem from the liver, bone marrow and spleen.
Bilirubin is transported in the plasma bound to albumin, and is normally 
excreted by the liver into bile after undeigoing a series of processes which 
are not fully understood. These include:
(i) Dissociation of unconjugated bilirubin from plasma albumin, and 
entry into the liver cell (either by active transport of passive diffusion), 
followed by binding to at least 2 cytoplasmic anion acceptor proteins (Levi, 
Gatmaitan & Arias, 1969).
(ii) Transfer to the endoplasmic reticulum (microscmes) where 
glucuronide conjugation occurs, catalysed by the enzyme bilirubin UDP - 
glucuronyl transferase (UDP-GT).
(iii) Finally active transport of the conjugated and now water 
soluble bilirubin diglucuronide takes pi,ace across the canalicular membrane 
into the bile ducts.
Brown & Zuelzer (1958) first dononstrated that the microsomal enzyme 
responsible for conjugation of bilirubin could be stimulated by drugs 
in studies in guinea pigs. Later phenobarbitone was shown to be capable 
of increasing the hepatic bilirubin conjugating capacity of mice and 
rabbits (Catz & Yaffe, 1962; 1968). The activity of glucuronidating 
enzymes is low in foetuses and newborns of several species including man 
(Pelkonen et al, 1973). Thus immaturity of this enzyme system may provide 
a partial explanation for the transient or "physiological" jaundice 
observed in newborn and premature infants, and impaired glucuronidation 
may contribute to the hyperbilirubinaemia associated with other causes of 
jaundice such as sepsis and haemolytic anaemia. Furthermore, patients with 
certain forms of congenital non-haarolytic unconjugated hyperbilirubina^nia 
have been shown to have a deficiency of this enzyme (Arias et al, 1969;
Black & Billing, 1969). Consequently this novel pharmacological approach 
for enhancing bilirubin UDP-GfT activity has been widely tested in the 
treatment of various types of jaundice.
Initial clinical reports described the use of phenobarbitone in the 
treatment of infants with non-haemolytic unconjugated hyperbilirubinaemia 
(Crigler & Gold, 1966, 1967; Yaffe et al, 1966} and in neonatal hyperbilirubin- 
^iïdâ CTrolie.^ , l968A>. i96SB-}; 'Subsequent- studies have 'also demonstrated the 
success of this form of therapy in reducing bilirubin levels (and require 
-ment for exchangetransfusion) in haemolytic jaundice in the newborn, and 
in obstructive jaundice due to intra hepatic cholestasis. Sane of the more 
recent reports are summarised in Tables 9 to 11. Interestingly, epileptic 
patients treated with phenobarbitone and other anticonvulsant drugs have 
also been shown to have significantly lower plasma bilirubin levels than 
control subjects (Tbicmpson, Eddleston et al, 1969), and phenobarbitone has 
also recently been shown to reduce bilirubin levels in patients with the 
conjugated hyperbilirubinaemia of the Dubin-Johnson syndrome (Shani et al, 
1974).
(b) Effect of drugs on bilirubin Kinetics
The plasma concentration of unconjugated bilirubin is determined by a 
balance between two processes: the rate at which newly synthesised bilirubin 
enters the plasma pool (bilirubin turnover) and the rate of irreversible 
bilirubin removal by the liver (hepatic bilirubin clearance).
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Early studies analysing plasm bilirubin curves following a tracer dose 
of radiolabelled bilirubin were interpreted as suggesting a defective 
uptake of bilirubin in patients with Gilbert's syndrome (Billing & Black, 
1971). In this condition (even in subjects in whom serum bilirubin levels 
were noimal) plasma disappearance curves for radiobilirubin showed a much 
slower decline than in normal controls. Approximately 25-40% of the 
administered dose was retained after 4 hours, compared to less than 10% 
in the normal subject. Moreover, when patients with Gilbert's syndrome 
were treated with phenobarbitone or glutethimide, the plasma disappearance 
curve for bilirubin returned to normal.
More sophisticated studies of bilirubin kinetics have been carried out by 
Berk et al, (1975). Plasma radiobilirubin disappearance curves were fitted 
by computer analysis, and hepatic bilirubin clearance and bilirubin turnover 
derived from calculations wAiich were independent of any hypothetical 
ccmpartmental model of bilirubin metabolism. Glutethimide (50.0mg/day) and 
phenobarbitone were shown to increase hepatic bilirubin clearance in both 
patients with Gilbert's syndrome and in nomal controls (Blaschke et al,
1974). In addition, a reduced bilirubin turnover was shown to contribute to 
the reduction in plasma bilirubin concentration, but administration of these 
drugs had no effect on haen catabolism or bilirubin production. Although 
these elegant pharmacokinetic techniques denonstrated increased bilirubin 
clearance as a result of drug therapy, they could not indicate which of the 
various theoretically possible mechanisms (see below) was responsible for 
this effect.
A more recent independent study of radiobilirubin kinetics in Gilbert's 
syndrome has confiimed that phenobarbitone accelerates bilirubin clearance, 
without affecting bilirubin production (Schmid, 1976). However in this 
study, drug administration did not appear to alter bilirubin turnover.
Again this pharmacokinetic model provided no infoimation on the 
physiological basis for drug enhanced increase in hepatic bilirubin clearance.
(2) REDUCTION OF PLASMA BILIRUBIN BY PHENOBARBITONE: SOME POSSIBLE MECHANISMS
The previous section described some of the studies which have now clearly 
established that administration of phenobarbitone results in reduction in 
the concentration of (unconjugated) bilirubin both in normal subjects and in 
patients with unconjugated hyperbi lirubinaemia due to several types of 
hepatic dysfunction.
This effect has been shown to be due to enhanced hepatic bilirubin 
clearance, while total bilirubin production is unaffected by the drug.
(Berk et al, 1975; Schmid, 1976).
Since phenobarbitone is a powerful enzyme inducing agent (Conney, 1967) 
and has been shown to stimulate the activity of bilirubin UDP-GT in 
animal studies (Catz & Yaffe, 1968; Blaschke & Berk, 1972) the 
implication in these clinical and experimental studies has been that 
bilirubin conjugation is enhanced as a result of induction of UDP-GT.
Indeed phenobarbitone has been reported to increase the activity of ^
bilirubin UDP-GT in Gilbert's syndrome (Black & Sherlock, 1970) and in 
patients vho had received the drug prior to laparotomy (Billing & Black,
1971).
However, an increasing number of additional alterations in hepatic 
physiology and cellular composition attributable to phenobarbitone could 
provide alternative explanations. Phenobarbitone and other enzyme 
inducing drugs enhance functional liver mass by stimulating liver cell 
growth and protein content (Platt & Cockrill, 1969; Pilcher et al, 1972), 
and increase the concentration of specific cytoplasmic acceptor proteins 
which bind bilirubin (Reyes et al, 1969). They also produce an increase in 
canalicular bile flow (Klaasen, 1969) which is independent of bile salt 
secretion (Berthelot et al, 1970) as well as an increase in hepatic blood 
flow (Ohnhaus et al, 1971). Furthermore, phenobarbitone and other drugs 
may have an indirect effect on plasma bilirubin by stimulating the 
secretion of D-glucaric acid, an end product of glucaric acid metabolism 
which is a potent inhibitor of JB glucuronidase (Chapter II). .-This could 
theoretically diminish biliary and/or intestinal deconjugation of bilirubin 
glucuronides and thus reduce the entero-hepatic circulation of bilirubin.
Experimental studies have shown that vhen large quantities of bilirubin 
are administered by intravenous infusion to animals with noimal liver 
function, saturation of the transport system for excretion of conjugated 
bilirubin into bile, rather than bilirubin conjugation, is the rate 
limiting step in the overall rate of transport of the pigment from blood 
to bile (Arias et al, 1961). Since phenobarbitone lowers the bilirubin 
levels of children with intra-hepatic biliary atresia (Sharp & Mirkin, 1972; 
Stiehl et al, 1972) and in other forms of intra-hepatic cholestasis 
(Thompson & Williams, 1970) it has been suggested that drug induced choleresis,
rather than an increase in activity of hepatic enzymes, may be the 
major factor in lowering bilirubin levels in man (Klaasen, 1969; Boyer, 
1971). Moreover, phenobarbitone therapy has recently been shown to 
reduce bilirubin levels in the Dub in-Johnson syndrane, a rare inherited 
form of conjugated hyperbilirubinaania which is thought to result from 
a congenital defect in hepatic excretory function without other 
associated hepato-cellular abnormality (Shani et al, 1974). This 
observation provides further support for the suggestion that phenobarbitone, 
in addition to inducing hepatic enzymes involved in the metabolian of 
drugs and endogenous substrates, may enhance biliary excretion of various 
cctiçjounds.
(3) EFFECT OF PHENCBARBITCNE ON BIIE FLOW AND BILIRUBIN METABOLISM: 
EXPERIMENTAL STUDIES IN MAN AND THE RAT.
In an effort to determine the relative importance of stimulation of 
bilirubin conjugation and of choleresis in the reduction of plasma 
bilirubin levels observed after phenobarbitone, the effects of this 
drug on bile flow, bilirubin metabolism and enzyme activity in the 
Wistar rat were studied. Experiments were also carried out in the 
homozygous Gunn rat which completely lacks bilirubin UDP-GT activity.
This experimental animal can therefore be used as a model to deteindne 
changes in the biliary excretion of bilirubin independent of any effects 
on conjugation. Parallel studies were also carried out in different 
groups of subjects (Maxwell, Hunter et al, 1973), But since in these 
clinical studies direct assay of hepatic enzymes and quantitative 
measurement of bile flow was not possible, these were assessed indirectly. 
The urinary excretion of D-glucaric acid was used to provide a 
quantitative index of hepatic microsomal enzyme activity (Chapter II1 
and in a group of patients with non-haemolytic unconjugated 
hyperbilirubinaemia (Gilbert's Syndrome) the maximum excretory rate of 
bromosulphthalein (TnBSP), which is known to be affected by changes in 
bile flow (O’Maille et al, 1966; Klaasen & Plaa,1968; Gronwall &
Cornelius, 1970) was also measured.
(a) Methods
(i) Wistar Rats: Phenobarbitone 90mg/kg body weight/day was administered 
intraperitoneally for up to 10 days to 60 male Wistar rats (350-450g) on
a standard Medical Research Council laboratory diet with water ad 
libitum. Twelve control rats received saline. Under light ether 
anaesthesia, the cotrmon bile duct was cannulated with polyethylene 
tubing (Portex PE 10) 1cm proximal to the duodenum. Animals were placed 
in restraining cages, and after recovery from anaesthesia bile was 
collected in the dark on ice for 3h. Room tenperature was maintained 
at 22^C and rectal temperature of the rats at 36.5 + 0.5^C. At the end 
of each experiment the rats were stunned and exsanguinated, and the 
livers rapidly removed, placed on ice, blotted and weighed. Microsomes 
were prepared from a 25% (W/V) homogenate of 2.5 - 3.0g portions of liver 
taken from the centres of hepatic lobes, in 0.25M sucrose, centrifuged 
at 10, OOOg for 20min, and the pellets rehomogenised with a volume of 
sucrose 4 X (V/W) the weight of the portion of liver and recentrifuged.
The pooled supernatants (now 12.5% W/V) were centrifuged at 105,000g for 
GOmin and the microsomal pellets suspended in 4.5ml buffered sucrose 
solution (0.25M sucrose O.IM tris-HCl buffer (ph 7.4) 1:2 V/V) and stored 
in aliquots at - 18^C. The content of cytochrome P450 was measured by 
the method of Qnura & Sato (1964) and the activity of glucuronyl 
transferase using bilirubin as substrate by the method of Van Roy & 
Heirwegh (1968). Results were related to microsomal protein concentration 
measured by the method of Lowry et al (1951). Plasma and biliary bilirubin 
concentration were measured by a modification of Michaelsson ' s method 
(Thompson 1969A).
(ii) Gunn Rats: Phenobarbitone was administered intraperitoneally (90mg/kg 
body weight/day) to four homozygous Gunn rats for 10 days, while paired 
controls received saline. The bile ducts were cannulated, body temperature 
maintained and the bile collected for 15min from the rats while under 
light ether anaesthesia. A bolus injection of conjugated bilirubin (1ml 
bile containing 60-80ûg conjugated bilirubin freshly collected from a 
Wistar rat) was given via the fanoral vein to each of a pair of treated 
and control Gunn rats and four 15min collections of bile obtained.
(iii) Investigations in Man: Nine adult males and three females with 
mild unconjugated hyperbilirubinaemia of Gilbert's syndrome (plasma 
bilirubin l-4mg/10Onl) were studied before and after 1 month's treatment 
with 60“100mg phenobarbitone daily (l~1.5mg/kg body weight).
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Effect of phenobarbitone on bile flow (ul/lOO g rat/h), ratio of 
liver weight to body weight (/t), specific content of cytochrome 
P 450 (nmol/mg protein), and specific activity of bilirubin glu.cu- 
ronyl transferase (O.D. units/mg protein) in the male Wistar rat.
Fifty-six subjects without liver disease were also investigated; 23 
hospital personnel (14 males and 9 females) not receiving drugs, and 
33 epileptic patients (14 males and 19 fanales) on anti-convulsant drug 
therapy. Blood samples were taken between 9.00 and 10.00am after a 
li^t breakfast, protected from light, and plasma bilirubin measurements 
performed as described within 4h. D-glucaric acid excretion was measured 
in 24 hour urine collections. Aliquots of urine were heated at lOO^C at 
ph 2.0 to convert glucaric acid to its lactone, and this was then 
measured by its specific inhibitory effect on a standard p  glucuronidase 
assay by the method of Marsh (1963) with minor modifications. The 
maximal excretory rate (Tin) and relative storage capacity (S) for BSP 
were determined by a standard technique (Wheeler et al, 1960; Preisig et 
al, 1966). The same infusion rates of dye were used for each subject 
before and after phenobarbitone treatment.
(b) Results
(i) Animal Studies:
In Wistar rats given phenobarbitone, bile flow reached a peak after 4-6 
days with values about 50% above the control bile flow of 250ul/100g body 
weight/h (SEM 0.03) (Fig. 8 ). There was a progressive rise in the ratio
of liver to body weight and an early and striking increase in the specific 
content of cytochrome P450 from a baseline of 0.70 umol/mg protein (SEM 
0.05) to about 2.5 times control values. The specific activity of bilirubin 
glucuronyl transferase was increased only slightly (9%) and the plasma, 
bilirubin levels in these animals (0.19mg/100ml SEM 0.03) did not differ 
significantly from values in the control animals (0.17mg/100ml SEM 0.02), 
nor did excretion of endogenous bilirubin differ between the two groups:™ 
0.69mg/kg body weight/3h (SEM 0.05) in controls and 0.68mg/kg body weight/
3h (SEM 0.07) after phenobarbitone.
The effect of pretreatment with phenobarbitone in the Gunn rats on bile 
flow and on the excretion of an injected load of conjugated bilirubin is 
shown in Table 12 .In the first l&nin after administration 30% more 
bilirubin was excreted than in controls, but the numbers studied were small, 
and this difference did not achieve statistical significance. Total recovery 
of bilirubin in Ih after administration of the exogenous bilirubin was 
slightly increased (Table 12 ).
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(ii) Clinical Studies:
In the patients with Gilbert ' s syndrcme there was a mean reduction of 
60% in the plasma bilirubin from a level of 1.92mg/100ml (SEM 0.28), to
0.74mg/10Qml (SEM 0.11) following 4 weeks treatment with phenobarbitone 
(P.<0.001). This was accanpanied by a large increase in urinary D- 
glucaric acid excretion fron 9,^pmol/day (SEM 1.3) to 7^.' ^)mK)l/day 
(SEM 7.4) (P.<0.01). BSP Ihi was unchanged with mean values of 9.24mg/ 
min (SEM 0.6) and 9.02mg/rain (SEM 0.4) before and after phenobarbitone. 
There was no significant change in BSP 8, the mean values being 43.8rg/ 
Ï Ï 0 ) (SEM 6.4) and 51.3mg/iig% (SEM 8.5) before and after phenobarbitone 
respectively (Table 13 ) ,and ELg. 9).
There was a significant correlation between plasma bilirubin levels and 
glucaric acid excretion in patients with Gilbert’s syndrane (r= -0.517; 
P.<0.05, Eig. 10) and a similar correlation was also observed in the 56 
subjects without liver disease (r = -0.56 P.<0.001).
(c) Discussion
(i) Drug dosage in comparative studies:
Enzyme induction is a dose dependent phenomenon (Blaschke â Berk, 1972; 
Breckenridge et al, 1973) and enzyme inducing drugs may only increase 
the activity of hepatic microsomal enzymes when given in doses which 
exceed the inmediate capacity of the liver to metabolise them (Hoffman 
et al, 1970; Remmer, 1970). As experimental animals generally metabolise 
drugs much more rapidly than man (Bums, 1968), it is not possible to 
calculate equivalent inducing doses in comparative studies. We therefore 
chose for the rat a dose of phenobarbitone which readily induces the 
activity of various enzymes in this animal (Conney, 1967; Pilcher et al,
1972). In man a standard therapeutic dose of the barbiturate (1.0 - 1.5mg/ 
kg) was selected, as this has been shown to reduce plaena bilirubin levels 
in normal subjects and those with Gilbert’s syndrane.
(ii) Effects on hepatic enzyme activity:
In the Wistar rats, phenobarbitone caused an early and striking rise
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in the specific content of cytochrome P450. However, there was no 
significant change in the specific activity of bilirubin UDP-GT, 
although the total hepatic activity of this enzyme increased as a 
result of liver enlargenent. This finding is in agreement with some 
previous reports (Potrepka & Spratt, 1971; Pilcher et al, 1972), but 
at variance with others which have demonstrated an increase in the 
specific activity of bilirubin UDP-GT after drug therapy (Catz & Yaffe, 
1968; Thompson, 1969B; Blaschke & Berk, 1972). These conflicting reports 
on the response of bilirubin UDP-GT to drug administration in laboratory 
animals may be due to species variation and differences in enzyme assay 
procedures employed (Thompson, 1969B; Winsnes, 1971).
In patients with Gilbert's syndrane, Black & Sherlock (1970) demonstrated 
small increases in the activity of bilirubin UDP-GT in needle biopsy 
specimens of liver after 2 weeks treatment with phenobarbitone IBOn^ 
daily, but found no correlation with the reduction in bilirubin levels.
The significant rise in the urinary excretion of D-glucaric acid in our 
patients receiving the drug suggests that even with the low dose used, 
there was increased activity of hepatic enzymes. Furthermore, the 
significant correlation between glucaric acid excretion and plasma 
bilirubin levels suggests that the reduction in plasma bilirubin may be 
related to increased activity of hepatic microscmal enzymes. A similar 
correlation was found in subjects with normal liver function. In anhmal 
studies we have reported a correlation between total microsomal cytochrome 
P450 concentration and D-glucaric acid excretion, (Hunter, Maxwell et al,
1973), but the possibility cannot be excluded that these are parallel but 
unrelated phenomena.
(iii) Effects on bile flow:
There is no method for directly measuring bile flow rates in man under
physiological conditions. Estimates of bile flow from aspiration of
duodenal juice are likely to be highly inaccurate, and measurements
obtained from T-tube studies are affected by the underlying pathology
and by depletion of bile salts. More recently the biliary clearance of 
14C raannitol has been utilised as an indirect measure of canalicular 
bile secretion in man (Boyer et al, 1973).
The method used in the present study, measurement of BSP Tta, again 
provides only an indirect estimate of bile flow, but several animal 
studies have shown that it is increased when canalicular bile flow is 
increased, for example following infusion of bile salts (Goresky & 
ICLuger, 1969; Gronwall & Cornelius, 1970) or after the non-bile salt 
dependent choleresis which follows phenobarbitone administration 
(Berthelot et al, 1970) although this relationship may not be obtained 
with all agents vhich stimulate canalicular bile flow (Erlinger &
Dumont, 1972).
Despite a significant reduction in plasma bilirubin, the patients with
Gilbert's syndrane showed no change in BSP Tn following phenobarbitone
administration. This finding suggests that , with the doses used, the
drug caused no change in bile flow. Our results differ from those of
Cartel et al (1971) who reported a significant increase in BSP Tin in
patients with Gilbert's syndrome, but not in normal subjects, after
lOCtog phenobarbitone/day for 1 month. The discrepancy is difficult to
explain particularly since these workers found a significant fall in
bilirubin in both their patients and noimal subjects. There is no good
evidence that phenobarbitone given in usual therapeutic doses affects
bile flow in man. Using the biliary clearance of mannitol as an
estimate of canalicular bile secretion Boyer et al,(1973) showed only
small increments in canalicular bile flow in 2 of 4 subjects after
administration of massive doses of phenobarbitone (8-10 x greater than
used in the present study). Sharp.& Mirkin (1972) treated a child with
intrahepatic biliary atresia with large doses of phenobarbitone (5mg/kg)
and showed an increase in the volume of duodenal aspirate. In another
report treatment of two further children with intra-hepatic cholestasis,
again using large doses of phenobarbitone (lOmg/kg), resulted in a fall
in serum bilirubin and bile salt concentrations, and an increase in 
131I Rose Bengal faecal excretion (Stiehl et al, 1972). It was 
speculated that these findings might have resulted fran barbiturate 
stimulation of bile secretion, but other explanations are not excluded.
Our animal studies confirm previous reports that administration of 
phenobarbitone will produce a hypercholeresis in the rat (Klaasen, 1969; 
Mok et al, 1974), rabbit (Berthelot et al, 1970) and monkey (Redinger & 
Small, 1973).
Liver hypertrophy after phenobarbitone is well recognised but it is 
of interest that in the present study changes in the ratio of liver 
to body weight did not parallel the increase',,in bile flow. This is 
further evidence that choleresis may not be related simply to liver 
cell mass, since compounds such as 3-methyl cholanthrene and 3,4- 
benzpyrene greatly increases liver weight, but have no effect on bile 
flow (Klaasen, 1969).
No detectable change in plasma bilirubin was observed in the rats 
after phenobarbitone, vsiiich was in contrast to the striking reduction 
found in patients with Gilbert's syndrcme in this and other studies 
(Black & Sherlock, 1970; Hunter et al, 1971). The lack of any change 
in the total biliary excretion of bilirubin in the Wistar rat is 
further evidence that bilirubin metabolism in this anhnal was 
unaffected by phenobarbitone. In the hanozygous Gunn rat, however, some 
increase in the excretion of a large exogenous load of conjugated 
bilirubin after phenobarbitone pretreatment was observed. Although the 
numbers studied were amll, these results are in keeping with previous 
reports that phenobarbitone administration increases the maximal biliary 
excretion of bile in the rat (Roberts & Plaa, 1967). Studies in the dog 
(Goresky & Kluger, 1969) and sheep (Upson et al, 1970) demonstrated that 
such an increase in Tta for bilirubin may be due to an increase in bile 
flow.
(iv) Species variation in response to phenobarbitone:
The importance, of species variation in the hepatic responses to inducing 
drugs is well known (Conney, 1967). In the present studies in. the Wistar 
rat, the lack of any effect of phenobarbitone on plasma bilirubin or 
biliary excretion of bilirubin, despite marked increases in bile flow, 
liver size and total content of bilirubin conjugating enzyme, suggests 
that this animal has an efficient apparatus for the disposal of 
endogenous bilirubin. However under the non-physiological conditions 
prevailing when a large exogenous load of bilirubin is administered or 
infused at Thi, biliary excretion is enhanced by pretreatment with 
phenobarbitone.
In contrast, in man the reduction in bilirubin levels following 
administration of therapeutic doses of phenobarbitone appears to be 
associated with increased activity of hepatic microsomal enzymes, 
without any accompanying change in bile flow.
These studies emphasise the need for caution before extrapolating the 
results of experiments in animals to man. However, our understanding 
of the precise mechanism whereby phenobarbitone and other enzyme 
inducing drugs increase hepatic bilirubin clearance and lower plaana 
bilirubin levels in man still remains incomplete. Unless bilirubin 
conjugation is rate-limiting, it is not clear that these data can 
explain the effect. Phenobarbitone does not seen to lower plasma 
bilirubin levels by displacing unconjugated bilirubin from its binding 
sites on plasma protein (Khanna et al, 1969). However, the other 
documented effects of the drug may equally be responsible. These include 
an increase in functional hepatic mass and intrahepatic binding proteins 
either alone or together with stimulation of bilirubin conjugation, and 
possibly also enhancement of hepatic excretory function. Further 
information about the kinetics of the individual steps in the bilirubin 
transport process, together with an understanding of the rate limiting 
step in bilirubin excretion under normally prevailing conditions in man, 
is necessary before this phenomenon can be satisfactorily explained.
CHAPTER V
CLINICAL IMPLICATIONS OF 
ENHANCED HEPATIC BICTRANSFORMATION
(1) DRUGS AND LIVER HYPERTROPHY: ADAPTIVE OR TOXIC RESPONSE?
It has long been recognised that many foreign compounds, including drugs 
and food additives, cause enlargement of the liver in e^ qaerimental 
animals which is usually accompanied by induced synthesis of microsomal 
processing enzymes, but without histologically detectable damage.
(CHAPTER II), Platt and Cockrill (1969) suggested that when a compound 
elicited increases in size, protein content and processing enzyme 
activity, but no frank pathological damage; to, the liver, the hepatic , 
enlargement could be regarded as a physiologically adaptive response to 
exposure to the foreign agent. Earlier however,^Barka & Popper (1967) 
in a discussion of liver enlargement due to drugs, speculated that the 
anabolic reaction, although beneficial in principle, might become 
detrimental, and proposed the concept of "anabolic liver cell injury." 
Subsequent investigation has failed to confirm their suggestion that 
drug mediated hypertrophy accoopanied by stimulation of enzyme activity 
is toxic to the hepatocyte per se, but has justified their concern for 
the possible adverse consequences of hepatic enzyme induction. There is 
now an increasing awareness that stimulation of hepatic microsomal 
enzyme in man is a "double-edged sword", with potential for both good and 
ill. Both aspects of this adaptive response will be discussed in this 
chapter.
(2) STIMULATION OF HEPATIC BIOTRANSEORMATION IN MAN
(a) Drug mediated hepatic enzyme induction
Over 200 drugs and foreign chemicals have been shown to stimulate the 
activity of hepatic microsomal enzymes in laboratory rodents, and a 
great deal of information is available about the factors regulating this 
phenomenon in the experimental animal. In laboratory studies many 
factors including species, strain, sex, age, diet, ambient temperatures, 
hormonal status and circadian rhythmn have been demonstrated to play a 
role in defining the response of microsomal enzymes to potential inducers. 
(CHAPTER II).
However, surprisingly little is known of the extent, regulation or 
significance of drug induced changes in hepatic biotransformation in man, 
and the clinical implications of hepatic enzyme induction have yet to be
fully evaluated. . In hie review on '^ Pharmacological implications of : 
microsomal enzyme induction," Conney (1967) devoted only 5 of 47 pages 
to studies in man. However, comparison of animal and human data is 
difficult, and extrapolation of results from the laboratory to the clini­
cal situation may be misleading.
Methods for the clinical assessment of drug mediated alterations in 
hepatic enzyme activity, and examples of their application have been 
discussed in CHAPTER II. Microsomal enzyme induction in man, as in the 
experimental animal has been shown to be dose-dependent (Breckenridge, 
Orme et al., 1973) under genetic control (Vesell, 1972), and affected by 
age and sex (O'Malley, Crooks et al., 1971). Those drugs which have been 
reported in clinical studies to stimulate hepatic biotransformation have 
recently been reviewed (Sher, 1971). However, this list is almost 
certainly incomplete.
Cb) Non-drug stimulants of human microsomal enzymes
In man, as in the experimental animal, stimulation of microsomal enzymes 
may result not only from drug administration, but also in response to 
other environmental inducing agents such as chlorinated hydrocarbon 
insecticides (Kolmodin, Azamoff et al., 1969; Poland, Stoith et al., 
1970; Smith et al., 1970; Hunter, Maxwell et al., 1972) and cigarette 
smoke (Welch, Harrison et al., 1969). It is not certain whether food 
additives, other anutrients, or even char broiled steaks (CHAPTER II) - 
all of which are capable of inducing microsomal enzyme activity in 
animals - may also have this effect in man. In addition endogenous 
substrates such as steroids may have an important regulatory role in 
the control of hepatic enzyme induction in animals (Marshall, 1971) 
and it has been speculated that they might contribute to the maintenance
of relatively normal drug metabolism in patients with conpensated chronic 
liver disease CCHAPTER III).
There is also some evidence that the massive increase in secretion of 
gestational steroids during human pregnancy is accompanied by enhanced 
activity of hepatic enzymes [see later section of this chapter).
C3) POSSIBLE THERAPEUTIC APPLICATIONS OF ENZYME INDUCTION
Recognition that hepatic microsomal enzyme activity in man could be 
manipulated has led to the investigation of the therapeutic possibilities 
of *'enzyme induction" in a number of clinical situations,
Ca) Jaundice
The use of enzyme inducing drugs in the treatment of various forms of 
hyperbilirubinaemia has been detailed in CHAPTER IV. The validity of 
this approach seems best established in the treatment (or prophylaxis) 
of neonatal hyperbilirubinaemia. Although controversy renains over 
the most appropriate therapeutic regimens, and the precise mode of 
action of these drugs, there is little doubt that they are effective in 
reducing bilirubin levels {and the need for exchange transfusion) in 
various forms of neonatal jaundice. However, paediatricians ranain 
cautious about the use of these drugs until the ultimate effects of 
this form of treatment have been established. (Behrman & Fisher, 1970; 
Sisson, 1971). Long term controlled prospective studies of phenobarbi- 
tone treated infants are necessary before the assets and liabilities 
of therapeutic "enzyme induction" can be accurately gauged and compared 
with alternative forms of treatment such as conventional exchange 
transfusion or phototherapy. Until this has been done its widespread 
adoption cannot be recommended (Wilson, 1971).
The efficacy of enzyme inducing drugs in lowering bilirubin levels in 
patients with non-haemolytic unconjugated hyperbilirubinaemia is also 
well documented (CHAPTER ly)^  but again the indications for such 
treatment are unclear.
Gilbert's syndrome appears to be a harmless biochemical anomaly, and in 
most patients with this disorder mild jaundice is discovered incidentally 
on laboratory screening. Under these circumstances it is debatable 
whether a "therapeutic white-wash" with powerful and potentially harmful 
drugs is appropriate (Hunter, Thompson et al., 1971). On the other hand 
Wiere jaundice is clinically apparent and socially embarrassing (as in 
the more pronounced hyperbilirubinaemia associated with the Crigler - 
Najjar Syndrome) the cosmetic improvement achieved with the use of 
chronic "enzyme induction" would seen to justify the risks involved.
In this setting the use of enzyme inducing agents with a prolonged 
half-life and duration of effect, such as dicophane, may offer an 
advantage (Thoipson, Stathers et al., 1969).
(b) Cushing's Syndrome
There is considerable information concerning the effects of enzyme 
inducing drugs on normal steroid metabolism (CHAPTER II) . Kuntzraan,
1969). Laboratory studies have provided evidence that the in vitro 
hydroxylation of various steroids including testosterone,'oestradiol, 
oestrone, progesterone, cortisol corticosterone and cortisone is 
increased in phenobarbitone treated animals. Furthermore in vivo 
studies have shown that phenobarbitone pretreatment decreases the 
effects of various steroids including the anaesthetic action of 
progesterone and the uterotrophic action of oestradiol in immature 
female rats.
The' stimulatory effect of various enzyme inducing drugs on the urinary 
excretion of 6 phydroxy cortisol has already been discussed (CHAPTER II) 
and this has suggested a possible therapeutic application for 
"enzyme induction" in cases of steroid overproduction. Clinical studies 
have suggested that the increased metabolian of cortisol following 
administration of phenytoin or o, p-DDD may be useful in the treatment of 
Cushing's syndrome. Amelioration in the biochemical and clinical signs 
of this disease was observed following treatment of two subjects with 
300 to 400 ng per day of Phenytoin (Werk et al., 1964).
o, p-DDD administration was also reported to reduce the symptoms of 
Cushing's syndrome before the drug produced any effect on adrenal 
cortisol secretion (Southren, Tochimoto et al., 1966). In epileptic 
subjects, with presumably normal adrenal function, the enhanced cortisol 
metabolism produced by inducing drugs (Phenytoin) was accompanied by 
increased cortisol secretion (Werk, Thrasher et al., 1971). However, 
Southren and coworkers have suggested that the increased amounts of 
hydroxylated cortisol metabolites vhich are formed following treatment 
with these compounds may ameliorate the symptoms of Cushing's syndrome 
by inhbiting the action of cortisol.
In sumnary, although hepatic enzyme induction has proved to be a 
theoretically attractive approach to the medical treatment of 
Cushing's syndrome, its practical application has been limited to a 
nunber of anecdotal reports, and its use appears to have been eclipsed 
by the introduction of selective inhibitors of adrenal secretion.
(c) Cholelithiasis
The recent major advances in the physiology of bile salt secretion 
have underlined the role of the liver in the pathogenesis of cholesterol 
gall stones, and have raised the intriguing possibility that hepatic 
enzyme induction may have a place in the treatment or prophylaxis of 
this disorder. The size of the bile acid pool is of fundamental 
importance in the production of gall stones, since a reduced bile acid 
pool is one of the major metabolic defects in patients with cholesterol 
gall stones, and bile from such patients is usually supersaturated with 
cholesterol. Re-expansion of the bile acid pool size improves 
cholesterol solubility in bile and promotes gall stone dissolution.
As enzyme inducing drugs may stimulate cholesterol metabolism to bile 
acids, there has been considerable interest in the possibility of using 
these drugs in the treatment or prevention of human cholelithiasis.
There is evidence both for and against the induction by phenobarbitone 
of the microsomal enzyme, cholesterol 7 hydroxylase, which is the 
rate limiting step in the conversion of cholesterol to bile salts 
(Kuntzman, 1969; Redinger & Shall, 1973). However both in the monkey 
(îtedinger & Small, 1973) and in the rat (Mok, Perry et al. 1974) 
phenobarbitone significantly enhances bile acid synthesis and pool size.
As there is no evidence that phenobarbitone affects intestinal bile 
acid absorption (Ostrower et al, 1973) it seems likely that the expanded 
bile acid pool and increased bile acid synthetic rates are due to a 
direct effect of phenobarbitone on hepatic bile acid synthesis.
Whether or not phenobarbitone enhances the specific activity of 
cholesterol 7 hydroxylase, the increase in liver size after phenobarbitone 
would alone adequately explain the net increase in synthesis and 
expansion of the bile acid pool in these animal studies.
There is disagreement as to whether an increase in bile acid pool size 
will in fact reduce the saturation of bile with cholesterol in man. 
Furthermore, Mok et al. (1974) were unable to show in two patients with 
gall stones that therapeutic doses of phenobarbitone had piy effect on 
bile lipid composition. However, in a controlled study oL 36 patients 
with gall stones both chenodeoxycholic acid and phenobarbitone 
(180 ng/day) significantly decreased biliary cholesterol saturation. 
Unfortunately, the change in lithogenic index induced by phenobarbitone 
alone was still above the line of cholesterol saturation and none of 
the patients in this group showed reduction in gall stone size after 
one year. Combined therapy did not significantly augment the effect 
of chenodeoxycholic acid alone. (Coyne et al, 1975),
(d) Enhancement of drug efficacy
Where a drug’s effects are due not to its parent compound, but to a 
metabolite (CHAPTER II). ; enhanced metabolian may result in increased 
efficacy or toxicity. The latter effect will be discussed in a 
subsequent section of this chapter, together with other potential 
adverse effects of enzyme induction.
Azathjqprine requires to be metabolised by microscmal mixed function 
oxidases before it is active as an immunosuppressive agent QVhelan 
& Sherlock, 1972) and there is also evidence that biotransformation 
activates cyclophosphamide (Sher, 1971). Experimental studies have 
demonstrated increased efficacy of chlorambucil after phenobarbitone 
pretreatment, which suggests that metabolic activation may be 
responsible for the anti-tumour activity of this compound (Hill, 1972). 
However, whether hepatic enzyme induction as a means of enhancing the 
activity of these or other similar drugs will have any useful clinical 
application remains to be established.
(e) Elimination of toxic drugs and chemicals
Chronic administration of enzyme inducing agents accelerates : the 
elimination not only of the compound itself, but of toxic drugs and 
chemicals subsequently administered. King Mithridates ’ pioneering 
application of the principles of drug tolerance in an attenpt to thwart 
would-be poisoners was mentioned in CHAPTER II,., A more recent advocate 
of "Mithridatisra" has suggested that occasional doses of organochlorine 
insecticides such as dicophane (EOT) which are very powerful and 
persistent inducers of microsomal enzymes (Hart, Shultice et al, 1963; 
Thompson, Stathers et al., 1969) might be given to patients who make 
repeated self-poisoning attaipts (Prescott, 1969). Unfortunately, 
enzyme induction does not seem to occur rapidly enough to be use in the 
treatment of an established drug overdose, and could be dangerous as a 
form of prophylaxis as it may enhance the effect of certain toxins 
whose activity is due to a metabolite (see subsequent section of this 
chapter on adverse effects of enzyme induction). The removal of 
pesticide residues in man is accelerated by barbiturates and phenytoin 
(Davies, Edmundson et al, 1969), an observation which has been used in 
veterinary medicine to accelerate the removal of dieldrin residues from 
contaminated dairy cattle (Braund et al, 1971). Prolonged treatment of 
rats with phenobarbitone has been shown to accelerate the tissue 
depletion of radiolabelled vitamin D (Silver et al, 1974), and this 
approach has been suggested for the clinical management of patients with 
vitamin D intoxication.
Since the first e^ qieriments 20 years ago demonstrated that induction of 
experimental animals with 3-^ethyl cholanthrene could inhibit the 
carcinogenicity of amino azo dyes (Conney, Miller & Miller, 1958) a 
number of studies have confirmed that it is possible to protect against 
the carcinogenic effects of a variety of chemical carcinogens by 
inducing increased activity of the microsomal mixed function oxidases 
(Wattenberg, 1972). The relevance of these studies to human carcinogenesis 
has yet to be established but it is possible, for example, that 
resistance to pulmonary neoplasms may depend on the body’s ability to 
incre^e detoxication of inhaled or ingested carcinogens present in 
cigarette smoke, such as benzpyrene. It is conceivable that a deliberate 
long-term increase of this detoxicating ability might protect against 
environmental carcinogens whose metabolic products are less toxic than 
the parent compound (Welch, Harrison et al, 1969). Interestingly, 
recent Danish data on cancer morbidity in epileptic patients treated 
with (enzyme inducing) anticonvulsant drugs for over 10 years showed a 
lower than expected incidence of carcinoma for a number of organs 
(Clarmesen et al, 1974). Thus despite the potential of an induced 
microsomal mixed function oxidase system to produce some adverse 
effects (see subsequent section of this chapter) from a biological 
stand point the system can be regarded as having essential survival 
value for the organism confronted with foreign organic compounds. This 
could be of considerable importance in our increasingly contaminated 
environment.
(f) Treatment of inherited enzyme deficiency states
The use of enzyme inducing drugs in the treatment of the jaundice of 
Gilbert’s Syndrome and the Crigler-Najjar syndrome (type 2) has 
already been discussed (CHAPTER IV),. In these disorders the 
hyperbilirubinaemia is considered to be at least partly related to 
reduced hepatic bilirubin HDP glucuronyl transferase activity, and 
reduction in bilirubin levels following drug therapy to be due to 
stimulation of the activity of this microsomal enzyme. Stimulation 
of the activity of hepatic enzymes by a large variety of drugs appears 
to be limited to the microsomal mixed function oxidases and conjugases.
However, certain enzymes located in other sites in the cell such as 
ALA-synthetase (mitochondria) or mouse kidney p glucuronidase 
(lysosomes) may be synthesised on the endoplasmic reticulum and then 
transferred to their site of action. In view of this, attenpts have 
been made to stimulate the activity of certain non-mlcrosomal 
enzymes with drugs, but without therapeutic benefit. Phenobarbitone 
had no effect on the activity of hexosamidase, a lysosoml enzyme 
deficient in the Sandhoff variant of Tay-Sachs disease (Applegarth 
& Dunn, 1972). Similarly no clinical benefit or reduction in red 
cell galactose was observed after progesterone was administered to 
children with congenital galactosaemia (Pesch, et al., 1960), or after 
attetrpted enzyme induction using phenobarbitone in children with 
alpha - 1 - anti trypsin deficiency (Porter et al, 1972). In a diild 
with glycogen storage disease, glucose - 6 - phosphatase was induced, 
but again without improvement of the more distal metabolic lesion 
(Moses, et al., 1966). In the hereditary hepatic porphyrias the primary 
genetic defect is considered to be a partial enzymatic block in haan 
synthesis. However, far from correcting this enzyme deficiency, pheno­
barbitone and other enzyme inducing drugs are known to be capable of 
precipitating life threatening acute attacks of the disease. Studies 
on the mechanism of the sensitivity to such drugs in this pharraaco- 
genetic disorder are presented in CHAPTER yi.
(4) ADVERSE CmSEQUENCES OP HEPATIC ENZYME INDUCTIOÏ
(a) Altered drug pharmacokinetics
Except in the rare instances where a drug metabolite is more active 
than the parent coipound or another drug interaction predominates 
(CHAPTER il), administration of enzyme inducing drugs accelerates the 
rate of drug inactivation and excretion and results in reduced 
pharmacological and toxic effects. Surprisingly little is known of 
the extent or significance of this interaction in man, but an up to 
date review of clinical reports describing the effects of one drug on 
the metabolism of a second drug or on its own metabolism has been 
provided by Sher (1971).
The most clinically significant of these interactions occur between 
enzyme inducing drugs and anticoagulants. The hydroxylation of 
coumarin anticoagulants is apparently stimulated in man if barbiturates 
or other compounds are given at the same time (Macdonald, Robinson 
et al., 1969).
The hypoprothrombinaemic effect of the anticoagulant is reduced over a 
period of one to two weeks and the dose may have to be doubled to 
maintain the desired effect on the prothronbin time. Consequently the 
patient is at risk from bleeding when inducing drugs are withdrawn, and 
fatal haanorrhage has been reported after the withdrawal of chloral 
hydrate and phenobarbitone in patients on oral anticoagulants (Cuccinell, 
Odessky et al, 1966; Robinson & Macdonald, 1966).
Phenylbutazone, a potent enzyme inducing drug, paradoxically potentiates 
the effect of Warfarin. This effect has been ascribed to displacement 
of the anti-coagulant drug (Aggeler et al,, 1967) a suggestion supported 
by the finding that in vitro phenylbutazone interferes with the binding 
of many drugs to albumin and markedly increases the concentration of free drug 
Warfarin is a mixture of R and S isomers, and recent studies suggest that 
interaction between this anticoagul#t and other drugs might be more ”
subtle and complex than previously suspected. Indeed phenylbutazone has 
been demonstrated to have a differential effect on the metabolism of the 
two isomers. Depression of the rate of clearance of the S isomer masked 
the stimulation of the clearance of the R isomer - while the overall 
rate of clearance of the raceraic Warfarin mixture was unaffected 
(Lewis, Trager et al., 1974). Since S Warfarin is 5 times more potent an 
anticoagulant than R Warfarin, inhibition of the metabolism of S Warfarin 
provides one mechanism for augmented anticoagulation which follows 
phenylbutazone.
Administration of inducing drugs may also have deleterious effects on 
steroid therapy. Phenobarbitone has been shown to decrease the half- 
life and increase the clearance rate of dexamethasone in asthmatic 
patients.
Prednisone dependent asthmatic patients showed clinical and spirometric, 
deterioration after phenobarbitone, and these changes were reversed 
after withdrawal of the barbiturate. Since dexamethasone and prednisone 
seem to be metabolised more rapidly when barbiturates are also administered, 
care is necessary when prescribing enzyme inducing, drugs to asthmatic 
patients treated with steroids (Brooks, Werk et al., 1972). More recently 
attention has been drawn to the possibility that enzyme inducing drugs 
may also impair the effectiveness of oral contraceptive steroids.
Rifampicin, a potent enzyme inducing drug in animals and man (Jezequel 
et al., 1971; Remner, Schoene et al., 1973) has been reported to result 
in an increased occurrence of pregnancy in tuberculous patients taking 
this drug together with oral contraceptives (Nocke-Finck et al., 1973).
The reduced effectiveness of oral contraceptives in these patients may 
be explained by the finding that the metabolism of oestradiol in liver 
microsomes from patients receiving rifampicin was increased more than 
fourfold. (Bolt et al., 1974; Mumford, 1974). Rifampicin has also been 
shown to lower plasma methadone levels and precipitate withdrawal 
symptoms in narcotic addicts (Kreek, et al., 1976). However, it is not 
known whether these effects are due to enhanced hepatic mdcrosomal 
drugHmetabolising activity.
(b) Enhanced drug toxicity
The microsomal mixed function oxidases are usually thought of as 
detoxicating enzymes, but some otherwise inert substances are activated 
by these processing enzymes to active or toxic molecules (CHAPTER II). 
The administration of enzyme inducing agents such as phenobarbitone or 
DDT greatly increases the hepatotoxic and lethal effects of carbon 
tetrachloride in animals, while the feeding of a lew protein diet 
(which diminishes drug metabolising activity) almost abolishes this 
effect. The toxicity of chloroform, retrorsine (Judah et al., 1970) 
bromobenzene (Mitchell et al., 1973) and cyclophosphamide (Sher, 1971) 
are similarly enhanced by prior enzyme induction. Interestingly, 
diethylnitrosamine #iich exerts its hepatotoxic effect through a meta­
bolite, is more toxic to pregnant than to non-pregnant rabbits (Texler 
et al., 1970), although there is disagreement about the effect of 
inducing drugs on the toxicity of this chemical (Magour & Nievel, 1971).
Of more immediate clinical significance has been the recognition that the 
fulminant hepatic and renal tubular necrosis vhich can follow overdose 
with paracetamol is also mediated by a toxic metabolic (Mitchell et al., 
1973, 1973A). Subjects whose hepatic microscmal enzymes are induced 
are thus theoretically at great risk frcra the hepatoxic effects of this 
analgesic drug, although this factor could not been implicated in a 
recent report of 49 patients with paracetamol induced hepatic necrosis 
(Clark et al., 1973).
The hepatotoxicity of these relatively stable substances appear to be due 
to the formation by hepatic microscmal enzymes of chemically reactive 
metabolites vhich bind covalently to vital hepatic macromolecules 
(Brodie et al., 1971; Jollow et ial., 1973). These findings have 
stimulated speculation that similar mechanisms might explain the 
occasional hepatotoxicity of halogenated aromatic hydrocarbon anaesthetic 
agents (pollery 1972).
An unusual example of enhanced drug toxicity after administration of 
enzyme inducing drugs was reported by Shahidi (1968) "who i^udied two 
sisters who readily developed methaemoglobinaama after exposure to 
phenacetin, and \’\ho were shown to excrete excessive 2-hydroxy derivatives 
of phenacetin, but relatively little of the normal de-ethylated metabolites. 
Pretreatment with phenobarbitone worsened the condition and the findings 
were interpreted as suggesting that in the relative absence of the 
usual de-ethylation pathway, alternative metabolites responsible for 
methaemogldbin formation were excreted in increased amounts.
Another concern is that hepatic enzyme induction may enhance the toxi­
city of environmental carcinogens. Frcra animal studies it appears that 
aflatoxin B1 and possibly other aflatoxins are themselves directly 
carcinogenic. They are converted to non-toxic metabolites by hepatic 
microsomal drug metabolising enzymes, and enzyme induction with pheno­
barbitone has been shown to diminish their carcinogenicity. Similarly, 
the carcinogenicity of benzpyrene is greater than that of its metabolites 
(Welch et al., 1969), and the carcinogenicity of a number of polycyclic 
hydrocarbons has been shown in animal studies to be diminished by induction 
of aryl hydrocarbon hydroxylase activity (Wattenberg, 1972),
In contrast, the toxicity and carcinogenicity of diethylnitrosamine 
seems to depend on a metabolite and not the parent compound. Its 
toxicity is not altered however by phenobarbitone or DDT, but is enhanced 
by benzpyrene which induces aryl hydrocarbon hydroxylase activity and 
a different spectrum (cytochrome P-448) of microsomal enzyme activity 
(McLean & Magee, 1970). In laboratory studies enzyme inducing drugs such 
as phenobarbitone (Walker et al., 1973; Thorpe & Walker, 1973) and DDT 
(Kemeny & Tarjan, 1966) have been reported to produce tumours in rodents 
but the clinical relevance is not clear. Reassuringly, a recent retro­
spective study from Denmark of patients receiving long term therapy with 
enzyme inducing drugs (anticonvulsants) showed no evidence of an 
oncogenic effect (Clemmesen et al, 1974). However long term prospective 
studies from various different regions are required, as different 
environmental carcinogens may exist elsewhere vho^ toxicity may be 
enhanced by inducing drugs. (Maxwe 11, 1976A).
(c) Metabolic disturbances related to vitamin deficiency
There is increasing concern over the possible adverse effects of chronic 
drug therapy. In:féw^disëases , are drugs administered in such quantities 
and over such prolonged periods as in epilepsy, and the untoward metabolic 
effects of anticonvulsant therapy are beginning to attract attention. 
Administration of enzyme inducing drugs such as the anticonvulsants has 
been associated with clinical deficiencies of vitamin D, folate and 
vitamin K. It now appears highly likely that anticonvulsant osteomalacia 
is a consequence of hepatic enzyme induction, but the evidence that this 
is the mechanism for folate deficiency, or the coagulation disturbances 
reported after the administration of these drugs is still circumstantial 
and incomplete.
i. Vitamin D - mriOCNVULSANT OSTEOIAIACIA
This condition has only recently been described, but is of considerable 
interest as it is the first metabolic disorder recognised to result from 
chronic therapy with enzyme inducing drugs, and because of its relevance 
to our understanding of vitamin D metabolian.
The earliest indication of the existence of this disorder was provided 
when biochemical abnormalities were noted in patients taking part in 
a clinical study of Trinuride, a potent combination anticonvulsant.
Wright (1965) reported that 10 of 50 patients .in a colony for adult 
epileptics treated with this drug over a period of one year developed 
raised serum alkaline pho^hatase levels, but this abnormal finding 
was also present in 7 of 44 control patients on phenytoin and pheno­
barbitone, Moreover, alkaline phosphatase activity remained elevated 
for a prolonged period after withdrawal of the drug. No explanation 
could be provided for this finding, although it was not considered 
to be due to disturbance of liver function, as BSP was normal, and 
there was no other abnormality in standard liver function tests. As a 
result of this interesting observation a survey of calcium metabolism 
was iniated in the epileptic patients resident at the centre. Before 
this was completed, however, the first reports that rickets might be 
associated with epilepsy in children appeared from Germany, and 
suggested that the bone disease might be related to long term drug 
treatment (Schmid, 1967; Kruse, 1968). The survey of adult epileptic 
patients at the Chalfont St Giles colony later provided support for 
this hypothesis, as an elevated alkaline phosphatase wa^-found in 
29% of patients, and separation of the iso-enzymes revealed a raised 
bone fraction in many cases. Serum calcium levels below 9.0 mg/10 ml. 
were found in 22.5%, and frank bone disease was present in a few patients 
(Richens & Rowe, 1970). Using a siirple scoring scheme, a quantitative 
assessment of anticonvulsant therapy was made for each patient.
Analysis of drug treatment in this way demonstrated a strong correlation 
between the presence of biochemical osteomalacia and the dose of 
anticonvulsant drugs administered to the patients. It was postulated 
that anticonvulsant osteomalacia might be due to induction of liver 
enzymes responsible for enhancing hydroxylation of vitamin D to 
inactive metabolites, and thereby greatly increasing the requirement for 
this vitamin (Dent, et al, 1970).
Lingfield Calcium Study
The opportunity to test this hypothesis was provided by the availability 
of an assay for urinary D-glucaric acid which was being evaluated as 
an index of hepatic microsomal activity in man (Hunter, IVIaxwell et al, 
1971; Chapter II)» Accordingly a study of the urinary excretion of 
D-glucaric acid in children with epilepsy at a residential school 
(Lingfield, Surrey) was planned. We were particularly interested in 
investigating whether a relationship existed between hepatic microsomal 
enzyme activity (as measured by the test) and the level of serum calcium 
and other biochemical criteria of osteomalacia in these children on 
anticonvulsant drug therapy.
Subjects and Methods:
105 children with epilepsy were investigated, aged between 10 and 
16 years. They included 60 boys and 45 girls. The children studied 
were all resident at the school, and thus the population was controlled 
for diet and sunshine exposure. A further 15 children aged 10 - 15 
years who were resident in a nearby heme for the mentally retarded, and 
were on no drug therapy, provided urine samples as controls for the 
epileptic patients.
Serum calcium, phosphate, and alkaline phosphatase values were determined 
by means of the SMA 12/60 Auto Analyzer in non-fasting blood sanples 
taken between 9 and 11 a.m. If the serum specific gravity differed from 
1027 the value for the serum calcium was corrected accordingly (Dent, 1962), 
The isoenzymes of alkaline phosphatase were separated by electrophoresis 
on polyacrylamide gel (Canapa-Anson & Rowe, 1970), the relative proportions 
of bone and liver alkaline phosphatase being determined visually.
The concentration of D-glucaric acid in a sample of urine obtained at the 
same time was determined by the inhibitory effect of glucarolactone 
to which D-glucaric acid is converted by heating at pH2, on p-glucuro- 
nidase as described by Marsh (1963).
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Values for serujn calcium, alkaline phosphatase and urinary glucaric 
acid excretion (expressed as umol of glucarolactone/g of creatinine) 
in 105 children with epilepsy shown in relation to the normal range 
(liatched area).
The result was related to the concentration of creatinine determined 
in the same urine sample - a ratio which was previously found both in 
epileptic and in normal subjects to correlate closely with the total 
daily D-glucaric acid excretion when measured in a complete 24-hour 
urine collection (r=0.97). The results were conpared with values found 
in the control series of urine samples obtained from 15 children vho 
were resident in a home for the mentally retarded, and not on any drug ' -
therapy.
Results:
Dietary assessment. Many of the children investigated were of subnormal 
intelleigence, and it was not possible to obtain individual dietary 
histories, but according to their supervisors none had noticeable food 
fads, and calculation of the vitamin D content of their diet over 
two separate weeks indicated an intake of 140-290 lU daily.
Biochamcal screening. This showed that the serum phosphate value was 
within the normal range in every instance, the mean value of the group 
being 3.8 mg/100 ml (range 2.5 - 4.8). Seinm alkaline phosphatase 
levels were raised in 25 children to above 295 mU/ml, the upper limit 
of normal for this age group (Bauer and De Vino, 1969). The highest 
level was 910 mU/ml, and nine children had levels above 500 mU/ml 
(Fig. 11 ). In every patient with values above 295 mU/ml electrophoresis 
showed that the percentage of bone isoenzymes was very high, ccmprising 
85 - 100% of the total amount of alkaline phosphatase present. In only 
nine patients was the liver isoenzyme the dominant one, and in all these 
the total serum level fell within the normal range. In 31 children 
C14 boys and 17 girls) the serum calcium was below 9 mg/100 ml, which is 
regarded as the lower limit of the normal range for the SMA 12/60 
Auto Analyzer (G. Walker, personal conmunication, 1971). Six children 
had a serum calcium of less than 8.5 mg/100 ml, and in four of these the 
calcium phosphate product (Ca X P) was below 30 mg/100 ml the lower limit 
of normal (Fraser & MacIntyre, 1970). In three of these children, as 
well as in the two with a normal Ca X P product, the serum alkaline 
phosphatase was markedly raised (298-640 mU/ml). These six children were 
considered to have biochemical osteomalacia.
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of creatinine) in I5 control and 75 epileptic children, and in 
20 epileptic adults.
All had been on anticonvulsant therapy for at least eight years and though 
most of the pupils in the school are of British descent, this group 
included two West Indians and one Italian. Two of the others had been 
resident at thë school for less than 12 months.
Drug ther^y. A detailed record of the present anticonvulsant regime 
and of the duration of therapy was taken in each case. The length of 
drug treatment varied widely frcm 2 to 15 years, as did the current dosage 
of drugs. In many of the children control of fits had finally been 
achieved only by the use of several drugs in combination. With the sinple 
scoring scheme of Richens and Rowe (1970) an index of the total daily 
dose of drugs was calculated for each child, but no correlation could 
be detected between this and the serum calcium level (r= -0.14, P>0.1).
Relationship to Urinary D-glucaric Acid. Increased concentrations 
indicating a raised total urinary excretion of D-glucaric acid were found 
in 99 of the 105 children. Four of the six children with values within 
the normal range had stopped anticonvulsant drugs several months pre­
viously because they had been free of fits for some years, and two were 
currently on small doses only. The increase in D-glucaric acid excretion 
were often considerable, the highest being 631 uM/g creatinine as 
coîipared with a mean in control subjects of 12 UM/g (Figure 12). The six 
children with biochemical evidence of osteomalacia all had a raised 
urinary D-glucaric acid, though the range of levels was wide (66-279u/M/g, 
Statistical analysis showed a significant correlation between the 
concentration of D-glucaric acid and the serum calcium level (r=3 -0.275,, 
P^O.Ol). This correlation was slightly hi^er when those on anticon­
vulsant drugs for more than eight years were considered separately 
(n=69, r = -0.312, P^O.Ol) and an analysis of those on treatment for a 
shorter period than this failed to show a significant correlation 
(n=33, r= -0.087, P’/O.l). No correlation could be detected between 
urinary D-glucaric acid and serum alkaline phosphatase levels (r = -0.040, 
P>0.1).
Discussion :
Recent major advances in the understanding of vitamin D metabolism have been 
reviewed by Stanp (1973) and Kbdicek (1974). It is now established that 
ingested vitamin D undergoes hepatic biotransformation to form an active 
metabolite, 25 hydroxycholecalciferol (25HCC) which is the major 
circulating foim of the vitamin (De Luca, 1969; Ponchon et al 1969A:;, 1969B). 
Further hydroxylations produce more polar metabolites of vitamin D.
One such metabolite, 1,25 dihydroxycholecalciferol (1,25 DHCXJ) which is 
synthesised only by the kidney, was later found to have an imnediate and 
powerful effect in promoting intestinal calcium absorption (Kodicek, 
et al, 1970), and is now regarded as the principal active hormonal form 
of the vitamin. Other polar metabolites of cholecalciferol have been 
isolated, but their physiological and clinical significance have yet to 
be evaluated.
Regulation of the synthesis of these active vitamin D metabolites 
appears to be subject to feed-back control mechanisms. The synthesis 
of 25H0C has been shown to be product inhibited and the accumulation of 
1,25DHCC in intestine and other organs is regulated in part by the 
plasma calcium concentration (Boyle, et al, 1972), so that a low calcium 
diet and associated hypocalcaeraia in vitamin D deficient rats results in 
rapid accumulation of 1,25DH0C. It is now established that control of the 
synthesis of this major active metabolite of vitamin D is effected by the 
parathyroid gland (Stamp, 1973).
The frequency of biochemical abnormalities in our Lingfield study of 
epileptic children - namely 30% with hypocalcaania and 24% with a raised 
alkaline phosphatase, is very similar to that reported by Richens &
Rowe (1970) in their earlier survey of 160 adult epileptics, and in a 
later biochemical and radiological study of adult epileptic patients from 
Finland, 30% of whom had low serum calcium levels and 32% an elevated 
alkaline phosphatase (Sotanieni, et al, 1972). Additional studies 
showing reduced bone mineral content in epileptics without biochemical 
signs of bone disease suggest the occurrence of latent osteomalacia in a 
high proportion of patients taking anticonvulsants (Christiansen, et al, 
1972). Interestingly, there have been few reports of frank anticonvulsant
osteomalacia from the United States, and biochemical abnormalities 
have been found less frequently (Hahn, Hendin et al, 1972), Indeed 
some American clinicians have questioned the existence of this condition 
(Livingston, Behrman et al., 1973). However, the rarity of anticonvulsant 
osteomalacia in North America is almost certainly explained by the 
universal practice of fortifying milk and other foodstuffs with 
vitamin D. This provides a large daily intake, occasionally as much as 
2000 - 3000 I.U. (American Acadony of Paediatrics, 1963).
Using Richen and Rowe’s sinple scoring system for drug intake we were 
unable to confim their observation of a correlation between serum 
calcium and the total daily dose of anticonvulsants that the children 
were receiving. A possible explanation for this discrepancy was that 
many of the children were taking combinations of drugs including seme less 
frequently used, such as carbamazepine and sulthl-ame, vhose inducing 
properties are unknown. However, the high excretion of urinary 
D-glucaric acid found in virtually all the treated epileptic children 
in our survey was indicative of pronounced induction of hepatic 
microsomal enzymes. Furthermore the significant correlation found 
between urinary D-glucaric acid and serum calcium is strong supporting 
evidence, although indirect, for the suggestion that enzyme induction 
was the primary cause of the hypocalcaemia associated with long term 
anticonvulsant therapy. The report of a case of anticonvulsant osteo­
malacia "Which was cured sinply by discontinuation of the drugs also 
supports the view that merely by altering vitamin D metabolism in the 
liver, significant deficiency of its active metabolites can occur and 
result in the osteomalacia or rickets. (Aponte & Petrelli, 1973).
After hydroxylation vitamin D is excreted largely as an inactive glucu- 
ronide. There is no evidence that activity of the 25-hydroxylase can be 
specifically induced. However, enhanced activity of the non-specific 
microsomal hydroxylase system might result in a change in the normal 
pattern of hepatic biotransformation of ingested or endogenous vitamin D, 
with diminished production of active metabolite. Alternatively, accel­
erated production of more polar, less active, derivative would result 
in shortening of the half life of the active metabolite and thus also 
in lower effective levels of anti-rachj.tic cholecalciferol derivatives.
The increased catabolism of cholecalciferol appears to be a major factor 
in the production of the lower levels of 25H0C observed in subjects on 
chronic anticonvulsant therapy. As discussed earlier, the biological 
activity of 25HCC in turn depends on its conversion to certain dihydroxy 
derivatives, especially the renal synthesis of 1,25DH(X, now regarded as 
the principal biologically active hormonal form of the vitamin. These 
further hydroxylations may also be disturbed, but the effects of anti­
convulsant therapy on the formation of such additional metabolites have not 
been defined. Furtheiraore the effect of drugs on other aspects of the 
kinetics of vitamin D such as its absorption, protein-binding, and 
elimination, have yet to be evaluated. Although genetically determined 
differences in enzyme inducibility have been recognised from twin studies 
(Chapter TI) it is not known whether these play a significant role in 
determining the severity of anticonvulsant osteomalacia. :Hahp (1973). has 
suggested that the most important factors influencing serum levels of 25HCC 
in patients on anticonvulsant therapy (and hence the clinical severity 
of the disorder since serum calcium levels and presumably target organ 
concentration of active vitamin D metabolites vary directly with the serum 
25HCC concentration) appear to be:
(a) total drug intake,
(b) vitamin D intake,
(c) sunlight exposure,
(d) race.
In the. institutionalised children who took part in our study exposure to 
sunlight and dietary vitamin D (estimated from the content of the school 
diet to be 140 - 290 lU/day) were comparable, and it is of interest that 
3 of the 6 epileptic children with frank biochemical evidence of osteo­
malacia were dark skinned immigrants. Dent & Snith (1969) have su^ested 
that 75Iu is the minimum daily adult requirement of vitamin D in the 
United Kingdom, although Lumb et al (1971) estimated that many people in 
the north west' of England have a dietary intake of only 30 to 60 lU.
Thus in Britain, with relatively little exposure to sunlight to compensate 
for those with marginal dietary intalîe of vitamin D, it is not surprising 
that deficiency arises vhen denand for the vitamin increases after hepatic 
enzyme induction.
Confiimation of this theory has been assisted by the demonstration of 
abnormally low levels of 25HCC in plasma from patients on anticonvulsant 
therapy, and by the demonstration of alterations in vitamin D metabolism 
induced by phenobarbitone.
In an American study of 48 adults epileptic outpatients receiving dironic 
conbined therapy with phenobarbitone and phenytoin significantly decreased 
25HCC levels were found in 33% of the epileptic patientswhile similar 
but less marked changes were seen in a group of patients given chronic 
therapy with either phenobarbitone or phenytoin alone (Hahn, Hendin et al, 
1972). A positive correlation was found between serum calcium and serum 
25HCC levels in both patients and control groups. Althou^ the serum 
25HCC level also correlated with the dietary intake of vitamin D, at any 
given intake the serum level was lower in the epileptic patients than in 
controls. In a parallel British study the levels of 25HCC in control and 
epileptic patients were lower than in their American counterparts, even 
although the estimations were performed in the same laboratory. This 
discrepancy is likely to be due to differences in vitamin supplementation 
(Stamp, Hound et al, 1972).
Study of the metabolic fate of tritiated vitamin in human subjects 
taking enzyme inducing drugs (a child with anticonvulsant rickets, and 
phenobarbitone - treated normal volunteers) demonstrated a marked reduction 
in the half-life of plasma vitamin D, with increased formation of more 
polar, apparently biologically inactive, vitamin D metabolites. This 
increased catabolism appears to occur in the liver since the in vitro 
incubation of tritiated vitamin D with liver microsomes from phenobarbitone 
treated rats resulted in rapid conversion of tritiated to metabolites 
chromatographically similar to those -seen in the plasma of phenobarbitone 
treated humans after tritiated vitamin administration (Hahn, Birge et 
al, 1972). These results are supported by the studies of Silver et al, 
(1974) vÆio showed a significant increase in the rate of synthesis of the 
more polar (peak iv) metabolites of cholecalciferol in rats given enzyme 
inducing drugs, and by the clinical observations of Schaefer, et al (1972) 
on the metabolism of labelled cholecalfierol in epileptic patients on 
anticonvulsant therapy, and in normal subjects.
As one of the practical itrplications of these studies it would seem 
prudent to consider prophylactic vitamin D supplementation in appropriate 
individuals on chronic anticonvulsant therapy. It has been estimated that 
the "average" adult epileptic on usual clinical doses of phenobarbitone 
and phenytoin may require over 600 lU vitamin D per day to maintain normal 
25HCC levels, an intake almost ten times the theoretical basal requirement 
(Hahn, 1973). Patients on multiple drug regimes with dark skins, or with 
limited exposure to sunli^t may require greater amounts,' although 
supplements should always be carefully titrated to individual needs (Hahn 
et al, 1975). A controlled trial of vitamin D supplementation has been 
shown to cause a small but significant increase in the bone mineral mass 
(measured by photon absoiptionetry) in epileptic patients on anticonvul­
sants (Christiansen, et al, 1973), but there is still no agreement as to 
which patients should be selected for prophylactic therapy, or to the 
appropriate dose or form of vitamin D (Rodbro & Christiansen, 1975/;Silwi,. l975)
In additon to the anticonvulsants a wide range of therapeutic agents are, 
capable of inducing hepatic microsomal enzyme activity (Chapter II), and 
thus drug induced acceleration of vitamin D biotransformation may 
theoretically occur in a variety of clinical situations. For exanple in 
the occasional patient with post-operative hypoparathyroidism lAho is 
resistant to vitamin D, concomitant therapy with sedatives should be 
considered as a possible contributory factor. A further practical 
^plication of these studies is the possibility that anticonvulsant or 
barbiturate drugs might provide effective and relatively non-toxic 
therapy for vitamin D intoxication.
In a subsequent section of this chapter some data is presented suggesting 
that hepatic enzyme induction may occur during normal human pregnancy, and 
in further studies, we have shown a significant reduction in 25HCC levels 
in coloured women at this time (Turton et al, 1977).
ii Folate - DRUGS AND FOLATE DEFICIENCY: AN EFFECT OF HEPATIC
ENZYME INDUCTION?
Anaemia occurring after treatment with anticonvulsant drugs was first 
reported in 1952 (Mannheimer, et al), and it is now recognised that the 
cause is folate deficiency resulting in a high incidence of macrocytosis 
(11 - 53%) and megaloblastic changes in the marrow (Reynolds 1968;
Reynolds et al, 1969). Although the role of Phenytoin has been most 
extensively investigated, folate deficiency may follow treatment with any 
of the cccmonly used anticonvulsants, and this complication has also been 
recognised after therapy,with a number of other drugs. Such changes 
occurring with methotrexate and trimethoprim, which are folate analogues 
and act as competitive inhibitors of enzymes required for utilisation of 
folate are well understood (Bertino, et al, 1964; Kahn, et al, 1968). F 
However, the mechanism of folate deficiency following chronic alcohol 
ingestion, (Eichner & Hillman, 1973) or prolonged therapy with anticon­
vulsant drugs, or oral contraceptives (Shojania, et al, 1971; Franklin 
& Rosenberg, 1971) where any structural relationship with folate is slight 
or absent, is still unclear.
L
Analysis of the possible mechanisms by which drugs such as the anticon­
vulsants might influence folate stores requires not only a knowledge of the 
chemistry and pharmacology of the drug, but also of the availability, 
absorption, distribution and functions of the vitamin. Understanding of 
the physiology of even the simplest folate compound, unreduced pteroyl 
monoglutamic acid (PGA), is still incomplete, but much has been learned 
since this cotipound was synthesised chanically and conjugated folate 
isolated from yeast, cystallised, and its structure identified. A 
comprehensive review of the digestion, absorption and biochemistry of 
folate has been provided by Rosenberg & Godwin (1971).
Approximately 75 to 90% of folate in a mixed diet is in the form of 
polyglutamate, with generally six or more glutamic acid residues attached 
to the pteroyl moiety. Pteroylheptaglutamic acid is the principal molecular 
form in yeast (and possibly other plant and animal tissues) while pteroyl 
triglutamic acid appears to be the major folate form in bacteria.
Methyl, formyl and methenyl derivatives of tetrahydrofelate make up 
90% of naturally occurring monoglutamates. The latter are generally 
absorbed much more readily than natural polyglut amic conjugates which 
require to be deconjugated to free or monoglutamate foims before intestinal 
transport. Current evidence points to the intestinal mucosa, rather 
than gastrointestinal secretions as the source and location of hydrolase 
enzymes which deconjugate food folate, and most of this conjugase 
activity is located intracellularly in the lysozymes (Perry & Chanarin, 
1972). Mbnoglutamate folate (either present as such in food, or released 
from conjugates after hydrolysis by intestinal enzymes) is the form in 
which folate is transferred across the intestinal lumen. Clinical and 
experimental evidence suggests that preferential absorption of folate occurs 
in the proximal jejunum. TVhether pteroylmonoglutamic acid, a relatively 
large (MW 441) negatively charged water soluble molecule, and its 
derivatives cross the intestinal wall by simple passive diffusion, 
driven in part by the pH differential inside and outside the call, or 
by a more efficent structure - specific energy-dependent process (active 
transport) is still uncertain. Recent studies in the rat suggest that 
the intestinal absorption of 5 methyl tetra-hydrofolic acid, the principal 
dietary and circulating monoglutamate, does not depend on - an energy 
dependent carrier mediated system, but occurs by diffusion. (Strum, et 
al, 1971). During the absoiption metabolic conversion of reduced mono­
glutamates to the methyl form occurs in the intestinal wall prior to release 
into the portal circulation. Folate circulates in the serum bound to 
plasma proteins (Markannen et al, 1972; Elsborg, 1972) and is stored in 
the liver (which is capable of further metabolic conversions) before 
release into bile or hepatic vein. Injected folic acid is initially 
concentrated in the hepatic microsomes vhere it is reduced before conversion 
to polyglutaraates (the major fom in which folate is stored in the liver) ' 
takes _ place in the cell sap and/or mitochondria (Corrocher & Hoffbrand, 
1972). However, the free (monoglutamate) form of folate is preferentially 
(perhaps exlusively) used as a cofactor for cellular enzymes, and 
reduction to tetrahydro folic acid (accomplished in vivo t^^Mihydrofolate 
reductase in the presence of TRSTH) is a basic requirement for coenzyme 
function.
The various enzymatic reactions in which folate coenzymes are known to 
participate include:
(a) certain aspects of purine and pyrimidine synthesis
(b) metabolism of various amino acids including the formation of 
methionine from homocysteine (Rosenberg & Godwin, 1971).
(c) hydroxylation reactions including those involving phenylalanine 
(Viukari, 1968; Lloyd, et al, 1971); batyl alcohol and 
other glyceryl ethers (Tietz, et al, 1964); progesterone 
(Hagerman, 1964) and other steroids (Lehoux, et al, 1972).
The proceeding outline of the digestion, absorption and biochemistry of 
folic acid surest s a number of possible mechanisms which might be 
responsible for drug related folate deficiency. The following hypo­
theses have been proposed.
1. EFFECT ON DIET. Anticonvulsants could conceivably effect the intake 
of folate. However, there is no evidence that folate deficiency and 
megaloblastic anaemia occur in patients on anticonvulsant therapy because 
the drug or disease state alters the dietary intake of folic acid 
(Hawkins & Meynell, 1958).
2. IMPAIRED FOLATE ABSORPTION. Anticonvulsant drugs might-impair the 
absorption of either polyglutamate or monoglutamate forms of folate.
(a) Polyglut amate absoiption: It has been proposed that phenytoin inhibits
intestinal conjugase activity and so might prevent enzymatic release of 
monoglut amate folate from its conjugated form, and thus result in decreased 
folate absoiption. However, the evidence is conflicting. Decreased blood 
levels of folate have been observed in normal subjects after feeding 
conjugated folate derived from yeast together with phenytoin and the 
in vitro deconjugation of polyglutamyl folate has been reported to be 
inhibited by phenytoin (Rosenberg et al, 1968; Hoffbrand & Necheles, 1968).
However, Baugh Ss Krumdieck (1969X, and Bernstein, et al, (1970) using 
purified preparations of human intestinal mucosa as the source of enzyme, 
and synthetic labelled polyglutamate as substrate, found that phenytoin 
did not inhibit conjugase activity.
More recently Perry & Chanaxin (1 9 7 2 ) -using a different test system 
(utilising the reaction between plasma conjugase and folate polyglutamate 
as substrate) were also unable to show any inhibitory effect of phenytoin 
on enzyme activity in vitro, nor did the drug interfere with the absorption 
of yeast polyglutamate in their clinical studies. Similar results were 
reported by Houlihan, et al (1972) and Fehling, et al (1973) \\h o investigated 
absorption of pure synthetic pteroyl triglutamate in normal volunteers 
and epileptic patients on anticonvulsant drugs.
Chanarin, Anderson et al, (1958) have shown that it is essential to give a 
loading dose of folic acid in order to saturate tissues if reproducible 
results are to be obtained from tolerance tests. The discrepant results 
obtained by earlier workers may have been e:xplalned,^ .at least in part, 
by the use of impure folate preparations (yeast polyglutamates may contain 
variable amounts of monoglutamates as well as natural inhibitors of folate 
ab^rption), and the failure to saturate tissue stores prior to performing 
absorption studies. Thus specific inhibition of conjugase activity by 
phenytoin is unproven, and in any case would not explain the folate 
deficiency seen after a variety of other structurally unrelated drugs. 
Definitive studies of the effects of drugs on the absorption of folate 
polyglutamates will require the use of pure radiolabelled synthetic 
pteroyl polyglutamates to avoid dependence on microbiological assays, and 
the problems involved in the use of impure extracts of yeast.
(b) Monoglutamate absorption. Whether drugs might effect the absorption 
of monc^lutamates is possibly of greater relevance to the problem of 
drug related folate deficiency, as these carpounds constitute up to 
20% of dietary folate and could, if efficently absorbed, provide all normal 
folate requirements. If anticonvulsants such as phenytoin were capable of 
blocking absorption of dietary monoglutamate; they might also affect the 
absorption of monoglutamates released from dietary conjugates. Unfortu­
nately analysis of the effects of phenytoin on intestinal absorption of 
folate monoglutamates has been restricted by the still incomplete under­
standing of the mechanisms of folate absorption, and by the limitations of 
investigative techniques.
Again the results of experimental studies have been conflicting.
Virtually all have utilised synthetic unreduced pteroyl monoglutamic 
acid (PGA) which represents less than 10% of dietary monoglut amate even 
after release from con jugates and the relevance of these findings to 
absorption of the more abundant foiras of monoglutamate in a normal diet is 
unknown.
Benn, et al (1971) suggested that folic acid (PGA) absorption might be 
impaired as a consequence of the elevated intestinal pH they observed in 
patients on phenytoin therapy. Since folic acid is a weak acid viiose 
dissociation and hence absorption mi^t be expected to be influenced by 
intestinal pH, conditions resulting in low pH in the intestinal lumen 
would theoretically favour folic acid absorption. Conversely, drugs such 
as phenytoin which are alkaline, might be expected to impair folate 
absorption on physico-chemical grounds. However, Doe, et al (1971) were 
unable to demonstrate any change in intra luminal ph in normal subjects 
by feeding phenytoin. Gerson, et al (1972) were also unable to detect 
any change in intra luminal pH after the administration of 24 mg of 
phenytoin (which resulted in an intra luminal concentration of 20 ug/ml) 
although larger concentrations (100 ug/ml) did raise the intra luminal pH. 
However, Perry & Chanarin (1972) who directly examined the effect of 
alteration of intestinal pH on folate absorption, found paradoxically 
that the presence of bicarbonate in fact enhanced the absorption of 
PGA as judged by serum folate levels.
Meynell (1966) and Dahlke & Mertens-Roessler, (1967) measuring serum 
levels after oral ingestion of synthetic PGA in human subjects and 
Hepner (1969) %ho measured the disappearance of HPGA from rat intestine 
suggested that phenytoin had an inhibitory effect on pteroyl monogluta­
mate absoiption. More recently Gerson, et al (1972) measured the 
absorption of synthetic radiolabelled monoglutamate by calculating the 
disappearance of %PGA from the intestinal lumen using direct intestinal 
perfusion studies in normal subjects. These workers reported a significant 
reduction in the absorption of tritiated folic acid when phenytoin was 
added to the perfusion solution in a concentration of 20 Ug/ml, a concen­
tration lower than that attained after ingestion of a 100 tablet.
No other drugs were examined for their effect on folate absorption. 
However, normal absoiption of folic acid in patients on anticonvulsant 
therapy was reported by Klipstein (1964). Rosenberg, et al (1968) were 
also unable to show that phenytoin (100 mg) had any effect on the 
intestinal absorption of free folate (PGA) as measured by a rise in 
serum folate activity, and similar results were reported by Fehling, 
et al (1973). Furthermore, Perry & Chanarin (1972) were also unable to 
find any difference in the peak serum folate levels or urinary folate ex­
cretion after an oral dose of PGA given with phenytoin (100 n^) and con­
cluded that the action of phenytoin on folate metabolism did not appear 
to be via an effect on absoiption, but required sane alternative 
explanation.
3. DISPLACEMENT OF FOLATE FROM PLASMA PROTEINS. Another mechanism which 
might theoretically account for folate deficiency in patients taking 
anticonvulsant drugs is the displacement of folate from its carrier plasma 
proteins(s) by these drugs. However, although this mi^t contribute to 
the lowering of serum folate levels it would not explain the associated 
reduction in tissue folate levels and accompanying deficiency syndrome 
(Klipstein, 1964).
4. INCREASED FOLATE EXCRErCIŒ. A further possible explanation for the 
depletion of tissue folate by anticonvulsant drugs might be that urinary 
excretion of folate is enchance by these drugs. This aspect of drug- 
folate interaction has not received much attention. Perry & Chanarin 
(1972) investigated the 6 hour urinary excretion of folate after an oral 
load of pteroyl monc^lutamate with and without phenytoin, and found no 
statistical difference in excretion.
5. ALTERED TISSUE UTILISATICH OF FOLATE. It has been suspected for some 
time that anticonvulsants might produce folate deficiency by causing a 
block in folic acid metabolian, although no evidence as to the site of 
such a postulated block has ever been presented. Girdwood & Lenman 
(1956) noted the structural similarities between jbenotaarbitone and folic 
acid, both of which contain a 6 membered pyrimidine ring. However the 
growth of L casei in vitro is not inhibited by anticonvulsant drugs when 
added to culture media, containing folic acid, or by serum folate from 
patients on phenytoin therapy with normal or low folate concentrations 
(Klipstein, 1964; Harafelt & Wilmanns, 1965).
No is there any evidence that anticonvulsants interfere with the uptake 
of folate by cells in the marrow (Corcino, et al, 1971).
It is known that folate is concerned with certain hydroxylations, and 
Olesen & Jensen (1970) suggested that folic acid might be necessary for 
the action of hepatic drug metabolising enzymes. The metabolism of 
phenytoin might thus cause an increased demand for the vitamin, and 
consequently decrease folate stores. Richens & Waters (1971) speculated 
that the disturbance in folate metabolism caused by phenytoin could be 
due to induction by the drug of liver enzyme systens vdiich might be 
concerned in folate metabolism. However, no precise hypothesis or 
experimental support for these suggestions was provided.
Lingfield Folate Study:
Anticonvulsant drugs are powerful enzyme inducing agents (Conney, 1967).
As folate is a cofactor in certain hydroxylations performed by microsomal 
enzymes, we considered the possibility that folate deficiency occurring 
after anticonvulsant therapy might result from increased metabolic 
requirements for the folate contact or by the liver as a consequence of 
increased activity of drug metabolising enzymes (Maxwell, Hunter, et al, 
1972), Using the measurement of the urinary excretion of D-glucaric acid 
as a quantitative index of microsomal enzyme activity in man (Chapter II), 
this hypothesis was tested by assessing the relationship between folate 
levels and microsomal enzyme activity in children with epilepsy receiving 
treatment with anticonvulsant drugs.
Subjects and Methods:
Seventy-five children (39 boys and 36 girls) aged 12 to 16 years were 
examined with parental consent. Many were retarded and it was not possible 
to obtain a reliable dietary history but all were receiving the standard 
school diet and had been resident for at least three months at the time of 
study. None were on folic acid or other vitamin supplements.
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Serum and red cell folate levels in 75 epileptic children. Hatched 
areas are normal ranges for our laboratory.
Some of these children were investigated at the same time as they were 
being screened for osteomalacia, (Hunter, Maxwell et al, 1971). (See 
earlier section of this chapter).
Serum and red cell folate concentration were measured in non-fasting 
blood taken between 9 and 11 a.m. by using a microbiological assay with 
Lactobacillus casei as the test organism. (Hoffbrand et al, 1966;
Chanarin, 1969). The concentration of D-glucaric acid in a urine sample 
collected at the same time was determined from the inhibitory effect of 
glucarolactone, to yhich it is converted by boiling at pH2, on ^ glucuron­
idase. This was related to the concentration of creatinine, in the same 
sample and ejqjressed as umol of glucarolactone/g of creatinine. Previous 
studies in epileptic and normal subjects showed that this ratio was closely 
related to the total 24-hour excretion of D-glucaric acid. (Hunter,
Maxwell et al, 1971).
The results of D-glucaric acid excretion were compared with values obtained 
in urine samples collected from a control group of 15 children of the same 
age In an institution for the mentally retarded, none of whom were on drug 
treatment. The values for serum, and red cell folate were conpared with 
the established normal range for these tests in our laboratory.
Results :
Serum folate was reduced below 3.5 ng/ml the lower limit of normal in 
44 (59%) of the 75 children investigated. The lower limit of normal 
for red cell folate is 100 ng/ml, and values lower than this were present 
in 42 (58%) of the 72 children in viiom measurements were made (Fig. 13). 
There was a significant correlation between serum and red cell folate 
(r=0.39, P 40.002). Both sexes had a similar frequency of reduced red 
cell and serum folate levels.
Increased concentrations of glucaric acid were found in 69 (90%) of the 
epileptic children (Fig. 12). Four of the six children with normal 
D-glucaric acid values were not on anticonvulsants as they had not had 
fits for some time, and the other two were on very small doses. The range 
of D-glucaric acid values in the epileptic children (9-631 umol/g) was 
comparable to that found by us in a study of adult epileptics (Fig. 12 ).
Children with high D-glucaric acid values were found to have reduced 
folate levels, and a linear relation was found to exist between D-glucaric 
acid concentration vhen plotted logarithmically and the serum folate and 
red cell folate values. Statistical analysis disclosed a significant.: 
inverse correlation between log glucaric acid and serum folate (r=0.35,
P ^ 0.002) and red cell folate (r=0.34, P ^0.002). There was also a 
significant correlation between the levels of serum and red cell folate 
in the individual children and the total daily dose of anticonvulsant drugs 
when expressed in units (Richens & Rowe, 1970) (r= -0.41, P ^ 0.001 and
r= -0.55, P ^0.001, respectively). (Fig. 14).
Discussion : ‘-
The finding of a significant association between the extent of microsomal 
enzyme induction and the levels of both serum and red cell folate is 
strong evidence, though not direct proof, for the hypothesis that folate 
deficiency may result from accelerated metabolism of folate after the 
induction of hepatic drug metabolising enzymes caused by anticonvulsant 
drug therapy. This would also explain the reported occurrence of folate 
depletion in women on oral contraceptives (Streiff, 1970; Shojania,
Homady a Barnes, 1968 and 1971) and the effect of chronic ethanol ingestion 
in accelerating the development of serum and tissue folate depletion in 
subjects on folate deficient diets (Eichner, Pierce & Hillman, 1971), for 
despite considerable differences in chemical structure ethanol and oestrogens, 
like the anticonvulsants, share the property of inducing the activity of 
microsomal enzymes (Conney, 1967; Mowat, 1968; Rubin & Lieber, 1971).
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Relationship between serum folate and urinary glucaric acid excretion 
(expressed as umol of glucarolactone/g of creatinine) in 75 epileptic 
children.
In most reported cases patients with folate deficiency occurring after 
anticonvulsant therapy have been on combinations of drugs and the effect 
appears to be dose related (Reynolds, 1968). In the cases reported by 
IWkins & Meynell (1958) macrocytosis occurred in 27% of patients on 
phenytoin alone and 34% of those of phenobarbitone alone, while macro­
cytosis occurred in 45% of those receiving both drugs. There is little 
evidence that any single anticonvulsant drug is particularly apt to 
produce these changes, although pheneturide may be more potent in this 
respect than phenobarbitone, phenytoin or primidone (Latham et al, 1973).
This hypothesis also provides a logical explanation for the finding that 
administration of folic acid to epileptic patients on phenytoin 
results in a lowering of the blood phenytoin levels (Baylis et al, 1971), 
and an increase in the urinary excretion of its principal metabolite 
(Kutt, et al, 1966) and for the clinical observation that deterioration 
in fit control may ensue (Reynolds, 1968). This is based on evidence from 
in vitro studies suggesting that folates may be required as cofactors in 
the hydroxylation of drugs as well as certain natural substrates.
Tietz et al, (1964) showed that liver microsomes lost their ability to 
oxidise batyl alcohol and other glyceryl ethers after repeated waging 
but that activity was fully restored and even augmented by the addition of 
folate or certain pteridines. These carpounds have also been shown to be 
required in the hydroxylation of phenylalanine (Lloyd et al, 1971) and 
progesterone (Hagerman, 1964; Lehoux et al, 1972). Furthermore, the 
clinical studies of Kutt et al, (1966) and Baylis et al, (1971 suggested 
that the folate depletion may limit the rate of metabolism of phenytoin 
vhich like other inducing agents is metabolised by microsomal enzymes.
Recent studies by Latham, et al, (1973) have supported our hypothesis 
that prolonged administration of any drug capable of inducing the 
activity of microsomal drug metabolising enzymes is likely to result in 
an increased demand for folate. As body stores are limited (Chanarin,
1970) and dietary intake is usually sufficient only for normal requirements, 
folate levels will fall until they reach a level at which lack of 
cofactor, rather than enzyme activity per se, rate limits drug metabolism. 
If this limitation is removed by administration of folic acid supplements, 
an increase in the rate of drug metabolism may be ejq^ ected to occur with
enhanced drug clearance, reduction in plasma steady state levels of the 
drug (as has been shown for phenytoin) and hence possible deterioration in 
fit control.
Thus folate deficiency may have to be added to anticonvulsant osteomalacia 
as another possible adverse metabolic consequence of prolonged induction 
of hepatic microsomal enzymes. Further clinical and laboratory investi­
gation of the role of folic acid in hepatic drug metabolism is required 
before this hypothesis can be established and the place of dietary folate 
supplements in patients at risk also requires further study.
iii Vitamin K: NEONATAL HAEIVDHRHAGE FOLLOWING MATERNAL 
ANTICONVULSANT THERAPY
In a prospective study Mountain et al, (1970) performed coagulation faotor 
assays on 16 neonates bom to 16 unselected epileptic mothers who were 
being treated with anticonvulsant drugs. Two of the neonates had clinical 
evidence of a bleeding tendency and a coagulation defect similar to that 
in vitamin K deficiency \ras found in 8 of the infants. These results 
suggested that anticonvulsant drugs, especially barbiturates, #ien given to 
the mother during pregnancy, decreased the levels of vitamin K dependent 
clotting factors in the infant during the early neonatal period. A further 
five cases were reported by Evans et al, (1970). In all cases the mothers 
were established epileptics receiving therapy with 2 or more anticonvulsants. 
There was no undue birth trauma, and the infants were of sufficiently high 
birth weight to make severe coagulation defects due to prematurity 
improbable. More information on the association of maternal anticonvulsant 
therapy and neonatal haemorrhage has come from a controlled retrospective 
study of pregnancy and its outcome in a group of 18 epileptic and 180 non­
epileptic women. (Speidel & Meadow, 1972). There were five still births 
and 10 neonatal deaths. in the off-spring of epileptic women, and all the 
perinatal deaths occurred in babies whose mothers took anticonvulsants 
during pregnancy. The higher death rate in the off-spring of epileptic 
mothers (almost twice that of controls) was due mainly to spontaneous 
haemorrhage (4 deaths) and congenital malformations (4 deaths) which to­
gether accounted for more than half the perinatal mortality.
Although dietary deficiency of the vitamin is thought to be exceptionally 
rare, the capacity of the body to store vitamin K is extremely limited, and 
deficiency as evidenced by hypoprothrcmbineaernia may be produced in 
experimental animals by diversion of intestinal , lynph or by biliayy 
fistulas (Woolf & Babior, 1972). Vitamin K is metabolised in the liver to 
glucuronide and sulphate conjugates (Losito /et al, 1968y Thompson,
Gerber et al, 1972) The combined effects of enzyme inducing drugs and 
pregnancy (see later section of this chapter) could conceivably accelerate 
this process, and hepatic enzyme induction with accelerated biotrans­
formation of vitamin K provides a theoretically plausible explanation for 
the neonatal coagulation defect. This remains speculative and further 
studies are required.
(d) Enzyme induction and teratogenesis:
An increased incidence of congenital malformations in the children of 
epileptic women has been noted. The malformations most commonly reported 
include cleft lip and palate, though other defects, especially cardiac 
anomalies have also been found. Such an association could be the result 
of either a direct or a genetic effect of maternal epilepsy on the foetus, 
or alternatively could be due to the anticonvulsant dngs used to treat 
epilepsy.
In retrospective study covering a period of 20 years Speidel & Meadow 
(1972) compared the incidence of malfoimations in offspring of 186 
epileptic women with that in 180 controls in Leeds. Major congenital 
malformations occurred with twice the frequency, and mental subnoitnality 
was 7 to 8 times commoner in offspring of epileptic mothers. Phenobarbi­
tone, phenytoin and Primidone, all potent enzyme-inducing agents, were 
the drugs most commonly prescribed in this survey. Interestingly, 
malformations were confined to offspring of epileptic women taking these 
drugs.
In a more recent study from Boston the frequencies of various malfor­
mations in over 50,000 pregnancies were compared between groups of 
children bom to epileptic mothers, and those bom to non-epileptic 
mothers. The highest malformation rate (61/1000) was observed in 
children exposed during the early months of pregnancy to daily phenytoin 
use, while the rate was lowest (25/1000) in children bom to_non-epileptic 
women. There appeared to be a trend between increasing ejqx)sure to the 
drug and risk of malformation, but the differences observed between 
children exposured regularly to phenytoin during early gestation, and chil­
dren bom to non-epileptic mothers could still reflect an effect of 
epilepsy rather than drug toxicity (Mbnson et al, 1973). However, Visser 
et al (1976) compared the malformation rate in offspring of a group of 
epileptic mothers in the pre-anticonvulsant era with that in a more recent 
group receiving medication. A substantial increase in malformations in 
offspring of treated mothers suggested an effect of anticonvulsant drugs.
Although not proven'; the possibility of a causal relationship between 
enzyme inducing drugs and congential birth defects is suggestive. This 
effect does not seem to be unique to any single anticonvulsant (Speidel & 
Meadow, 1972) and animal studies provide evidence for a carnal association 
(Harbison & Becker, 1969) with enzyme inducing agents. However, such an 
association requires to be established by a prospective study (Barry & 
Banks, 1974). Ideally, this should provide information not only on the 
prevalence of malformations, but also on blood levels of anticonvulsants 
attained during pregnancy, and some measure of alterations in hepatic 
enzyme activity in the mother, such as changes in 6 p hydroxycortisol or 
D-glucaric acid excretion (Chapter II).
5. INDUCTION OF HEPATIC ENZYMES DURING NORMAL HUMAN PREŒANCY
The activity of hepatic microsomal enzymes may be stimulated in animals 
by high doses of naturally occurring steroids, including oestrogens and 
progestogens (Kuntzman, 1969). In normal human pregnancy there is a large 
and progi'essive increase in placental steroid production with an abrupt 
return to normal at delivery (Amoroso & Porter, 1970). Growth of gastric 
mucosa (Crean & Rumsey, 1971) and an increase in liver wqight of up to 
50% (Song & Kappas, 1968) have been found during the course of pregnancy 
in the rat. Enhanced hepatic microsomal enzyme activity has been demon­
strated in the rat following high doses of progesterone (Hall, Fahim et 
al, 1971) but it was not known whether such changes occurred in the course 
of human pregnancy. Accordingly, we measured the urinary excretion of 
D-glucaric acid (Chapter II) in an attanpt to assess possible changes in 
the activity of hepatic enzymes in pregnant women. (Davis et al, 1973).
Pregnancy Study:- Patients and Methods
Spot urine samples were obtained from 142 healthy pregnant; - wonen 
attending the ante-natal clinics at King's College Hospital. In patients 
with amenorrhoea of less than 8 weeks duration, pregnancy was confirmed 
by immunological testing with "Pregnosticon." Urine samples were 
obtained from a further 58 women at one and 6 weeks post partum. The 
control group comprised 24 women using intra-uterine contraceptive devices. 
Subjects were excluded from the study if they were taking any drugs other 
than routine haematinics.
D-glucaric acid was assayed as its lactone (glucuro - 1,4 lactone^ by the 
method previously described (Chapter II). The concentration of the lac­
tone present in the urine after boiling at pH 2 UM was determined by the 
degree to vhich the urine inhibited the activity of p-glucuronidase. 
Results are expressed as umol glucurolactone/g of creatinine, 'which was 
shown to correlate well with the total 24 hours urinary excretion of 
d-glucaric acid. (r=0.97. Hunter, Maxwell et al, 1971).
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Results :
The distribution of results was markedly skewed in each of the groups 
studied, but was normalised by logarithmic transformation. Consequently 
statistical analysis of the data was performed using logarithims of 
the results.
Figure 15 shows the variation in D-glucaric acid excretion during normal 
human pregnancy and in the post-partum period. Following a significant 
(P^0.005) decrease from the control value at 5 to 8 weeks of. gestation, 
there was a return to normal by 12 weeks and thereafter a progressive 
increase in D-glucaric acid excretion with a maximum mean excretion of 
18.7 umol/g of creatinine by 36 - 40 weeks of gestation. One week post 
partum the level of D-glucaric acid had fallen to 15.6 umol/g of creatinine, 
a value not significantly different from control (P)»0.1).
Discussion :
Electron microscopic studies of liver biopsies taken in the course of 
normal human pregnancy have shown proliferation of the smooth endoplaanic 
reticulum (Perez et al, 1971). The present studies suggest that enzyme 
activity increases progressively throughout pregnancy after the 12th week 
of amenorrhoea, paralleling the rise in endogenous oestrogen and proges­
terone excretion (Amoroso & Porter, 1970). The delayed fall in D-glucaric 
acid output after delivery vhen the levels of steroids abruptly drop, has 
been seen when exogenous inducing agents, such as phenobarbitone, are 
withdrawn (Hunter, Maxwell et al, 1971). Our^  findings are in keeping with 
animal studies which have shown increased activity of S -ALA synthetase 
(Kappas, Song et al, 1968) in response to administration of oestrogens 
and progestogens. This enzyme is considered to be rate limiting in the 
production of haemoproteins involved in microsomal drug metabolism and 
its activity can be stimulated by enzyme inducing drugs. (Chapter yi ).
Neale and Parke (1969), have shown that the capacity for hepatic drug 
metabolism increases in the pregnant rat, but that this is due more to 
an increase in liver size than to a rise in specific activity of the 
enzyme involved. Information on changes in liver size during normal 
human pregnancy is lacking although the storage capacity for bromsul-3x: 
phthalein (BSP), which may reflect functional liver capacity, is 
reported to be increased in pregnant women (Mieeler, Epstein et al,
1960; Wheeler, Meltzer & Bradley, 1960). Although the highest levels of 
D-glucaric acid output attained during pregnancy were substantially 
lower than those previously documented after phenobarbitone treatment 
(Hmter, Maxwell et al, 1971) the greater than four fold Increase 
observed during the third trimester is unlikely to be due simply to an 
increase in liver mass.
The significant drop in D-glucaric acid excretion below control levels 
between the fifth and eightiiweek of pregnancy might be explained by the 
initial inhibitory effect of certain inducing agents on microsomal 
enzyme activity. Some progesterone metabolites are inhibitory to 
glucose - 6 - phosphate dehydrogenase (Marks & Banks, I960) and 
glucuronyl transferase (Hsia, et al, 1963), enzymæboth involved in 
synthesis of D-glucaric acid from glucose (Chapter II ). These enzymes are 
both induced by gonadal steroids (Shibata, et al, 1966; Higgins & Yao, 
1959) and during early pregnancy the effects of enzyme inhibition could 
outweigh those of induction.
The factors controlling the pharmacokinetics of drugs administered during 
pregnancy are corrplex, and the effect of increased hepatic enzyme activity 
has yet to be fully evaluated. Although induction of hepatic microsomal 
enzymes per se might be expected to enhance drug metabolian in pregnancy, 
the effect on biotransformation of drugs and other foreign substances 
in vivo will also be determined by other factors such as the relative 
affinities of drugs and gestational steroids fbr common binding sites on 
microsomal processing enzymes, and changes in protein binding and volume 
of distribution of the drug. Both oestradiol and progesterone have been 
shown to be caipetitive inhibitors of microsomal oxidases for drugs such 
as ethylmorphine and hexobarbital (Tephly & Mannering, 1967). Thus the 
in vivo clearance of some drugs may actually be reduced during pregnancy
as has been shown for hexobarbital in the rat (Quinn, et al, 1958).
However, the metabolism of dicophane (DDT) is said to be increased in 
pregnancy (Kroger, 1972) and recent studies suggest that the metabolism 
of organochlorine pesticides may be accelerated in the immediate post 
partum period (Rowan, Hunter & Maxwell, 1975). Thus there is some 
evidence that increased oestrogen and progesterone production during 
pregnancy may lead to enzyme induction but that any effect on drug 
metabolian may be slight as steroids are also competitive inhibitors of 
microsomal enzymes. However, after delivery steroid levels fall, but the ■ 
induced state persists for a few days, tenporarily increasing the rate of 
drug metabolism (Hunter, 1976).
Induction of hepatic microsomal enzymes during normal pregnancy has a 
number of clinical inplications. Administration during pregnancy of those 
drugs or chemicals which are metabolised by hepatic microsomal enzymes to 
produce active or toxic metabolites could have deleterious effects on both 
mother and foetus. It has been shown, for instance, that dimethylnitro- 
samine which exerts its hepatotoxic effect through an activated mexabolite, 
is more toxic to pregnant than non-pregnant rabbits (Texler, et al, 1970), 
It is interesting to speculate vbether this mechanism might also explain 
the occasional hepatotoxicity observed after administration of large doses 
of tetracycline to pregnant women. Folic acid deficiency is pregnancy 
might also be explained, at least in part, by increased activity of 
hepatic processing enzymes at this time (Maxwell, Hunter et al, 1972).
We have also recently reported that the well known fall in plasma calcium 
levels during pregnancy, is accompanied by a significant reduction in 
plasma 25 hydroxycholecalciferol (Turton et al, 1977). Althou^ multiple 
factors may contribute to the pathogenesis of hypocalcaemia observed at 
this time, it may in part be related to increased microsomal enzyme 
activity during pregnancy.
CHAPTER VI
DRUG SENSITIVITY IN HEREDITARY 
HEPATIC PORPHYRIA
(1) HEREDITARY HEPATIC PORPHYRIAS
(a) Pharmacogenetics
Sir Archibald Garrod (1902), who pioneered the study of inborn 
errors of metabolism, was the first to suggest that unusual 
reactions to drugs might be caused by genetically determined 
aberrations in metabolic pathways. This far-sighted obser­
vation was neglected for many years. However, with the recog­
nition in the 1950's that several "idiosyncratic" drug 
reactions such as primaquine-induced haemolytic anaemia and 
suxamethonium-induced prolonged apnoea could be explained on 
the basis of genetically determined enzyme deficiencies, phar­
macogenetics was established. Initially the term referred only 
to hereditary disorders involving adverse reactions to drugs that 
were uncovered by administration of the particular agents.
This definition seemed too restrictive, as it excluded from 
consideration genetically determined differences in drug-meta- 
holism or disposition (pharmacokinetics) and drug response 
(pharmacodynamics) between healthy non-medicateii subjects 
(Vesell, 1975). When it became apparent that the interplay 
between genetics and pharmacology influenced the action of many 
drugs, the scope of pharmacogenetics was extended to include 
all studies at the interface of these two sciences. Pharmaco­
genetics now incorporates all clinically important hereditary 
variations in drug metabolism and response.
This chapter is devoted to a consideration of the hereditary 
hepatic porphyrias - a group of classical pharmacogenetic 
disorders. (Maxwell & Meyer, 1977). Recent clinical and labo­
ratory studies will be presented which suggest that many of the 
previously unexplained features of this group of disorders can 
be understood on a mechanistic basis, and that the "idiosyn­
cratic" reaction to many common drugs, which is such a charac­
teristic feature of hereditary hepatic porphyrias, is a direct 
consequence of the primary genetic defect in porphyrin and 
heme biosynthesis.
(b) Clinical Features and Enzyme Defects
The hepatic porphyrias are a group of disorders whose princi­
pal clinical manifestations are intermittent attacks of 
neuropsychiatrie dysfunction and/or photosensitivity. They 
include intermittent acute porphyria (lAP), hereditary copro­
porphyria (HOP) variegate porphyria (VP.>oandv;^ôrphyr3La. cutanea 
tarda.:(PCT) . li All.'fouriare biochemically Characterized by"increased 
formation, accumulation and excretion of porphyrin precursors and/ 
or porphyrins in the liveri reflecting dysfunction of hepatic 
heme biosynthesis,(Meyer -and Schmid,:i977).
lAP, HOP and VP constitute the three classical hereditary hepatic 
porphyrias. In these three disorders acute, often life- 
threatening attacks of an identical neuropsychiatrie syndrome 
commonly are precipitated by normal therapeutic doses of a 
variety of drugs. These three forms of hepatic porphyria can be 
distinguished, however, on the basis of additional clinical 
manifestations (such as the presence or absence of skin photo­
sensitivity) and a unique pattern of porphyrin precursor and/ 
or porphyrin excretion.
In PCT, less clearly defined genetic and acquired abnormalities 
of hepatic heme biosynthesis interact in causing hepatic accu­
mulation of porphyrins. In contrast to lAP, HCP and VP, the 
major clinical manifestations of PCT are limited to the skin 
and the disease frequently is associated with evidence of 
hepatic dysfunction. Acute attacks of neuropsychiatrie dis­
turbance and the associated massive excretion of porphyrin 
precursors do not occur in PCT; moreover, drugs that aggravate 
or precipitate symptoms in lAP, HCP and VP in general have no 
adverse effect in PCT, In regard to the sensitivity to drugs,
PCT therefore clearly is different from the classical hereditary 
hepatic porphyrias.
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Schematic representation of haem biosynthesis and excretion patterns of 
porphyrin precursors and porphyrins in hereditary hepatic porphyrias. 
The heavy arrow for ALA-synthetase illustrates the increased activity 
for this enzyme. (Meyer et al, 1972).
In all the hepatic porphyrias, the liver appears to be the 
major site where the inborn enzymatic error manifests itself 
metabolically by accumulation and, consequently, by excretion 
of porphyrins and porphyrin precursors. This does not mean 
that the genetic defect is limited to the liver, as in lAP 
for example, characteristic enzymatic abnormalities have 
been demonstrated in other tissues studied (Meyer, 1973). It 
is now established that increased activity of hepatic S 
- aminolevulinic acid synthetase (ALA-synthetase), the first 
and rate limiting enzyme in heme synthesis, is an enzymatic 
abnormality common to the three classical hereditary hepatic 
porphyrias (Elder et al.-, 1972; Meyer Schmid, 1973; Fig. 16 ).
Furthermore, there is some evidence that during acute attacks 
the activity of this enzyme is enhanced still further 
(Taddeini and Watson, 1968; Strand et al., 1970; McIntyre 
et al., 1971) apparently contributing to the accumulation of 
porphyrin precursors characteristically seen at this time. 
However, although strikingly increased activity of hepatic 
ALA-synthetase is a constant feature lAP, HCP and VP, this is 
not seen in PCT, even in severe cases (Meyer and-Schmid, 1977). 
Furthermore it has to be realized that increased activity of 
ALA-synthetase could not by itself account for the distinct 
patterns of porphyrin or porphyrin precursor excretion that 
typifies each of the hepatic porphyrias (Fig. 13 ).
Recent studies indicate that in lAP, reduced activity of>uro­
porphyrinogen I synthetase (which catalyses the condensation 
of 4 moles of PBG to one mole of uroporphyrinogen) represents 
the primary genetic defect in heme synthesis (Meyer, et al., 
1972), A partial block at this site conveniently explains both 
the specific pattern of porphyrin precursor excretion in lAP, 
and suggests that increased hepatic ALA-synthetase activity is 
a secondary phenomenon, possibly the result of a decreased 
negative feedback regulation by heme (Sassa and Granick, 1970; 
Strand et al., 1972). The demonstration of a primary partial 
defect in heme synthesis in lAP supports the concept that the 
other forms of hereditary hepatic porphyria may be explained 
by analogous enzymatic defects at more distant sites in the 
pathway of heme biosynthesis. (Elder et al, 1976).
1. Intermittent Acute Porphyria (lAP)
is characterised by acute attacks of neuropsychiatrie mani­
festations including abdominal colic, hypertension, periphe­
ral and central neuropathies and mental disturbance. Photo­
sensitivity does not occur. Acute attacks are frequently 
precipitated by drugs as well as by hormonal,^ nutritional and 
other metabolic factors. Like the other hereditary hepatic 
porphyrias it is inherited as an autosomal dominant disorder. 
The primary genetic defect in lAP is a generalized deficiency 
or uroporphyrinogen I synthetase. In the liver this defect 
results in a secondary rise and apparently in enhanced 
"inducibility" of ALA-synthetase. As a consequence, urinary 
excretion of the porphyrin precursors 5-aminolevulinic acid 
(ALA) and porphobilinogen (PBG) is increased, without a 
proportional increase in porphyrin excretion (Fig.XL6 ).
ii. Hereditary Coproporphyria (HCP)
resembles lAP both in its drug sensitivity and the occurrence : 
of acute attacks with neuropsychiatrie manifestations. In 
addition photosensitivity may occur. It is inherited as an 
autosomal dominant disorder with variable clinical expres­
sion. The suspected defect is a deficiency of coproporphy­
rinogen oxidase, which secondarily affects the regulation 
of hepatic ALA-synthetase. The characteristic chemical 
finding is the unremitting excretion of large amounts of 
coproporphyrin in the faeces and, to a lesser extent, in the 
urine. During acute attacks, urinary excretion of the 
porphyrin precursors ALA and PBG is increased.
Recent studies have shown that the activity of coproporphyrin­
ogen oxidase in cultured skin fibroblasts from patients with 
hereditary coproporphyria is approximately half that in normal 
subjects or patients with other forms of porphyria (Elder et al,
1976) .
iii. Variegate Porphyria (VP)
also is inherited as an autosomal dominant disorder; charac­
terized by drug sensitivity, and may present with neuro­
psychiatrie manifestations. However, in addition, chronic 
skin sensitivity to light and to mechanical trauma is a 
prominent feature. Biochemically VP is characterized by 
greatly enhanced excretion of faecal protoporphyrin and, to 
a lesser degree, of coproporphyrin. The suspected primary 
defect is a deficiency of an enzyme between protoporphyrinogen 
and heme. As in HCP, the urinary excretion of ALA and PBG is 
increased during acute attacks.
iv. Porphyria Cutanea Tarda (PCT)
Photosensitivity is the only noteworthy clinical manifestation 
of this form of hepatic porphyria. Biochemically it is 
characterized by excessive urinary excretion of uroporphyrins, 
together with smaller amounts of copro- and other porphyrins. 
Recent research suggests that, at least in some patients,
PCT may be related to a dominantly inherited defect in uropor­
phyrinogen decarboxylase, but the metabolic expression of this 
genetic anomaly appears to require additional acquired 
factors such as hepatic iron overload, alcohol and oestrogens. 
In PCT, the underlying primary genetic defect (in contrast to 
the classical hereditary hepatic porphyrias) does not appear 
to result in significantly altered regulation of the heme 
pathway, as ALA-synthetase activity remains normal or only 
minimally increased, even in overt cases. This observation 
probably accounts for the critical clinical and biochemical 
difference between PCT and the classical hereditary hepatic 
porphyrias - namely the absence of acute neuropsychiatrie 
attacks, normal urinary excretion of porphyrin precursors 
ALA and PBG and the lack of sensitivity to drugs such as 
barbiturates.
(c) Biochemical Basis for Clinical Features in the 
Hepatic Porphyrias
It has been difficult to establish a causal relationship 
between the metabolic defects in porphyrin and heme bio­
synthesis and the various clinical abnormalities in the 
hereditary hepatic porphyrias, because little is known 
of the pharmacological effects of porphyrins and porphyrin 
precursors. However, it is most likely that porphyrin 
accumulation in plasma or skin is responsible for photo­
sensitivity in VP, HCP, and PCT (Rimington et al., 1967).
The other noncutaneous features characteristic of an acute 
attack of hereditary hepatic porphyria can all be explained 
by disturbances of central or peripheral nervous system 
function (Ridley, 1969), but the pathogenetic link between 
the biochemical abnormality in heme synthesis and these- 
clinical manifestations remains obscure. Numerous hypotheses 
have been advanced to explain the neuropsychiatrie mani­
festations but none is supported by convincing experimental 
evidence. The neurological dysfunction cannot ÿet be defined 
in biochemical terms, but a partial enzymatic block in heme 
synthesis has a number of possible theoretical implications 
for the pathogenesis of neurotoxicity. If it is assumed that 
enzyme activity is also deficient in cells of the nervous 
system, this could lead to intraneuronal accumulation of por­
phyrin precursors, and possibly result in neurocytotoxicity. 
Alternatively, if heme synthesis in the nervous system were 
regulated in a different manner from that in the liver, the 
enzymatic defect could result in impaired availability of 
heme for hemoproteins which might in turn result in metabolic 
impairment. It is also conceivable that the neuropsychiatrie 
manifestations might be caused by depletion of critical meta­
bolites or by accumulation of neurotoxic substances which, while 
not directly related to heme synthesis, may be a consequence 
of the inherited defect (Meyer and Schmid, 1974). However, 
the most attractive explanation at present for the neuropsy­
chiatrie phenomena is that excess porphyrin precursors
(ALA and/or PEG) formed in the liver may gain access to the 
nervous system, and there exert a toxic effect. This hypo­
thesis is supported by the observation that the neurological 
manifestations occur only in those hepatic porphyrias in which 
there is excessive hepatic accumulation and urinary excretion 
of porphyrin precursors (lAP, VP and HCP). Moreover, in 
patients with lAP, a rough correlation has been found between 
the concentration of ALA and PEG in serum, and the extent of 
neuropsychiatrie manifestations (Dhar et al, 1975). Further­
more, the recently demonstrated effectiveness of haematin 
infusion in patients with acute attacks of hepatic porphyria 
(Watson, 1975) is also consistent with the concept that ele­
vated plasma levels of ALA and/or PEG may be causally related 
to the pathogenesis of the neurological lesion. Eecause of 
the similarities between some clinical features of lead 
poisoning and acute porphyria (Dagg et al., 1965) ALA is a 
prime suspect as a mediator of the neurological lesion. Although 
various studies have shown ALA and PEG to affect nerve function 
in vitro, the significance of these effects for, the patho­
genesis of acute porphyria remains controversial. The neuro­
toxicity of the porphyrin precursors has not been conclusively 
demonstrated in vivo, but no studies have yet been carried 
out in the animal models of hepatic porphyria with generalized 
partial blocks in heme synthesis mimicking the genetic defect 
in man.
Table 14
ALCOHOL
ANTICONVULSANTS
BARBITURATES
CHEr<IOTHERAPElJTICS
HYPNOTICS
HYPOGLYCAEMICS
HYPOTENSIVES
TRANQUILLISERS
STEROIDS
Ethyl alcohol
Hydantoinsy Succinimides
All varieties including thiopentone
Griseofulvin; Sulphonamides
Dichloralphenazone; Glut ethimide
Tolbutamide
Methyldopa
Meprobamate
Oestrogensy Progestagens
Some drugs known or reported to precipitate acute,attacks of 
porphyria.
(2) DRUGS AND PORPHYRIA
(a) Precipitation of Hereditary Hepatic Porphyrias 
by Drugs
In his classical monograph on intermittent acute porphyria 
published in 1937, Waldenstrom drew attention to the role of 
barbiturates in precipitating acute porphyria, an association 
which had first been reported some 30 years earlier by 
Dobrschansky (1906). Further evidence of a relationship 
between drug administration and acute attacks of hepatic 
porphyria has come from South Africa, where a large genetic 
reservoir of one form of inherited porphyria - variegate 
porphyria - has existed for over two centuries. Interestingly 
the clinical expression of this genetic disorder was virtually 
unrecognized until the therapeutic revolution of the past 
three to four decades, resulting in the widespread use of 
drugs such as the barbiturates. Since that time acute attacks 
of variegate porphyria have become a substantial problem in 
South Africa (Dean, 1963).
In all forms of the hereditary hepatic porphyrias both the 
intermittent nature of the clinical disorder, and the exis­
tence of latent cases (With, 1963; Meyer, 1973) provide 
evidence that the primary genetic defect is frequently not 
expressed, and have emphasized the importance of additional 
endogenous or environmental factors in initiating acute 
attacks. Imprudent drug administration appears to be 
particularly important in this respect, and has been impli­
cated as a precipitating factor in between 50 and 75% of 
acute attacks (Stein and Tschudy, 1970; Bales, 1971).
Moreover it has been claimed that drug related attacks are 
associated with a more severe neurological disturbance than 
spontaneous episodes of acute porphyria (Goldberg, 1959). 
Barbiturates remain the drugs most commonly associated with 
acute attacks of hepatic porphyria, and in one report featured 
in over 50% of acute attacks (Bales, 1971). A heterogeneous 
group of non-barbiturate sedatives and other structurally 
dissimilar drugs have also been implicated (Table 14 ) as
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possible precipitating factors of the acute attack. The 
association of drugs and acute attacks may have been under­
estimated as cases of deliberate suppresion of a history of 
prior drug ingestion have been recognised. The natural course 
of the disease is variable and unpredictable, and because of 
this the evidence associating any given drug with an acute 
attack is open to question. Many patients have been taking 
several drugs at the time of an acute attack, and under these 
circumstances it is difficult to implicate one drug rather 
than another. Furthermore, the primary indication for drug 
treatment (e.g. infection), rather than the drug itself 
(e.g. sulphonamide), may have been the major factor respon­
sible for precipitating an acute attack (Stein and Tschudy, 
1970; Sales, 1971). However, for the barbiturates at least, 
the evidence for a causal relationship between drug intake and 
an acute attack seems undeniable. There are many well 
documented reports of previously healthy individuals who 
developed acute attacks following thiopentone anaesthesia for 
minor extraabdominal surgery. On the other hand the sus­
ceptibility of porphyric subjects to barbiturates seems to be 
unpredictable, as there are may patients who have undergone 
drug administration or thiopentone anaesthesia without ill 
effect.
(b) Toxic and Experimental Porphyria
In contrast to the large number of common drugs which have 
been implicated in precipitating acute attacks in the here­
ditary hepatic porphyrias, a much smaller number of compounds 
is known to be capable of producing an experimental form of 
porphyria in laboratory rodents or cell culture which bio­
chemically resembles the genetic variety (Tschudy & Bonowsky,
1972). (Fig. .17)
The concept of toxic porphyria originated from the report by 
Stokvis in 1889 of a patient who passed red urine, became 
paralysed and died after ingesting Sulphonal (diethylsulfondi- 
methylmethane). This sedative proved to be highly toxic, 
and it was later estimated that between 7 and 10% of patients 
who took it developed symptoms of acute porphyria (With, 1971). 
This figure is greatly in excess of the prevalence of inherited 
hepatic porphyria (estimated at between 1:10,000 and 1:100,000 
in European and North American populations) thus suggesting 
that Sulphonal was directly porphyrogenic and not simply 
responsible for precipitating acute attacks in genetically 
predisposed subjects. This and subsequent clinical observa­
tions provided the basis for the development of experimental 
models of porphyria in laboratory animals. Later studies, 
prompted by the clinical observation that Sedormid (ally- 
lisopropylcarbamide) resulted in the development of porphyria 
in a patient who had ingested large quantities of the sedative 
(Duesberg, 1932), demonstrated that this drug was also por­
phyrogenic in rodents (Schmid & Schwartz, 1952). Subsequent 
investigation., of various other allyl substituted compounds 
revealed that allylisopropylacetamide (AIA), a more soluble 
and less sedative congener of Sedormid, was very active in 
producing hepatic porphyria in rodents (Goldberg & Rimington, 
1955). This compound has been extensively investigated and is 
now widely used as an experimental porphyrinogen. A further 
example of an experimental porphyrinogen developed on the 
basis of earlier clinical observations is hexachlorobenzene. 
Accidental ingestion of this compound which was developed as 
a wheat fungicide resulted in thousands of cases of hepatic 
porphyria with cutaneous manifestations (Schmid, 1960).
Later laboratory studies confirmed that hexachlorobenzene, too, 
could produce a chemical porphyria in rodents (Ockner &
Schmid, 1961). Griseofulvin, a clinically useful fungicidal 
antibiotic with some structural similarity to hexachloro­
benzene has also been shown to produce an experimental 
chemical porphyria in rodents (De Matteis and Rimington, 1963), 
as have other compounds related to hexachlorobenzene.
One of the most potent and widely used experimental por- 
phyrinogenic compounds is l,4-dihydro-3,5-dicarbethoxy- 
collidine (DDC), a trimethylpyridine derivative which is 
unrelated to any common drug (Solomon & Pigge, 1959)
Experimental porphyrinogenic compounds have been shown to 
reproduce the biochemical features of an attack of hepatic 
porphyria by causing marked induction of hepatic ALA- 
synthetase with overproduction, accumulation and massive 
excretion or porphyrins and porphyrin precursors in labo­
ratory rodents and cell culture (De Matteis, 1971; Tschudy 
a Bonkowsky, 1972).
For any given member of this small group of compounds 
(Fig. 17 ) structure does seem critical in determing activity 
For example with AIA and its analogues, the porphyrino- 
genicity of the molecule appears to be associated with the 
allyl moiety. Similarly, modifications of griseofulvin 
(such as its hydroxy ether analogue, or iso-griseofulvin) 
are unable to produce the chemical porphyria seen with the 
parent compound (Tschudy & Bonkowsky, 1972). However the 
experimental porphyrinogens are chemically diverse, and the 
separate members of this group of compounds do not share any 
obvious structural features which might account for the 
activity. Despite the lack of structural parallels between 
these potent porphyrinogenic compounds, they do share the 
property of lipid solubility, and thus are potential inducers 
of hepatic microsomal enzymes (Conney, 1967). Indeed, in 
addition to their well recognised effects involving heme 
synthesis, these compounds initiate extensive morphological 
and biochemical changes characteristic of hepatic microsomal 
enzyme induction, including tubular hypertrophy of the SER 
and increase in hepatic size and portein content (Sweeney 
et al, 1971); Tschudy & Bonkowsky, 1972). Interestingly, 
the non-porphyrinogenic analogues of these compounds retain 
the capacity to produce these striking effects on liver 
structure and function.
A first clue to understanding the mechanism of action of 
the potent porphyrinogens came from the recognition that 
all these compounds share the crucial property of (initially.) 
lowering the intracellular concentration of hepatic heme and 
hemoproteins (such as cytochrome P450 and catalase) (Schmid 
& Schwartz, 1952; Meyer & Marver, 1971; De Matteis, 1971,
1973). Griseofulvin apparently produces this effect by 
inhibiting the activity of ferrochelatase, the terminal 
enzyme in heme biosynthesis, while AIA and its analogues 
accelerate the degradation of heme and hemoproteins to as 
yet unidentified green pigments. DDC appears to have effects 
on both ferrochelatase and heme degradation (for review of 
these findings see Tschudy & Bonkowsky, 1972).
The activity of allyl substituted porphyrinogenic compounds 
depends on transformation of the allyl moiety to an active 
metabolite by the liver microsomes. Experimental studies 
have shown that prior treatment of an animal with pheno- 
barbitone which stimulates microsomal drug metabolism, 
enhances the capacity of subsequently administered AIA to 
degrade heme, presumably by increasing the activity of the 
microsomal mixed function oxidase system responsible for 
converting the allyl group to its active metabolite (De Mat­
teis, 1973). Paradoxically, however, such prior treatment 
with enzyme inducing drugs diminishes the porphyrinogenic 
capacity of AIA (Kaufman et al, 1970).
Whatever the primary mode of action of an individual porphy­
rinogenic compound in diminishing the intracellular hepatic 
heme concentration, the consequences are the same, namely 
depression of heme and cytochrome p450 concentrations. Because 
of the role of heme in the feedback regulation of the path­
way this may explain the massive reciprocal increase in 
ALA-synthetase (Fig. 16 ).
As barbiturates are the most frequent offenders in pre­
cipitating clinical attacks of acute porphyria in gene­
tically predisposed subjects, they are widely used as the 
prototype drug in experimental studies. Like the various 
porphyrinogenic compounds already discussed, barbiturates 
and other drugs implicated in precipitating acute attacks 
in patients with inherited porphyria are structurally diverse 
However, this varied group of drugs again shares with the 
experimental porphyrinogenic compounds the property of lipid 
solubility. Indeed, many of these drugs are recognised as 
potent inducers of cytochrome P450 and the non-specific 
hepatic microsomal mixed function oxidase system (Conney, 
1967). Normally induction of cytochrome P.450 by such drugs 
in laboratory animals is preceded by a slight rise in 
hepatic ALA-synthetase activity. This response has been 
interpreted as providing the additional heme required for 
increased synthesis of hemoproteins, and contrasts 
strikingly with the divergent effect of porphyrinogenic 
compounds on hepatic ALA-synthetase activity and cytochrome 
P450 concentration already mentioned, 'p
Barbiturates do not cause clinical attacks of porphyria in 
normal subjects nor do they increase porphyrin or porphyrin 
precursor excretion in laboratory rodents. These and other 
common drugs, which are innocuous in normal individuals, 
but which provoke acute attacks in subjects with inherited 
hepatic porphyria, are thought to do so by eliciting a 
sustained increase in ALA-synthetase activity (Elder et al, 
1972). Why they should cause this idiosyncratic reaction 
in patients with a genetically determined abnormality in 
heme synthesis has until recently been unexplained. Studies 
from various laboratories have indicated that a similar 
basic regulatory mechanism may account for massive induction, 
of hepatic ALA-synthetase in both experimental porphyria 
and the human pharacogenetic disorder.
The subsequent sections of this chapter describe our laboratory studies 
on an experimental model for the exacerbation of hereditary hepatic 
porphyria by drugs. From these studies we have developed a hypothesis 
which may explain the idiosyncrasy to cannon drugs shown by 
susceptible patients and the development of experimental chemical 
porphyria in a variety of laboratory models.
(3) STUDIES WITH EXPERIMENTAL PARTIAL BLOCKS IN HEME SYNTHESIS
The commonest cause of acute porphyria in Europe and North America is 
intermittent acute porphyria (lAP) which is clinically characterised by 
intermittent attacks of neuro-psychiatric symptoms (Meyer & Schmid,
1977). As discussed earlier, these attacks are frequently precipitated 
by therapeutic doses of commonly used drugs and steroids, but the 
idiosyncrasy to these otherwise innocuous agents has remained unexplained. 
Acute attacks are associated with excessive urinary excretion of the 
porphyrin precursors ^ -aminolaevulinic acid (ALA) and porphobilinogen 
(PEG), which appears to be a result of greatly increased activity of 
hepatic Ô-aminolaevùlinic acid synthetase (ALA-synthetase) (Tschudy et 
al, 1965; Strand et al, 1970; Sweeney et al, 1970) the initial and 
rate-controlling enzyme in heme biosynthesis (Fig. 16 ).
The present experimental studies were prompted by recent observations 
indicating that lAP is further characterised by a partial deficiency of 
uroporphyrinogen I synthetase (URO-synthetase) which catalyses the 
conversion of PEG to uropoiphyrinogen (Fig. 16 ). Enzymatic studies 
in vitro (Strand et al, 1970; Miyagi et al, 1971; Meyer et al, 1972; 
Meyer, 1973; Sassa et al, 1974) and metabolic investigations in vivo 
(Meyer et al, 1972) suggest that this partial block of heme synthesis 
at the level of URO-synthetase represents the primary genetic defect 
which secondarily may lead to derepression of ALA-synthetase through 
negative feedback regulation.
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(c^-amino laevulinic acid synthetase); ALA-dehydrase (A"-aminolaevùlinic 
acid dehydrase): URO I-synthetase (uroporphyrinogen I-synthetase);
COPRO-oxidase (coproporphyrinogen oxidase); ALA ( -aminolaevùlinic acid); 
PBG (porphobilinogen); URO GPU (uroporphyrinogen); GOPRO GSR (copropor- 
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(a) Effect of lead on Hepatic ^ -aminolaevùlinic acid synthetase 
activity in the rat: A model for drug sensitivity In
intermittent acute porphyria
In the present studies we tested the hypothesis that the unique 
sensitivity to many drugs, which is a characteristic.feature, of lAP 
(and the other hereditary hepatic porphyrias), may be a consequence 
of the primary defect in heme synthesis.
Partial inhibition of heme synthesis was produced experimentally in 
rats by lead, which inhibits several enzymes of the pathway (Fig. IS) 
including ALA-dehydratase, URO-synthetase and ferrochelatase (Lichtman 
& Feldman, 1963; Dresel & Falk, 1956; Kreimer-Bimbaura & Grinstein, 
1965; Tephly et al, 1971; Goldberg, 1972; Piper & Tephly, 1974).
i. Methods: animals
Male Sprague-Dawley rats (130 - ISOg) were fasted for 12 hours before^ 
and during the course of the experiments. Lead (administered intra­
venously by tail vein injection and given as lead chloride, PbC12) and 
sodium phenobarbitone (administered intra-peritoneally) were dissolved 
in 0.9% sodium chloride and given in various doses as indicated in the 
lengends to Pigs. 19 to 21. Cycloheximide was administered intra- 
peritoneally and the appropriate dose to inhibit drug induced enzyme 
synthesis (2 ng/kg) was determined from preliminary survival experi­
ments (Table 15) and from the inhibition of cytochrome P 450 synthesis 
after phenobarbitone (Fig. 33).
HEPATIC ENZYME STUDIES. At various times after treatment, as indicated 
in the legends to Figsl9-.2ibhe animals were decapitated, the livers 
perfused in situ with cold isotonic saline, excised and homogenised in 
0.25 M cold sucrose, and enzyme activities determined in homogenates and 
microsomes.
URINARY ALA EXCRETTICN. Fasted rats were kept for a further 24 hours in 
metabolic cages without food, but with water ad libitum. Urine was 
collected, and the total 24 hour urinary ALA excretion was determined 
(Fig. 25 ).
IN VIVO DRUG METABOLISM was assessed by Pentobarbital sleeping time 
(Borzecella & Manthei, 1957). Pentobarbital (20 mg/kg) was administered 
intra-peritoneally to various groups of control and treated rats as 
described in the legend to Table 16, ,
The time taken from injection of pentobarbital to return of the righting 
reflex was noted in two phases - "early", and "conplete." The latter 
was taken as the end-point for determining sleeping time. The tests 
were all performed in a "blind" fashion with the observer unaware of the 
treatment category, or of the time of pentobarbital injection.
Analytical Methods
ALA-synthetase activity in liver hŒûogenates was assayed by the incor­
poration of 1, 4 (14C) succinate into ^ -aminolaevùlinic acid, followed 
by isolation of the ALA-14C by three sequential chromatographic pro­
cedures (Strand et al, 1972A). Cytochrome P 450 content of liver micro­
somes was measured by the method of Qnura & Sato (1964) using an 
Aminco DW-2 spectrophotometer. Paranitro anisole (pNA) - demethylase 
activity was determined in microsomes by the method of Netter & Seidel 
(1964). Protein concentration was measured by the method of Lowry et 
al (1951). Urinary ALA and PBG were estimated by the method of Davis & 
Andelman (1967) using disposable Bio-Rad Columns.
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SiLrvival of fasted male rats given phenobarbitone (100 mg/kg intraperito­
neally) with cycloheximide in varying doses (2 to 50 Qig/kg intraperito­
neally) observed for up to 24 hours.
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Composite slide of Pigs. 19. to 21 Phenobarbitone and lead chloride 
were injected at zero time to male rats fasted for 24 hours. Groups of rats 
were killed at the times indicated, and enzyme activity was determined in 
liver homogenates and microsomes. Results at each time point are expressed 
mean + 8#I from at least 4 experiments each utilising pooled livers from 
2 to 4 rats.
ii. Results
EEPECT of LEAD and PBENOBARBITŒE on HEPATIC ALA-SYNTHBTASE
ACTIVITY
The effect of a single injection of lead or of phenobarbitone or of 
a combination of the two, on the activity of ALA-synthetase, the 
concentration of cytochrane P 450 and the pNA demethylase activity, 
are shown in Figs. 19 to 21 At these doses (PbC12 10 nig/kg intra­
venously, phenobarbitone 100 mg/kg intraperitoneally) both lead and 
phenobarbitone caused a rise in ALA-synthetase activity which was 
maximal 12 - 18 hours after injection (121% and 82% above control for 
lead and phenobarbitone respectively). However, when phenobarbitone 
was given in combination with lead, induction of ALA-synthetase was 
greatly enhanced (430% above control), Cycloheximide (2 rag/kg), 
intraperitoneally administered 30 minutes before the injection of 
either lead, phenobarbitone, or the combination of lead and pheno­
barbitone, coîïpleted abolished the rise in ALA-synthetase activity 
(Fig 24) .
Additional studies revealed that the potentiation of the effect of lead 
on drug mediated induction of ALA-synthetase activity was related both 
to the dose of lead and also to the dose of the inducing agent, pheno­
barbitone. Dose response studies for both phenobarbitone (5 to 100 n^/kg 
intraperitoneally), with and without lead (10 n^/kg intravenously), and 
lead (2.5 to 20 i%/kg intravenously), with and without phenobarbitone 
(100 n^/kg intraperitoneally) were performed.
From the earlier time-response study of the effect of lead (10 n^/kg 
intravenously) and phenobarbitone (100 mg/kg intraperitoneally) on 
ALA-synthetase activity (Fig. 19 ) it was observed that maximum enzyme 
activity occurred approximately 12 hours after drug administration.
This time was thus selected for the dose-response study illustrated in 
Fig. 2 6 *  , . although the assumption that maximal activity of ALA- 
synthetase occurred at this time for all doses of the drugs administered 
was not tested.
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As is shown in Fig. 26 phenobarbitone in a dose of 5 mg/kg had no 
effect on the activity of ALA-synthetase either alone or in combination 
with lead. In doses of 10 and 25 mg/kg again there was no effect 
with phenobarbitone alone, but in rats in which heme synthesis was 
partially blocked by lead, these same doses caused marked induction 
of ALA-synthetase activity.
A similar synergistic effect of lead was observed with other barbi­
turates (aprobarbital, barbital, butabarbital, hexobarbital, pento­
barbital, secobarbital and thiopental) all given in equimolar doses 
(100 umol/kg); antipyrine 25 mg/kg; chloral hydrate 100 mg/kg, and 
small doses of the porphyrogenic compound 2-allyl-2-isopropylaceta- 
mide (AIA). ALA-synthetase activity 12 hours after administration of 
AIA (100 mg/kg intraperitoneally) was 52% above the control value, 
vhile a 220% increase was seen when AIA was administered with lead.
EFFECT of LEAD and PHENOBAEBITCME on URINARY ALA 
EXCRETICN
The effects of lead and phenobarbitone on hepatic ALA-synthetase 
activity were paralleled by similar changes in the urinary excretion of 
the porphyrin precursor ALA (Fig. 25 ). lead chloride in a single
dose (10 mg/kg) intravenously caused a significant increase in the 
urinary excretion of ALA over the subsequent 24 hours, from the control 
value of 181“ 25 mg/kg to 2925 - 170 mg/kg/24 h (mean - SEM). 
Phenobarbitone (100 mg/kg) intrperitoneally given alone had no effect 
on urinary ALA excretion, but when the drug was administered in combi- 
nation with lead, ALA excretion was strikingly enhanced to 10230 - 
790 ug/kg/24 h. These effects on urinary ALA excretion (like those 
on hepatic ALA-synthetase activity) were dose related. PBG excretion 
was not detectably increased in treated animals.
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.Dose-response study of the effect of lead and phenoharbitone on hepatic 
ALA-synthetase activity. Dose-response for phenobarbitone (5 to 100 mg/kg 
intraperitoneally) in the presence and absence of lead (100 mg/kg intra­
venously) on the right ; and for lead chloride (2*5 to 20 mg/kg intra­
venously), in the presence and absence of phenobarbitone (100 mg/kg 
intraperitoneally) on the left; Fasted male rats were Injected and killed 
12 hours later, and enzyme activity determined in liver homogenates. Results 
are expressed as means 4- SIM from at least 4 experiments each utilising 
pooled livers from 2 to”4 rats. Ihe shaded area indicates the normal range 
for AIA-synthetase activity in rat liver homogenates.
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EFFECT of LEAD and PHENOBARBITONE on MICROSOMAL CYIOCHROME 
P 450 OONGENTRATICN and Œ  DRUG METABOLISM in vitro and in 
vivo
Lead administration resulted in a significant initial fall in hepatic 
cytochrome P 450 concentration, and the combination of lead and 
phenobarbitone delayed and inpaired the well-known adaptive rise 
in cytochrome P 450 concentration normally observed after phenobar­
bitone treatment. Microsomal pNA-demethylase activity paralleled 
cytochrome P 450 concentration under these three experimental con­
ditions (Fig. ). Pentobarbital sleeping time of rats given 
phenobarbitone and lead was significantly greater than that of control 
rats or rats given phenobarbitone alone (Table 16 ).
iii. Discussion
These findings suggest that while partial inpairment of heme biosynthesis 
by small doses of lead has only a minor effect on ALA-synthetase 
activity it greatly enhances the sensitivity of ALA-synthetase to 
induction by drugs which when given alone have little or no inducing 
effect on the enzyme.
The massive induction of ALA-synthetase caused by lead and phenobarbitone 
in combination is reminiscent of the effect of potent poiphyrogenic 
chemicals such as allylisopropylacetamide (AIA), 3,5-diethoxycarbonyl-l, 
4-dihydro-2,4,Gytrimethylpyridine (DDC) and griseofulvin. Their effect 
may be related in part to the decrease in the intracellular concentration 
of heme and cytochrome P 450 abserved after administration of these 
chemicals (Wada et al, 1968; Waterfield et al, 1969; De Matteis, 1970; 
Meyer & Marver, 1971; Sweeney et al, 1972; Satyanarayana et al, 1972;
De Matteis, 1973B; De Matteis & Gibbs, 1975).
Drug metabolism is further coiproniised by the failure of induction of 
cytochrome P 450 and drug metabolising enzymes normally seen in response 
to inducing drugs such as phenobarbitone (Fig. 20 ),
/SUV
Table
SLEEPING TIT-IE (uiin)
CONTROL 
(n “ 8)
Mean SP
55.7 19,2
PHEITOBARBI- 
TONE (n = 7) 60,6 12.2 P.S,
LEAP
+
P.HS.NO 
(n “ 6) 86,8 24.7 p <o;.oo5
Effect of phenobarbitone (100 mg/kg intraperitoneally) alone, and lead 
(10 mg/kg intravenously) + phenobarbitone (IOO mg/kg intraperitoneally) on 
pentobarbitol sleeping time. Rats were fasted for 12 hours before 
injection, and after a further 12 hours pentobarbitol (4O mg/kg intra­
peritoneally) was administered, and sleeping time (complete return of 
righting reflex) determined in a "blind" fashion. Control rats received 
intravenous and/or intraperitoneal saline injection.
One consequence of impaired metabolism of an inducing agent in this 
setting is that its stimulatory effect on ALA-synthetase will be 
enhanced, as enzyme induction is a dose dependent phenomenon (Conney,
1967) and is influenced by the rate of biotransformation of the 
inducer in the target organ (Rerrmer, 1970). Inducers of experimental 
porphyria are detoxified by drug metabolising enzymes of the hepatic 
endoplasmic reticulum, and augmentation of this transformation reduces 
the bioavailability of the inducer and thereby its effectiveness 
(Kaufman et al, 1970). Conversely, slowing the metabolism of an 
inducing drug would increase its effectiveness as an inducer and thus 
may contribute to massive induction of ALA-synthetase. In the present 
studies (confirming the earlier reports of Alvares et, al, 19720 and Scoppa 
et al (1973,). administration of lead to rats impaired drug^metàbolism in vitro, 
and also in vivo as assessed by pentobarbitol sleeping time.
The idiosyncratic reaction to many cannon drugs in patients with the 
hereditary hepatic poiphyrias has naturally inhibited clinical studies 
of drug metabolism in this group of disorders. However it is of 
interest that two recent clinical studies demonstrated impaired 
hydroxylation of salicylamide and antipyrine in patients \vith overt 
lAP, while glucuronidation (phase II drug metabolism) was unaffected.
(Song et al, 1974; Anderson et al, 1976).
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(4) œ m m  basis for human and experimental porphxria
The experimental studies described above have shown that vÆiile partial 
impairman of heme biosynthesis in laboratory rodents has only minor 
effects on ALA-synthetase activity, it greatly enhances the sensitivity 
of ALA-synthetase to induction by a variety of drugs and steroids which 
when given alone, have little or no inducing effect on the enzyme. 
Curiously however such drugs are by themselves capable of causing 
striking induction of ALA-synthetase and porphyrin accumulation in 
cultured chick embryo liver cells (Grauick, 1966). The chick embryo 
liver system thus appears to be a model for human inherited hepatic 
porphyria and has been used to screen for drugs potentially dangerous 
to porphyria subjects (Rifkind et al, 1973). In the chick embryo liver, 
the stimulatory effect on ALA-synthetase activity appears to be 
related to the lipid solubility of the test drug (De Matteis, 1971).
(a) Dual Requirements for Massive Induction of Hepatic 
5 “Aminolaevulinic Acid Synthetase
i
A wide variety of drugs have been inplicated in precipitating acute 
attacks in patients with hereditary hepatic porphyrias (Table ; 
Goldberg, 1959; Taddeini & Watson, 1968; Stein & Tschudy, 1970;
Bales, 1971). Although of diverse chemical structure, they have in 
common the general property of lipid solubility. Many of these 
compounds induce the microscmal heroprotein, cytochrome P450, an effect 
which is preceded by a modest increase in ALA-synthetase activity, 
presumably to provide additional heme for hemoprotein synthesis. 
However, even at high concentration, administration of these drugs to 
animals is not accompanied by porphyrin accumulation nor do they 
result in a porphyria-like syndrome in normal subjects.
In marked contrast to this large nunber of commonly used drugs is the 
small group of compounds, including AI A, DDC, and griseofulvin, vhich 
cause massive induction of ALA-synthetase and produce a biochenical 
situation in rodents mimicking human hepatic porphyria. (Fig/'^  ).
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Interestingly, these lipid soluble compounds, although apparently 
structurally unrelated, all interfere with the intracellular concen­
tration of heme, either by inhibiting enzymatic steps in heme biosyn­
thesis (for example, DDC; griseof ulvin) or by accelerating break­
down of heme and hemoproteins (for example, AIA) resulting in initial 
falls in cytochrome P450 concentration. By decreasing intracellular 
heme, these chemicals may affect ALA-synthetase activity, at least in 
part, by interfering with the feedback regulation of this enzyme.
(Sassa Ss Granick, 1970; Strand et al, 1972B; Sinclair & Granick, 1975).
A unifying explanation both for the drug idiosyncrasy seen in the 
hereditary hepatic porphyrias, and for the mode of action of the potent 
porphyrinogenic agents in laboratory animals, is suggested by the 
studies presented above. Thus, the mechanism of action of the potent 
porphyrinogenic conpounds may be analogous to the combination of lead 
and phenobarbitone, in that they all possess the dual properties of 
affecting heme (by inhibiting its synthesis or increasing its breakdown) 
and having the lipid solubility characteristics of inducers of 
ALA-synthetase and of microsomal enzymes. Indeed a similar potentiation 
of ALA-synthetase activity has recently been observed when- phenobarbitone 
or phenylbutazone were administered together with small doses of DDC 
or AIA (De Matteis & Gibbs, 1972; Bock et al, 1973; Padmanaban et al, 
1973).
Increased activity of hepatic ALA-synthetase with consequent overproduc­
tion of porphyrins and/or porphyrin precursors (features common to both 
the acute attadks- of hereditary hepatic porphyria and experimental cheni- 
cal poiphyria) appears to result fron the coexistence of two separate 
requirements, each of which alone may have only moderate or no effect 
on the enzyme. These are a) an effect on heme synthesis or degradation, 
and b) exposure to lipid soluble inducers of hemoprotein synthesis, such 
as certain drugs, and possibly endogenous substances (Fig^7 ). Thus 
experimental reduction of a certain pool of intracellular heme, for exarrple 
when heme synthesis is partially blocked by lead, may moderately induce 
ALA synthetase.
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Lâlcewise phenobarbitore and other inducers of hemoprotein cytochrome 
P450 may also moderately stimulate the activity of this enzymes, but 
without affecting the poiphyrin or porphyrin precursor excretion.
However, vhen both factors are present together, a synergistic effect 
is seen with massive induction of ALA-synthetase (depicted by the broad 
arrow in Fig.27 ), which is accompanied by greatly enhanced excretion
of precursors (Mfetxwell and IVfeyer, 1974,1976).
The analogy with ZAP is clear, as in this clinical setting, defective 
adaption of heme synthesis is a consequence of the intrinsic genetic 
disorder. It has been proposed that the partial defect in heme synthesis 
in ZAP may result in derepression of ALA-synthetase throu^ negative 
feedback regulation, and that because of the kinetic properties of the 
enzymatic steps following ALA-synthetase, the increase in PBG 
production may be sufficient to partially overcome the defect in heme 
synthesis (Meyer and Schmid, 1973). Thus, despite the partial block, 
the "effective" hone concentration and heme available for basal 
hemoprotein synthesis may approach normal levels, provided ALA-synthetase, 
and, therefore, heme synthesis remains induced. Such a "compensated" 
block may reflect the situation in a patient with "latent" prophyria 
vhere clinical symptoms are absent and precursor excretion in the urine 
may be negligible. However, this precarious equilibrium is readily 
disturbed by any of a large number of drugs (and possibly naturally 
occurring endogenous inducers) which have little or no effect of 
ALA-synthetase in the normal hepatocyte but may precipitate "acute 
poiphyria" in individuals with a genetic defect in heme synthesis.
The exact mechanism of increased sensitivity of ALA-synthetase to 
induction in the presence of partial inhibition of heme synthesis remains 
to be determined but it appears to be related to the negative feedback 
regulation of heme synthesis. Thus, the inability of an hepatocyte 
with cotipranised heme synthesis to respond appropriately to a sudden 
demand for increased synthesis ,of heme (such as is created by inducers 
of hemoprotein cytochrome P450) would result in persistence of the 
regulatory feedback signal and hence exaggerated stimulation of 
ALA-synthetase activity. Recent studies (Correia and Meyer, 1975) 
have shown that partial enzymatic blocks in heme synthesis disturb the
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normally closely coordinated synthesis of mitochondrial heme and 
microsomal apoprotein during induction of cytochrome P450, and 
result in a relative excess of free apocytochrome P450 in the liver. 
Further studies have suggested that increased synthesis of apocyto­
chrome P450 is the primary event in drug-mediated induction of holo- 
cytochrome P450 (Correia and Bfeyer, 1975; Rajamanickam et al., 1975). 
This has provided support to the speculation that free apocytochrome 
P450 may quantitatively reflect the regulatory signal for induction 
of ALA-synthetase by drugs. Massive induction of ALA-synthetase by 
inducers of cytochrome P450 in the presence of partial blocks in 
heme synthesis may represent an attenpt to overcoræ the block and 
provide the heme required for combination with free apocytochrome 
P450. Whether the regulatory signal for synthesis of ALA-synthetase 
is mediated directly via free apoprotein concentration ("positive 
feedback") (Padmanaban et al., 1973) or in response to the prevailing 
deficiency of a certain heme pool ("negative feedback") (De Matteis 
and Gibbs, 1972) or by some other mechanism ^remains to be determined.
The recent clinical studies indicating impaired hepatic biotransformation 
of salicylamide and antipyrine in patients with lAP (Song et al., 1974; 
Anderson et al., 1976) raises the possibility that inpaired hepatic 
biotransformation may contribute to the drug idiosyncrasy in hepatic 
porphyria. Our experimental studies were consistent with these 
observations as the in vitro studies in lead treated rats showed impaired 
déméthylation of paranitroanisole (Maxwell & Meyer, 1976), and pento­
barbital sleeping times were prolonged. One consequence of impaired 
metabolism of an inducing agent is that its stimulatory effect on 
ALA-synthetase activity will be enhanced as enzyme induction is a dose- 
dependent phenomenon and may be influenced by the rate of biotrans- 
foimation of the inducer in the target organ. Slowing the metabolism 
of an inducing drug would increase its effectiveness as an inducer, and 
thus may contribute to the massive induction of ALA-synthetase.
The scheme depicted in Fig2 7 may also be relevant to an understanding of 
the mechanism of action of potent experimental porphyrinogenic compounds 
such as AIA, DDC and griseof ulvin. These compounds may functionally be 
analogous to the experimental combination of lead and phénobarbital in
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that each possesses in a single molecule the dual properties for 
massive induction of ALA-synthetase. This duality is most readily 
apparent with allyl substituted compounds where the allyl group is 
responsible for the effect on heme, while the remainder of the lipid 
soluble molecule may provide the inducing moiety.
The paradoxical effect of prior exposure of an experimental animal to 
enzyme inducing drugs in enhancing heme degradation, but at the same 
time diminishing the porphyrinogenic effect of subsequently admini­
stered AIA (Kaufman et al., 1970; De Matteis, 1973a; Schmid, 1973) 
can now also be understood on a rational basis. Thus, while micro­
somal enzyme induction will enhance the effect of AIA on here
degradation by accelerating the biotransformation of the allyl moiety 
to the active metabolite responsible for this effect (De Matteis, 1971b) 
it also accelerates the metabolism of the remainder of the molecule 
(the inducing moiety) ( Kaufman et al., 1970) reducing its availability 
and thus its inducing potential. This latter effect apparently 
negates the former, and could account for the net reduction in 
ALA-synthetase activity observed.
Finally, the concept of dual requirements for massive induction of 
ALA-synthetase and consequent porphyrin and/or precursor excretion may 
also explain vhy the chick embryo liver provides a model for the drug 
sensitivity of hereditary hepatic poiphyria. Recent observations 
indicate that there may be relative defects in heme synthesis in
chick embryo liver cells in culture (Doss, 1971; De Matteis, 1973c).
Such defects in home synthesis (analogous to the genetic defect in 
lAP or that experimentally produced-in rats by lead) could explain the 
ready induction of ALA-synthetase and porphyrin accumulation in response 
to barbiturates and other common drugs in the chick embryo liver. 
Interestingly in this systan the effect of drugs appears to be most 
strongly correlated with their lipid solubility (De Matteis, 1971)
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(b) Role of Enzyme Inducing Agents in Acute Human 
Porphyria
The laboratory studies described in the earlier section of this 
chapter are of some practical clinical relevance. Many of the 
previously unexplained features of the hereditary hepatic porphyrias 
can now be understood on a mechanistic basis. In particular the 
"idiosyncratic" reaction to many drugs which is such a characteristic 
feature of the hereditary hepatic porphyrias can be seen now to be 
a direct consequence of the primary genetic defect in porphyrin and 
heme synthesis. Clearly, drugs with enzyme-inducing properties 
(Table 14 ) pose a major threat to these patients and should be avoided. 
Thus acute attacks of porphyria can be regarded as another adverse 
effect of enzyme induction (in genetically predisposed individuals).
A necessary corollary to this definition of the hereditary hepatic 
poiphyrias as a group of pharmacogenetic disorders of heme synthesis 
characterised by a unique sensitivity to enzyme inducing agents is the 
recognition that those drugs which may be safely used in this group of 
patients are relatively weak or ineffective inducers of microsomal 
haemoproteins (Table 17). (Maxwell, 1976). A further consequence of 
the dual requirements underlying massive induction of hepatic 
ALA-synthetase is the recognition that it is inappropriate to screen 
drugs as safe for use in patients with inherited hepatic poiphyria 
simply on the basis of their failure to affect ALA-synthetase activity 
in laboratory animals with an intact îieme pathway, as for example in 
the report of Beattie et al., (1973).
While these recent studies have given some insight into the basis of 
these pharmacogenetic disorders of heme synthesis, the concept of dual 
requirements for massive induction of ALA-synthetase in lAP, HOP and 
VP is necessarily an oversimplification. In an individual with the 
underlying genetic disorder, response to drug administration is 
unpredictable, and it is lilcely that a number of factors will determine 
whether or not an acute attack will be precipitated.
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Table 47
ANALGESICS
ANTIBIOTICS
ANTIHISTAMINES
CARDIOVASCULAR
HYPOTENSIVES
MISCELLANEOUS
Aspirin; morphine and related 
opiates; Paracetamol
Penicillin
Diphenhydramine; Mepyramine
Digoxin; Propranolol
Bethanidine; Guanethidine; 
Propranolol
Atropine; Neostigmine/Prostigmine; 
Vitamins B, C, E,
Some drugs considered to be safe (or probably safe) in the 
hereditary hepatic porphyrias.
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These include the genetically determined activity of the defective 
enzymejdose of drug absorbed and its inducing potential. A variety of 
other factors such as the hormonal environment and nutritional state 
("glucose effect" Bonkowsky et al., 1973) have been shown to influence 
the inducibility of mitochondrial ALA-synthetase and there is consi­
derable evidence that the inducibility of the microsomal P450 system is 
to a large extent genetically determined (Vesell, 1975). Moreover, the 
apparent insensitivity of patients with PCT to the effects of enzyme 
inducing drugs is puzzling. However, the explanation for this discrepancy, 
as suggested earlier, sears to lie in the fact that in this foira of 
hereditary hepatic porphyria, the partial enzymatic defect is insufficient 
to affect the feedback-regulation of ALA-synthetase by heme. Hence 
ALA-synthetase activity and its inducibility remain unaltered. Finally, 
our explanation for the pathogenesis of this group of pharmacogenetic 
disorders requires that the development of the neurological syndrome is 
directly related to massive induction of ALA-synthetase and consequent 
accumulation of porphyrin precursors, for which there is as yet only 
indirect evidence (Meyer and Schmid, 1974).
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